


**CUMULATIVE  
SUPPLEMENT 8  
AUGUST 2012**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**32nd EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Generic Drugs**

2012

Prepared By  
Office of Generic Drugs  
Center for Drug Evaluation and Research  
Food and Drug Administration

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**32<sup>nd</sup> EDITION**

**Cumulative Supplement 8**

**August 2012**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION .....	iii
1.1 How to use the Cumulative Supplement .....	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	.vi
1.5 Availability of the Edition .....	vii
1.6 Report of Counts for the Prescription Drug Product List .....	vii
1.7 Cumulative Supplement Legend .....	.viii
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**32nd EDITION**

**CUMULATIVE SUPPLEMENT 8  
August 2012**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [drugproducts@fda.hhs.gov](mailto:drugproducts@fda.hhs.gov). Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff  
Office of Generic Drugs, HFD-610  
7620 Standish Place  
Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ABBOTT LABORATORIES (ABBOTT LABS)  (ABBOTT)	ABBVIE INC (ABBVIE)  (ABBVIE)
ABBOTT LABORATORIES HOSP PRODUCTS DIV (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT LABORATORIES PHARMACEUTICAL (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT PRODUCTS (ABBOTT)	ABBVIE INC (ABBVIE)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)

ROSS LABORATORIES DIV ABBOTT  
LABORATORIES  
(ABBOTT)

ABBVIE INC  
(ABBVIE)

SOLVAY PHARMACEUTICALS  
(ABBOTT)

ABBVIE INC  
(ABBVIE)

#### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001

LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly



data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

## DEFINITIONS

### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

## REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711	14834		
SINGLE SOURCE	2451 (16.9%)	2446 (16.6%)	2428 (16.4%)		
MULTISOURCE	11953 (82.5%)	12187 (82.8%)	12328 (83.1%)		
THERAPEUTICALLY EQUIVALENT	11792 (81.4%)	12037 (81.8%)	12187 (82.2%)		
NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)	141 (1.0%)		
EXCEPTIONS <sup>1</sup>	76 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES					
APPROVED	6	8	7		
NUMBER OF APPLICANTS	810	826	826		

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

1-1

ABACAVIR SULFATE

TABLET; ORAL  
 ABACAVIR SULFATE  
 AB MYLAN PHARMS INC EQ 300MG BASE A091294 001 Jun 18, 2012 Jun NEWA  
 ZIAGEN  
 AB + VIIIV HLTHCARE EQ 300MG BASE N020977 001 Dec 17, 1998 Jun CFTG

ACARBOSE

TABLET; ORAL  
 ACARBOSE  
 AB EMCURE PHARMS LTD 25MG A202271 001 Feb 07, 2012 Jan NEWA  
 AB 50MG A202271 002 Feb 07, 2012 Jan NEWA  
 AB 100MG A202271 003 Feb 07, 2012 Jan NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL  
 BUTAPAP  
 + MIKART 325MG;50MG A089987 001 Oct 26, 1992 Jun CRLD  
 PHRENILIN  
 @ VALEANT 325MG;50MG A087811 001 Jun 19, 1985 Jun DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL  
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE  
 >A> AA LANNETT HOLDINGS INC 325MG;50MG;40MG A200243 001 Sep 13, 2012 Aug NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL  
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE  
 NEXGEN PHARMA INC 300MG;50MG;40MG;30MG A076560 002 Jul 19, 2012 Jul NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL  
 ACETAMINOPHEN AND CODEINE PHOSPHATE  
 AA + PHARM ASSOC 120MG/5ML;12MG/5ML A087508 001 Jan CRLD  
 SUSPENSION; ORAL  
 CAPITAL AND CODEINE  
 + VALEANT 120MG/5ML;12MG/5ML A086024 001 Jan CTEC  
 + VALEANT PHARMS LLC 120MG/5ML;12MG/5ML A086024 001 Jun CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN  
 @ NESHER PHARMS 500MG/15ML;7.5MG/15ML A040366 001 Jan 23, 2002 Jun DISC  
 AA VISTAPHARM 325MG/15ML;7.5MG/15ML A200343 001 Jan 25, 2012 Jan NEWA  
 TABLET; ORAL  
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN  
 AA AUROLIFE PHARMA LLC 325MG;5MG A201013 001 Apr 11, 2012 Mar NEWA  
 AA 325MG;7.5MG A201013 002 Apr 11, 2012 Mar NEWA  
 AA 325MG;10MG A201013 003 Apr 11, 2012 Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS TOTOWA	325MG;7.5MG	A040800 001	Apr 03, 2012	Mar	NEWA
AA		325MG;10MG	A040800 002	Apr 03, 2012	Mar	NEWA
AA	ALVOGEN INC	325MG;7.5MG	A202677 001	Jul 26, 2012	Jul	NEWA
AA		325MG;10MG	A202677 002	Jul 26, 2012	Jul	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	325MG;37.5MG	A202076 001	Mar 30, 2012	Mar	NEWA
>A>	ZYDUS PHARMS USA INC	325MG;37.5MG	A090460 001	Sep 06, 2012	Aug	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880 001	May 09, 2012	Apr	NEWA
AP	+ X GEN PHARMS	EQ 500MG BASE/VIAL	A040784 001	Dec 10, 2008	Apr	CRLD
	DIAMOX					
	@ TEVA WOMENS	EQ 500MG BASE/VIAL	N009388 001	Dec 05, 1990	Apr	DISC

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	INNOPHARMA INC	20%	A203853 001	Jun 21, 2012	Jun	NEWA
----	----------------	-----	-------------	--------------	-----	------

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

	+ FOREST LABS INC	0.375MG/INH	N202450 001	Jul 23, 2012	Jul	NEWA
--	-------------------	-------------	-------------	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

	@ HERITAGE PHARMS INC	200MG	A074889 001	Oct 31, 1997	May	CAHN
--	-----------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

	@ HERITAGE PHARMS INC	400MG	A074891 001	Oct 31, 1997	May	CAHN
--	-----------------------	-------	-------------	--------------	-----	------

	@	800MG	A074891 002	Oct 31, 1997	May	CAHN
--	---	-------	-------------	--------------	-----	------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

GEL; TOPICAL

ADAPALENE

AB	TOLMAR	0.3%	A200298 001	Jun 14, 2012	Jun	NEWA
----	--------	------	-------------	--------------	-----	------

DIFFERIN

AB	+ GALDERMA LABS LP	0.3%	N021753 001	Jun 19, 2007	Jun	CFTG
----	--------------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

DIFFERIN

	+ GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010	Apr	CAHN
--	--------------------	------	-------------	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

@ TEVA PARENTERAL 3MG/ML A078676 001 Jul 31, 2008 Mar DISC  
 @ 3MG/ML A076564 001 Jun 16, 2004 Jan DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ SANDOZ INC EQ 0.083% BASE;0.017% A076867 001 Dec 21, 2006 Apr DISC

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB FOUGERA PHARMS 0.05% A076973 001 Jul 12, 2005 Jan CAHN

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB FOUGERA PHARMS 0.05% A076884 001 Jul 18, 2005 Jan CAHN

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL

BINOSTO

+ MISSION PHARMA EQ 70MG BASE N202344 001 Mar 12, 2012 Mar NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

>A> AB AUROBINDO PHARMA LTD 10MG A079060 001 Aug 30, 2012 Aug NEWA  
 AB INVAGEN PHARMS 10MG A090284 001 Jan 17, 2012 Jan NEWA  
 AB WOCKHARDT LTD 10MG A090221 001 Aug 10, 2012 Jul NEWA

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@ GENZYME 80 UNITS/ML N020057 003 Apr 05, 1991 Mar DISC

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ SANDOZ INC 0.5MG A077777 001 Jun 30, 2006 Mar DISC  
 @ 1MG A077777 002 Jun 30, 2006 Mar DISC  
 @ 2MG A077777 003 Jun 30, 2006 Mar DISC  
 @ 3MG A077777 004 Jun 30, 2006 Mar DISC  
 @ VINTAGE PHARMS 0.5MG A078442 001 Oct 15, 2007 Jul DISC  
 @ 1MG A078442 002 Oct 15, 2007 Jul DISC  
 @ 2MG A078442 003 Oct 15, 2007 Jul DISC  
 @ 3MG A078442 004 Oct 15, 2007 Jul DISC

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

AB UCB INC 0.25MG N021726 001 Jan 19, 2005 Jan CAHN  
 AB 0.5MG N021726 002 Jan 19, 2005 Jan CAHN  
 AB + 1MG N021726 003 Jan 19, 2005 Jan CAHN  
 AB 2MG N021726 004 Jan 19, 2005 Jan CAHN

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+ CUBIST PHARMS 12MG N021775 001 May 20, 2008 Feb CAHN

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB + FOUGERA PHARMS 0.1% A076065 001 May 15, 2003 Jan CAHN

LOTION; TOPICAL

AMCINONIDE

+ FOUGERA PHARMS 0.1% A076329 001 Nov 06, 2002 Jan CAHN

OINTMENT; TOPICAL

AMCINONIDE

AB + FOUGERA PHARMS 0.1% A076096 001 Nov 19, 2002 Jan CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ HOSPIRA EQ 50MG BASE/ML A063263 001 Nov 30, 1994 Jun DISC

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN 15% (300GM/2000ML) A091112 002 Apr 13, 2012 Mar NEWA

15% (150GM/1000ML) A091112 001 Apr 13, 2012 Mar NEWA

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE 15% (15GM/100ML) A020512 001 Aug 30, 1996 Jun CAHN

NOVAMINE 15%

@ HOSPIRA INC 15% (75GM/500ML) N017957 004 Nov 28, 1986 Mar CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@ CLOVER PHARMS 250MG/ML N015229 002 Mar CAHN

SYRUP; ORAL

AMICAR

AA + CLOVER PHARMS 1.25GM/5ML N015230 002 Mar CAHN

TABLET; ORAL

AMICAR

AB CLOVER PHARMS 500MG N015197 001 Mar CAHN

+ 1GM N015197 002 Jun 24, 2004 Mar CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ BEDFORD 50MG/ML A076018 001 Oct 15, 2002 Jun DISC

@ BEDFORD LABS 50MG/ML A076299 001 Oct 24, 2002 Jun DISC

@ TEVA PARENTERAL 50MG/ML A076163 001 Sep 05, 2003 Jan DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB MURTY PHARMS 200MG A077069 001 Apr 08, 2005 May CAHN

AB 400MG A077069 002 Apr 08, 2005 May CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	CARACO	10MG	A040816 002	Jun 27, 2008	Apr	NEWA
AB		50MG	A040816 003	Jun 27, 2008	Apr	NEWA
AB		75MG	A040816 004	Jun 27, 2008	Apr	NEWA
AB		100MG	A040816 005	Jun 27, 2008	Apr	NEWA
AB		150MG	A040816 006	Jun 27, 2008	Apr	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297 002	Dec 10, 1986	Feb	CTEC
+		EQ 25MG BASE;10MG	A071297 001	Dec 10, 1986	Feb	CRLD
	LIMBITROL					
	@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001		Feb	DISC
	LIMBITROL DS					
	@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380 001	Apr 13, 2012	Mar	NEWA
AB		EQ 10MG BASE	A201380 002	Apr 13, 2012	Mar	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239 001	Sep 05, 2012	Aug	NEWA
>A>	AB		EQ 5MG BASE;10MG	A202239 002	Sep 05, 2012	Aug	NEWA
>A>	AB		EQ 5MG BASE;20MG	A202239 003	Sep 05, 2012	Aug	NEWA
>A>	AB		EQ 5MG BASE;40MG	A202239 004	Sep 05, 2012	Aug	NEWA
>A>	AB		EQ 10MG BASE;20MG	A202239 005	Sep 05, 2012	Aug	NEWA
>A>	AB		EQ 10MG BASE;40MG	A202239 006	Sep 05, 2012	Aug	NEWA

AMOXICILLIN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

	@ RANBAXY LABS LTD	600MG	A065159 001	Dec 04, 2003	Apr	DISC
--	--------------------	-------	-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ INC	200MG/5ML;EQ 28.5MG BASE/5ML	A065098 001	Dec 16, 2002	Jul	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065098 002	Dec 16, 2002	Jul	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065358 001	Aug 13, 2007	Jul	CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA
AB	SANDOZ INC	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002	Jul	CAHN
AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AB	ADDERALL XR 10								
	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG		N021303	001	Oct 11, 2001	Jun	CFTG	
AB	ADDERALL XR 15								
	SHIRE	3.75MG;3.75MG;3.75MG;3.75MG		N021303	006	May 22, 2002	Jun	CFTG	
AB	ADDERALL XR 20								
	SHIRE	5MG;5MG;5MG;5MG		N021303	002	Oct 11, 2001	Jun	CFTG	
AB	ADDERALL XR 25								
	SHIRE	6.25MG;6.25MG;6.25MG;6.25MG		N021303	004	May 22, 2002	Jun	CFTG	
AB	ADDERALL XR 30								
AB	+ SHIRE	7.5MG;7.5MG;7.5MG;7.5MG		N021303	003	Oct 11, 2001	Jun	CFTG	
AB	ADDERALL XR 5								
	SHIRE	1.25MG;1.25MG;1.25MG;1.25MG		N021303	005	May 22, 2002	Jun	CFTG	
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE								
AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG		A077302	001	Jun 22, 2012	Jun	NEWA	
AB		2.5MG;2.5MG;2.5MG;2.5MG		A077302	002	Jun 22, 2012	Jun	NEWA	
AB		3.75MG;3.75MG;3.75MG;3.75MG		A077302	003	Jun 22, 2012	Jun	NEWA	
AB		5MG;5MG;5MG;5MG		A077302	004	Jun 22, 2012	Jun	NEWA	
AB		6.25MG;6.25MG;6.25MG;6.25MG		A077302	005	Jun 22, 2012	Jun	NEWA	
AB		7.5MG;7.5MG;7.5MG;7.5MG		A077302	006	Jun 22, 2012	Jun	NEWA	

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

	INDEPENDENCE PHARMS	5MG		A200166	001	Aug 09, 2012	Jul	NEWA	
+		10MG		A200166	002	Aug 09, 2012	Jul	NEWA	

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+	ALKOPHARMA USA	50MG/VIAL		N050729	001	Nov 22, 1996	May	CAHN	
+		100MG/VIAL		N050729	002	Nov 22, 1996	May	CAHN	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>D>	AP	ACIC FINE CHEMS	EQ 250MG BASE/VIAL	A090354	001	Dec 28, 2009	Aug	CAHN	
>D>	AP		EQ 500MG BASE/VIAL	A090354	002	Dec 28, 2009	Aug	CAHN	
>D>	AP		EQ 1GM BASE/VIAL	A090354	003	Dec 28, 2009	Aug	CAHN	
>D>	AP		EQ 2GM BASE/VIAL	A090354	004	Dec 28, 2009	Aug	CAHN	
>A>	AP	ANTIBIOTICE	EQ 250MG BASE/VIAL	A090354	001	Dec 28, 2009	Aug	CAHN	
>A>	AP		EQ 500MG BASE/VIAL	A090354	002	Dec 28, 2009	Aug	CAHN	
>A>	AP		EQ 1GM BASE/VIAL	A090354	003	Dec 28, 2009	Aug	CAHN	
>A>	AP		EQ 2GM BASE/VIAL	A090354	004	Dec 28, 2009	Aug	CAHN	

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE		N020333	001	Mar 14, 1997	Jan	CAHN	
	ANAGRELIDE HYDROCHLORIDE								
	@ SANDOZ INC	EQ 0.5MG BASE		A076683	001	Apr 18, 2005	Mar	DISC	
	@	EQ 1MG BASE		A076683	002	Apr 18, 2005	Mar	DISC	



ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	APOTEX INC	1MG	A200654 001	May 11, 2012	Apr	NEWA
AB	IMPAX LABS INC	1MG	A091242 001	May 31, 2012	May	NEWA

APROTININ

INJECTABLE; INJECTION

TRASYLOL

@	BAYER HLTHCARE	10,000KIU/ML	N020304 001	Dec 29, 1993	May	DISC
---	----------------	--------------	-------------	--------------	-----	------

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000	Jan	CTNA
----	---	--------	------------------------	-------------	--------------	-----	------

ARGATROBAN

AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012	Jan	NEWA
----	--	--------------------	------------------------	-------------	--------------	-----	------

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB		MYLAN PHARMS INC	50MG	A200043 001	Jun 01, 2012	May	NEWA
----	--	------------------	------	-------------	--------------	-----	------

AB			150MG	A200043 002	Jun 01, 2012	May	NEWA
----	--	--	-------	-------------	--------------	-----	------

AB			250MG	A200043 003	Jun 01, 2012	May	NEWA
----	--	--	-------	-------------	--------------	-----	------

>A>		WATSON LABS INC	100MG	A200156 002	Aug 29, 2012	Aug	NEWA
-----	--	-----------------	-------	-------------	--------------	-----	------

>A>			200MG	A200156 004	Aug 29, 2012	Aug	NEWA
-----	--	--	-------	-------------	--------------	-----	------

NUVIGIL

AB		CEPHALON	50MG	N021875 001	Jun 15, 2007	May	CFTG
----	--	----------	------	-------------	--------------	-----	------

AB			150MG	N021875 003	Jun 15, 2007	May	CFTG
----	--	--	-------	-------------	--------------	-----	------

AB	+		250MG	N021875 004	Jun 15, 2007	May	CFTG
----	---	--	-------	-------------	--------------	-----	------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA		NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	A090145 001	Jan 25, 2012	Jan	NEWA
----	--	----------------	--	-------------	--------------	-----	------

MOVIPREP

AA	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	N021881 001	Aug 02, 2006	Jan	CFTG
----	---	--------------	--	-------------	--------------	-----	------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

		ORGANON SUB MERCK	EQ 5MG BASE	N022117 001	Aug 13, 2009	Jul	CAHN
--	--	-------------------	-------------	-------------	--------------	-----	------

+			EQ 10MG BASE	N022117 002	Aug 13, 2009	Jul	CAHN
---	--	--	--------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN
----	--	-------------	-------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN
----	-------------	------------------	-------------	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

@	ZYDUS PHARMS USA INC	18MG	A079017 001	Sep 17, 2010	Jun	DISC
@		25MG	A079017 002	Sep 17, 2010	Jun	DISC
@		40MG	A079017 003	Sep 17, 2010	Jun	DISC
@		60MG	A079017 004	Sep 17, 2010	Jun	DISC
@		80MG	A079017 005	Sep 17, 2010	Jun	DISC
@		100MG	A079017 006	Sep 17, 2010	Jun	DISC

STRATTERA

LILLY		10MG	N021411 002	Nov 26, 2002	Jun	CTEC
		18MG	N021411 003	Nov 26, 2002	Jun	CTEC
		25MG	N021411 004	Nov 26, 2002	Jun	CTEC
		40MG	N021411 005	Nov 26, 2002	Jun	CTEC
+		60MG	N021411 006	Nov 26, 2002	Jun	CTEC
		80MG	N021411 007	Feb 14, 2005	Jun	CTEC
		100MG	N021411 008	Feb 14, 2005	Jun	CTEC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	APOTEX INC	EQ 10MG BASE	A090548 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A090548 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A090548 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A090548 004	May 29, 2012	May	NEWA
AB	DR REDDYS LABS LTD	EQ 10MG BASE	A091650 001	Jul 17, 2012	Jul	NEWA
AB		EQ 20MG BASE	A091650 002	Jul 17, 2012	Jul	NEWA
AB		EQ 40MG BASE	A091650 003	Jul 17, 2012	Jul	NEWA
AB		EQ 80MG BASE	A202357 001	Jul 17, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 10MG BASE	A091226 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A091226 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A091226 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A091226 004	May 29, 2012	May	NEWA
AB	SANDOZ INC	EQ 10MG BASE	A077575 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A077575 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A077575 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A077575 004	May 29, 2012	May	NEWA
AB	TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A078773 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A078773 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A078773 004	May 29, 2012	May	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901 001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091489 001	Feb 17, 2012	Feb	NEWA
ATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	+	BEDFORD	10MG/ML	A074900 001	Jul 18, 1997	Feb	CTEC
AP		SAGENT PHARMS	10MG/ML	A091488 001	Feb 17, 2012	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	0.025MG/5ML; 2.5MG/5ML	A087708 001	May 03, 1982	Apr	CRLD
		LOMOTIL					
		@ GD SEARLE LLC	0.025MG/5ML; 2.5MG/5ML	N012699 001		Apr	DISC

AVANAFIL

TABLET; ORAL

STENDRA

		VIVUS	50MG	N202276 001	Apr 27, 2012	Apr	NEWA
			100MG	N202276 002	Apr 27, 2012	Apr	NEWA
	+		200MG	N202276 003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL

INLYTA

		PFIZER	1MG	N202324 001	Jan 27, 2012	Jan	NEWA
	+		5MG	N202324 002	Jan 27, 2012	Jan	NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

	+	BAYER HLTHCARE	15%	N021470 001	Dec 24, 2002	Jun	CAHN
--	---	----------------	-----	-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		ALCON PHARMA	0.05%	A202305 001	May 31, 2012	May	NEWA
----	--	--------------	-------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

ASTEPRO

>D>	+	MEDA PHARMS	EQ 0.1876MG BASE/SPRAY	N022371 001	Aug 31, 2009	Aug	CFTG
>A>	AB		EQ 0.1876MG BASE/SPRAY	N022371 001	Aug 31, 2009	Aug	CFTG

AZELASTINE HYDROCHLORIDE

>A>	AB	APOTEX INC	EQ 0.1876MG BASE/SPRAY	A201846 001	Aug 31, 2012	Aug	NEWA
	AB	SUN PHARMA GLOBAL	EQ 0.125MG BASE/SPRAY	A090423 001	May 23, 2012	May	NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

	+	MEDA PHARMS	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	N202236 001	May 01, 2012	May	NEWA
--	---	-------------	--	-------------	--------------	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

		TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL	N200796 001	Feb 25, 2011	Apr	CAHN
	+		EQ 80MG MEDOXOMIL	N200796 002	Feb 25, 2011	Apr	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

		TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL; 12.5MG	N202331 001	Dec 20, 2011	Apr	CAHN
	+		EQ 40MG MEDOXOMIL; 25MG	N202331 002	Dec 20, 2011	Apr	CAHN

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

@	PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	A065265 001	Jan 18, 2007	Jul	DISC
@	TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809 001	Dec 19, 2006	Jun	DISC
@		EQ 2.5GM BASE/VIAL	N050809 002	Dec 19, 2006	Jun	DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT		AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213 001	Jul 25, 2012	Jul	NEWA
AT	+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068 001	Oct 30, 1995	Jul	CTEC

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

		CNS THERAPS INC	1MG/ML	N022462 004	Jun 22, 2012	Jun	NEWA
--	--	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

BACLOFEN

AB		PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB			20MG	A077088 001	Oct 31, 2007	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@	UCB INC	10MG	N021589 001	Oct 30, 2003	Jan	CAHN
@		20MG	N021589 002	Oct 30, 2003	Jan	CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GIAZO

+		SALIX PHARMS	1.1GM	N022205 001	Feb 03, 2012	Feb	NEWA
---	--	--------------	-------	-------------	--------------	-----	------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

+		TEVA BRANDED PHARM	0.08MG/ACTIVATION	N202813 001	Mar 23, 2012	Mar	NEWA
---	--	--------------------	-------------------	-------------	--------------	-----	------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

@	NESHER PHARMS	100MG	A040795 001	Oct 31, 2007	Jun	DISC
@		200MG	A040795 002	Oct 31, 2007	Jun	DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

AB		VALEANT INTL	5%;EQ 1% BASE	N050756 001	Dec 21, 2000	Apr	CAHN
BT	+		5%;EQ 1% BASE	N050756 002	Apr 20, 2007	Apr	CAHN

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		PERRIGO ISRAEL	5%;1.2%	A090979 001	Jun 26, 2012	Jun	NEWA
AB	+	STIEFEL	5%;1.2%	N050741 001	Aug 26, 2002	Jun	CFTG

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+	VALEANT INTL	5%;3%	N050557 001	Oct 26, 1984	Jan	CAHN
		BENZAMYCIN PAK					
	+	VALEANT INTL	5%;3%	N050769 001	Nov 27, 2000	Jun	CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		EMCURE PHARMS LTD	50MG	A202061 001	Jan 27, 2012	Jan	NEWA
----	--	-------------------	------	-------------	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP		APP PHARMS LLC	1MG/ML	A090233 001	Jul 28, 2009	May	CAHN
		COGENTIN					
AP	+	OAK PHARMS AKORN	1MG/ML	N012015 001		Feb	CAHN

TABLET; ORAL

BENZTROPINE MESYLATE

		@ LANNETT HOLDINGS INC	0.5MG	A088877 001	Apr 11, 1985	Jan	DISC
		@	1MG	A088894 001	Apr 11, 1985	Jan	DISC
		@	2MG	A088895 001	Apr 11, 1985	Jan	DISC
AA		PROSAM LABS	0.5MG	A040699 001	Feb 14, 2008	Feb	CMFD
AA			1MG	A040705 001	Feb 14, 2008	Feb	CMFD
AA			2MG	A040706 001	Feb 14, 2008	Feb	CMFD
AA	+	USL PHARMA	0.5MG	A040103 001	Dec 12, 1996	Jan	CRLD
AA	+		1MG	A040103 002	Dec 12, 1996	Jan	CRLD
AA	+		2MG	A040103 003	Dec 12, 1996	Jan	CRLD

BETAMETHASONE

SYRUP; ORAL

CELESTONE

		@ SCHERING	0.6MG/5ML	N014215 002		May	DISC
--	--	------------	-----------	-------------	--	-----	------

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137 001	Jun 26, 1984	Jan	CAHN
		CREAM, AUGMENTED; TOPICAL					
		BETAMETHASONE DIPROPIONATE					
AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215 001	Dec 09, 2003	Jan	CAHN
		GEL, AUGMENTED; TOPICAL					
		BETAMETHASONE DIPROPIONATE					
AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276 001	May 13, 2003	Jan	CAHN
		LOTION, AUGMENTED; TOPICAL					
		BETAMETHASONE DIPROPIONATE					
AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111 001	May 21, 2007	Jan	CAHN
		OINTMENT, AUGMENTED; TOPICAL					
		BETAMETHASONE DIPROPIONATE					
AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373 001	Jun 22, 1999	Jan	CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL  
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE  
 AB FOUGERA PHARMS EQ 0.05% BASE;1% A075502 001 Jun 05, 2001 Jan CAHN  
 LOTION; TOPICAL  
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE  
 AB FOUGERA PHARMS EQ 0.05% BASE;1% A076516 001 Jun 16, 2005 Jan CAHN  
 LOTRISONE  
 AB + SCHERING CORP EQ 0.05% BASE;1% N020010 001 Dec 08, 2000 Feb CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL  
 LUXIQ  
 + STIEFEL EQ 0.12% BASE N020934 001 Feb 28, 1999 Jan CAHN

BISOPROLOL FUMARATE

TABLET; ORAL  
 ZEBETA  
 AB TEVA WOMENS 5MG N019982 002 Jul 31, 1992 Jan CAHN  
 AB + 10MG N019982 001 Jul 31, 1992 Jan CAHN

BOCEPREVIR

CAPSULE; ORAL  
 VICTRELIS  
 + MERCK SHARP DOHME 200MG N020258 001 May 13, 2011 Mar CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS  
 VELCADE  
 + MILLENNIUM PHARMS 3.5MG/VIAL N021602 001 May 13, 2003 Jan CDFR

BOSENTAN

TABLET; ORAL  
 TRACLEER  
 ACTELION PHARMS LTD 62.5MG N021290 001 Nov 20, 2001 May CAHN  
 + 125MG N021290 002 Nov 20, 2001 May CAHN

BUDESONIDE

POWDER, METERED; INHALATION  
 PULMICORT  
 @ ASTRAZENECA 0.16MG/INH N020441 002 Jun 24, 1997 Jun DISC  
 SUSPENSION; INHALATION  
 BUDESONIDE  
 AN WATSON LABS INC 0.25MG/2ML A078404 001 Jul 31, 2012 Jul NEWA  
 AN 0.5MG/2ML A078404 002 Jul 31, 2012 Jul NEWA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION  
 SYMBICORT  
 + ASTRAZENECA 0.08MG/INH;0.0045MG/INH N021929 001 Jul 21, 2006 Jan CDFR  
 + 0.16MG/INH;0.0045MG/INH N021929 002 Jul 21, 2006 Jan CDFR

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

@	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Jul	DISC
---	-------------------	------------------------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

>D>	AB	ROXANE	EQ 8MG BASE	A078633	002	Oct 08, 2009	Aug	CRLD
>A>	AB	+	EQ 8MG BASE	A078633	002	Oct 08, 2009	Aug	CRLD
>D>		SUBUTEX						
>D>	AB	RECKITT BENCKISER	EQ 2MG BASE	N020732	002	Oct 08, 2002	Aug	DISC
>A>		@	EQ 2MG BASE	N020732	002	Oct 08, 2002	Aug	DISC
>D>	AB	+	EQ 8MG BASE	N020732	003	Oct 08, 2002	Aug	DISC
>A>		@	EQ 8MG BASE	N020732	003	Oct 08, 2002	Aug	DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

>A>		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	Apr	CAIN
>A>			EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	Aug	NEWA
>A>		+	EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Apr	CAIN
>A>			EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Aug	NEWA

TABLET; SUBLINGUAL

SUBOXONE

		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733	001	Oct 08, 2002	Apr	CPOT
		+	EQ 8MG BASE;EQ 2MG BASE	N020733	002	Oct 08, 2002	Apr	CPOT

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>A>	AB1	WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	Aug	NEWA	
>A>	AB1		150MG	A201331	002	Aug 30, 2012	Aug	NEWA	
>A>	AB1		200MG	A201331	003	Aug 30, 2012	Aug	NEWA	
		FORFIVO XL							
		+	EDGEMONT PHARMS LLC	450MG	N022497	001	Nov 10, 2011	Mar	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

		@ APOTEX	5MG	A075521	001	Apr 05, 2002	Mar	DISC
		@	10MG	A075521	002	Apr 05, 2002	Mar	DISC
		@	15MG	A075521	003	Apr 05, 2002	Mar	DISC
		@ EGIS	5MG	A075119	001	Mar 14, 2002	Mar	DISC
		@	10MG	A075119	002	Mar 14, 2002	Mar	DISC
		@	15MG	A075119	003	Jan 23, 2003	Mar	DISC
		@ NESHER PHARMS	5MG	A075572	001	Feb 27, 2002	Jun	DISC
		@	10MG	A075572	002	Feb 27, 2002	Jun	DISC
		@	15MG	A075572	003	Feb 27, 2002	Jun	DISC
		@ PROSAM LABS	5MG	A075388	001	May 09, 2002	Mar	DISC
AB			5MG	A075388	001	May 09, 2002	Feb	CMFD
		@	10MG	A075388	002	May 09, 2002	Mar	DISC
AB			10MG	A075388	002	May 09, 2002	Feb	CMFD
		@	15MG	A075388	003	May 09, 2002	Mar	DISC
AB			15MG	A075388	003	May 09, 2002	Feb	CMFD

## TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	PROSAM LABS	30MG	A078302 001	Dec 17, 2007	Feb	CMFD
----	-------------	------	-------------	--------------	-----	------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

@ PERRIGO ISRAEL 2%

A200923 001	May 18, 2012	Apr	NEWA
-------------	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
----	----------------	------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

>A>	AP	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090827 001	Aug 29, 2012	Aug	NEWA
-----	----	---------------	------------------------------------	-------------	--------------	-----	------

SOLUTION; ORAL

CAFCIT

AA	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
----	----------------	------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

>A>	AA	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A091102 001	Aug 29, 2012	Aug	NEWA
-----	----	---------------	------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

AB	TOLMAR	0.005%	A200935 001	May 30, 2012	May	NEWA
----	--------	--------	-------------	--------------	-----	------

DOVONEX

AB	+ LEO PHARMA AS	0.005%	N020554 001	Jul 22, 1996	May	CFTG
----	-----------------	--------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008	Jan	CAHN
----	----------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	PADDOCK LLC	EQ 169MG CALCIUM	A091312 001	Jun 01, 2012	May	NEWA
----	-------------	------------------	-------------	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085 001	May 10, 2012	Apr	NEWA
----	-------------------	------------------	-------------	--------------	-----	------

AB		37.5MG;200MG;150MG	A079085 002	May 10, 2012	Apr	NEWA
----	--	--------------------	-------------	--------------	-----	------

STALEVO 100

AB	ORION PHARMA	25MG;200MG;100MG	N021485 002	Jun 11, 2003	Apr	CFTG
----	--------------	------------------	-------------	--------------	-----	------

STALEVO 150

AB	ORION PHARMA	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003	Apr	CFTG
----	--------------	--------------------	-------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

AB	UCB INC	10MG;100MG	A076699 001	Aug 27, 2004	Jan	CAHN
----	---------	------------	-------------	--------------	-----	------

AB		25MG;100MG	A076699 002	Aug 27, 2004	Jan	CAHN
----	--	------------	-------------	--------------	-----	------

AB	+	25MG;250MG	A076699 003	Aug 27, 2004	Jan	CAHN
----	---	------------	-------------	--------------	-----	------



CARBOPLATIN

## INJECTABLE; INJECTION

## CARBOPLATIN

AP	CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
AP		150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
AP		450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN
AP	ONCO THERAPIES LTD	50MG/VIAL	A091510 001	May 29, 2012	May	NEWA
AP		150MG/VIAL	A091510 002	May 29, 2012	May	NEWA
AP		450MG/VIAL	A091510 003	May 29, 2012	May	NEWA
	PARAPLATIN					
	@ CORDEN PHARMA	50MG/VIAL	N019880 001	Mar 03, 1989	Feb	CAHN
	@	150MG/VIAL	N019880 002	Mar 03, 1989	Feb	CAHN
	@	450MG/VIAL	N019880 003	Mar 03, 1989	Feb	CAHN

## INJECTABLE; IV (INFUSION)

## CARBOPLATIN

AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	Jan	NEWA
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
AP		150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
AP		450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
AP		600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN

CARFILZOMIB

## POWDER; INTRAVENOUS

## KYPROLIS

+	ONYX PHARMS	60MG/VIAL	N202714 001	Jul 20, 2012	Jul	NEWA
---	-------------	-----------	-------------	--------------	-----	------

CARISOPRODOL

## TABLET; ORAL

## CARISOPRODOL

AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN
----	-------------	-------	-------------	--------------	-----	------

CEFACLOR

## CAPSULE; ORAL

## CEFACLOR

## @ RANBAXY

## @

	EQ 250MG BASE	A064156 001	Aug 28, 1997	Apr	DISC
	EQ 500MG BASE	A064156 002	Aug 28, 1997	Apr	DISC

## FOR SUSPENSION; ORAL

## CEFACLOR

## @ RANBAXY

	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Apr	DISC
AB	+ EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Feb	CTEC
	@ EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Apr	DISC
AB	+ EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Feb	CTEC
	@ EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Apr	DISC
AB	+ EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Feb	CTEC
	@ EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Apr	DISC
AB	+ EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Feb	CTEC
AB	YUNG SHIN PHARM EQ 125MG BASE/5ML	A065412 001	Feb 17, 2012	Feb	NEWA
AB	EQ 187MG BASE/5ML	A065412 002	Feb 17, 2012	Feb	NEWA
AB	EQ 250MG BASE/5ML	A065412 003	Feb 17, 2012	Feb	NEWA
AB	EQ 375MG BASE/5ML	A065412 004	Feb 17, 2012	Feb	NEWA

## TABLET, CHEWABLE; ORAL

## RANICLOR

@	RANBAXY LABS LTD	EQ 125MG BASE	A065092 001	Dec 22, 2003	Apr	DISC
@		EQ 187MG BASE	A065092 002	Dec 22, 2003	Apr	DISC
@		EQ 250MG BASE	A065092 003	Dec 22, 2003	Apr	DISC
@		EQ 375MG BASE	A065092 004	Dec 22, 2003	Apr	DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

## CAPSULE; ORAL

## CEFADROXIL

@	RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999	Apr	DISC
---	------------------	---------------	-------------	--------------	-----	------

## TABLET; ORAL

## CEFADROXIL

>D>	+	IVAX SUB TEVA PHARMS	EQ 1GM BASE	A062774 001	Apr 08, 1987	Aug	CAHN
	@	RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999	Apr	DISC
>A>	+	TEVA PHARMS	EQ 1GM BASE	A062774 001	Apr 08, 1987	Aug	CAHN

CEFAZOLIN SODIUM

## INJECTABLE; INJECTION

## CEFAZOLIN AND DEXTROSE

B BRAUN	EQ 2GM BASE/VIAL	N050779 003	Jan 13, 2012	May	NEWA
---------	------------------	-------------	--------------	-----	------

CEFDITOREN PIVOXIL

## TABLET; ORAL

## SPECTRACEF

VANSEN PHARMA	200MG	N021222 001	Aug 29, 2001	Mar	CAHN
+	400MG	N021222 002	Jul 21, 2008	Mar	CAHN

CEFEPIME HYDROCHLORIDE

## INJECTABLE; INJECTION

## CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202268 001	Jul 30, 2012	Jul	NEWA
AP		EQ 2GM BASE/VIAL	A202268 002	Jul 30, 2012	Jul	NEWA

CEFIXIME

## CAPSULE; ORAL

## SUPRAX

+	LUPIN LTD	400MG	N203195 001	Jun 01, 2012	Jun	NEWA
---	-----------	-------	-------------	--------------	-----	------

CEFOTAXIME SODIUM

## INJECTABLE; INJECTION

## CLAFORAN

AP	+	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD

CEFOXITIN SODIUM

## INJECTABLE; INJECTION

## CEFOXITIN

AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Jul	CAIN
AP		EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Jul	CAIN
AP		EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Jul	CAIN

CEFPROZIL

## FOR SUSPENSION; ORAL

## CEFPROZIL

AB	APOTEX INC	125MG/5ML	A065351 001	Feb 29, 2012	Feb	NEWA
----	------------	-----------	-------------	--------------	-----	------

## FOR SUSPENSION; ORAL

	CEFPROZIL						
AB	APOTEX INC	250MG/5ML	A065351	002	Feb 29, 2012	Feb	NEWA
	@ RANBAXY LABS LTD	125MG/5ML	A065202	001	Jun 30, 2006	Apr	DISC
	@	250MG/5ML	A065202	002	Jun 30, 2006	Apr	DISC

## TABLET; ORAL

	CEFPROZIL						
	@ RANBAXY LABS LTD	250MG	A065198	001	Dec 13, 2006	Apr	DISC
	@	500MG	A065198	002	Dec 13, 2006	Apr	DISC
	CEFZIL						
	@ CORDEN PHARMA	250MG	N050664	001	Dec 23, 1991	Feb	CAHN
	@	500MG	N050664	002	Dec 23, 1991	Feb	CAHN

CEFTAZIDIME

## INJECTABLE; INJECTION

	FORTAZ						
AP	+ COVIS PHARMA	500MG/VIAL	N050578	001	Jul 19, 1985	Apr	CAHN
AP	+	1GM/VIAL	N050578	002	Jul 19, 1985	Apr	CAHN
AP	+	2GM/VIAL	N050578	003	Jul 19, 1985	Apr	CAHN
AP	+	6GM/VIAL	N050578	004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

## INJECTABLE; INJECTION

	FORTAZ IN PLASTIC CONTAINER						
	@ COVIS PHARMA	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr	CAHN
	+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr	CAHN
	+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr	CAHN

CEFTRIAZONE SODIUM

## INJECTABLE; INJECTION

	CEFTRIAZONE							
>A>	AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Aug	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Aug	NEWA
	AP	+ SANDOZ INC	EQ 1GM BASE/VIAL	A065204	001	May 03, 2005	Mar	CRLD
	AP	+	EQ 2GM BASE/VIAL	A065204	002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

## TABLET; ORAL

	CEFUROXIME AXETIL						
	@ RANBAXY LABS LTD	EQ 125MG BASE	A065043	003	Feb 15, 2002	Apr	DISC
	@	EQ 250MG BASE	A065043	002	Feb 15, 2002	Apr	DISC
	@	EQ 500MG BASE	A065043	001	Feb 15, 2002	Apr	DISC

CEFUROXIME SODIUM

## INJECTABLE; IM-IV

	ZINACEF						
AB	+ COVIS PHARMA	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Apr	CAHN
	INJECTABLE; INJECTION						
	ZINACEF						
AP	+ COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr	CAHN
AP	+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr	CAHN
	ZINACEF IN PLASTIC CONTAINER						
	+ COVIS PHARMA	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Apr	CAHN
	+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Apr	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

KEFLEX

@ SHIONOGI INC	EQ 100MG BASE/ML	N050406 003	Jul	CAHN
@	EQ 125MG BASE/5ML	N050406 001	Jul	CAHN
@	EQ 250MG BASE/5ML	N050406 002	Jul	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	@ RANBAXY LABS LTD	5MG/5ML	A077472 001	Jun 18, 2008	Jul	DISC
	SILARX	5MG/5ML	A078876 001	May 11, 2012	Apr	NEWA

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+	ASPEN GLOBAL INC	2MG	N010669 002		May	CAHN
---	------------------	-----	-------------	--	-----	------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	CORNERSTONE THERAP	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012	Jun	NEWA
----	--------------------	---	-------------	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

	NYCOMED GMBH	0.08MG/INH	N021658 002	Jan 10, 2008	May	CAHN
+		0.16MG/INH	N021658 003	Jan 10, 2008	May	CAHN

AEROSOL, METERED; NASAL

ZETONNA

+	NYCOMED GMBH	0.037MG/INH	N202129 001	Jan 20, 2012	Jan	NEWA
---	--------------	-------------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

OMNARIS

+	NYCOMED GMBH	0.05MG/INH	N022004 001	Oct 20, 2006	May	CAHN
---	--------------	------------	-------------	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076435 001	Dec 29, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A077896 001	Jun 10, 2008	Jan	CAHN
AB	GLENMARK GENERICS	0.77%	A091595 001	Feb 29, 2012	Feb	NEWA

SHAMPOO; TOPICAL

CICLOPIROX

AT	FOUGERA PHARMS	1%	A090146 001	May 25, 2010	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT	MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007	Feb	CAHN
----	------------------	----	-------------	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076422 001	Aug 06, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP	EMCURE PHARMS LTD	EQ 75MG BASE/ML	A202501 001	Jul 26, 2012	Jul	NEWA
AP	MYLAN LLC	EQ 75MG BASE/ML	A201276 001	Jun 27, 2012	Jun	NEWA
VISTIDE						
AP	+ GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638 001	Jun 26, 1996	Jun	CFTG

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@	HOSPIRA	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995	Jun	DISC
@		EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995	Jun	DISC

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@	TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006	Mar	DISC
@		400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006	Jan	DISC
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
@	BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008	Jun	DISC
@		400MG/200ML	A077888 002	Mar 18, 2008	Jun	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005	Jan	DISC
@		EQ 250MG BASE	A076426 002	Jun 15, 2005	Jan	DISC
@		EQ 500MG BASE	A076426 003	Jun 15, 2005	Jan	DISC
@		EQ 750MG BASE	A076426 004	Jun 15, 2005	Jan	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007	Apr	NEWA
----	--------------------	-------------------------	-------------	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	SANDOZ INC	EQ 2MG BASE/ML	A200159 001	Feb 03, 2012	Jan	NEWA
CISATRACURIUM BESYLATE PRESERVATIVE FREE						
AP	SANDOZ INC	EQ 2MG BASE/ML	A200154 001	Feb 03, 2012	Jan	NEWA
AP		EQ 10MG BASE/ML	A200154 002	Feb 03, 2012	Jan	NEWA
NIMBEX						
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 001	Dec 15, 1995	Jan	CFTG
NIMBEX PRESERVATIVE FREE						
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 003	Dec 15, 1995	Jan	CFTG
AP	+ ABBOTT	EQ 10MG BASE/ML	N020551 002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP	ONCO THERAPIES LTD	1MG/ML	A091062 001	Apr 18, 2012	Apr	NEWA
@	TEVA PARENTERAL	1MG/ML	A074814 001	May 16, 2000	Mar	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D>	AB	IVAX SUB TEVA PHARMS	EQ 10MG BASE	A077048 001	Nov 16, 2004	Aug	CAHN
>D>	AB		EQ 20MG BASE	A077048 002	Nov 16, 2004	Aug	CAHN
>D>	AB		EQ 40MG BASE	A077048 003	Nov 16, 2004	Aug	CAHN
>D>	AB	SANDOZ	EQ 10MG BASE	A077035 001	Oct 28, 2004	Aug	DISC
>A>	@		EQ 10MG BASE	A077035 001	Oct 28, 2004	Aug	DISC
>D>	AB		EQ 20MG BASE	A077035 002	Oct 28, 2004	Aug	DISC
>A>	@		EQ 20MG BASE	A077035 002	Oct 28, 2004	Aug	DISC
>D>	AB		EQ 40MG BASE	A077035 003	Oct 28, 2004	Aug	DISC
>A>	@		EQ 40MG BASE	A077035 003	Oct 28, 2004	Aug	DISC
>A>	AB	TEVA PHARMS	EQ 10MG BASE	A077048 001	Nov 16, 2004	Aug	CAHN
>A>	AB		EQ 20MG BASE	A077048 002	Nov 16, 2004	Aug	CAHN
>A>	AB		EQ 40MG BASE	A077048 003	Nov 16, 2004	Aug	CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+	FERRING PHARMS AS	12GM/PACKET;3.5GM/PACKET;10MG/PAC	N202535 001	Jul 16, 2012	Jul	NEWA
		KET				

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	AUROBINDO	250MG	A065489 001	Jul 25, 2012	Jul	NEWA
AB		500MG	A065489 002	Jul 25, 2012	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

>D>	AB	SANDOZ	500MG	A065250 001	Aug 25, 2005	Aug	DISC
>A>	@		500MG	A065250 001	Aug 25, 2005	Aug	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>A>	AA	LYNE	EQ 75MG BASE/5ML	A201821 001	Aug 28, 2012	Aug	NEWA
-----	----	------	------------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 2% BASE	A065139 001	Dec 27, 2004	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A064160 001	Jan 28, 2000	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639 001	Aug 30, 1989	May	CFTG
AP	+		EQ 12MG BASE/ML	N050639 002	Aug 30, 1989	May	CFTG
AP	+		EQ 18MG BASE/ML	N050639 003	Apr 10, 1991	May	CFTG

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692 001	May 31, 2012	May	NEWA
AP			EQ 12MG BASE/ML	A201692 002	May 31, 2012	May	NEWA
AP			EQ 18MG BASE/ML	A201692 003	May 31, 2012	May	NEWA

## LOTION; TOPICAL

	CLINDAMYCIN PHOSPHATE								
AB	FOUGERA PHARMS	EQ 1% BASE		A065067	001	Jan 31, 2002	Jan	CAHN	

## SOLUTION; TOPICAL

	CLINDAMYCIN PHOSPHATE								
AT	FOUGERA PHARMS	EQ 1% BASE		A065254	001	Feb 14, 2006	Jan	CAHN	

CLINDAMYCIN PHOSPHATE; TRETINOIN

## GEL; TOPICAL

	VELTIN								
BX	+ STIEFEL GSK	1.2%;0.025%		N050803	001	Jul 16, 2010	May	CRLD	

CLOBAZAM

## TABLET; ORAL

	ONFI								
	LUNDBECK LLC	5MG		N202067	001	Oct 21, 2011	Mar	CAHN	
		10MG		N202067	002	Oct 21, 2011	Mar	CAHN	
	+	20MG		N202067	003	Oct 21, 2011	Mar	CAHN	

CLOBETASOL PROPIONATE

## AEROSOL, FOAM; TOPICAL

	CLOBETASOL PROPIONATE								
AB1	PERRIGO ISRAEL	0.05%		A077763	001	Mar 10, 2008	Jul	CTEC	
AB2		0.05%		A201402	001	Aug 14, 2012	Jul	NEWA	
	OLUX								
AB1	+ STIEFEL LABS INC	0.05%		N021142	001	May 26, 2000	Jul	CTEC	
	OLUX E								
AB2	+ STIEFEL LABS INC	0.05%		N022013	001	Jan 12, 2007	Jul	CFTG	

## CREAM; TOPICAL

	CLOBETASOL PROPIONATE								
>D>	@ COREPHARMA	0.05%		A075338	001	Feb 09, 2001	Aug	CAHN	
	@ G AND W LABS INC	0.05%		A074139	001	Aug 03, 1994	Jun	CAHN	
>A>	@ RENAISSANCE PHARMA	0.05%		A075338	001	Feb 09, 2001	Aug	CAHN	
	CLOBETASOL PROPIONATE (EMOLLIENT)								
>D>	@ COREPHARMA	0.05%		A075733	001	Aug 22, 2001	Aug	CAHN	
AB2	FOUGERA PHARMS	0.05%		A075430	001	May 26, 1999	Jan	CAHN	
>A>	@ RENAISSANCE PHARMA	0.05%		A075733	001	Aug 22, 2001	Aug	CAHN	
	TEMOVATE								
AB1	+ FOUGERA PHARMS	0.05%		N019322	001	Dec 27, 1985	Jan	CAHN	
	GEL; TOPICAL								
	CLOBETASOL PROPIONATE								
AB	FOUGERA PHARMS	0.05%		A075368	001	Feb 15, 2000	Jan	CAHN	
	TEMOVATE								
AB	+ FOUGERA PHARMS	0.05%		N020337	001	Apr 29, 1994	Jan	CAHN	
	LOTION; TOPICAL								
	CLOBETASOL PROPIONATE								
AB	TARO	0.05%		A200302	001	Jul 02, 2012	Jun	NEWA	
	OINTMENT; TOPICAL								
	CLOBETASOL PROPIONATE								
>D>	@ COREPHARMA	0.05%		A075057	001	Aug 12, 1998	Aug	CAHN	
AB	FOUGERA PHARMS	0.05%		A074407	001	Feb 23, 1996	Jan	CAHN	
>A>	@ RENAISSANCE PHARMA	0.05%		A075057	001	Aug 12, 1998	Aug	CAHN	
	TEMOVATE								
AB	+ FOUGERA PHARMS	0.05%		N019323	001	Dec 27, 1985	Jan	CAHN	

SHAMPOO; TOPICAL

	CLOBETASOL PROPIONATE						
AB	PERRIGO ISRAEL	0.05%	A090974	001	Aug 09, 2012	Jul	NEWA
	SOLUTION; TOPICAL						
	CLOBETASOL PROPIONATE						
AT	FOUGERA PHARMS	0.05%	A075391	001	Feb 08, 1999	Jan	CAHN
	@ G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Jun	CAHN
	TEMOVATE						
AT	+ FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jan	CAHN

CLONIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

	DURACLON						
AP	MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615	001	Oct 02, 1996	Feb	CAHN
AP	+	5 MG/10 ML (0.5 MG/ML)	N020615	002	Apr 27, 1999	Feb	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	KAPVAY						
	SHIONOGI INC	0.2MG	N022331	004	Sep 28, 2010	May	CMFD

CLOPIDOGREL BISULFATE

## TABLET; ORAL

	CLOPIDOGREL BISULFATE						
AB	APOTEX INC	EQ 75MG BASE	A076274	001	May 17, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540	001	May 17, 2012	Apr	NEWA
AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008	Mar	CMFD
AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023	001	May 17, 2012	Apr	NEWA
AB	GATE PHARMS	EQ 300MG BASE	A091216	001	May 17, 2012	Apr	NEWA
AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665	001	May 17, 2012	Apr	NEWA
AB		EQ 300MG BASE	A077665	002	May 17, 2012	Apr	NEWA
AB	ROXANE	EQ 75MG BASE	A078004	001	May 17, 2012	Apr	NEWA
AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494	001	May 17, 2012	Apr	NEWA
AB	TEVA	EQ 75MG BASE	A076999	001	May 17, 2012	Apr	NEWA
AB	TEVA PHARMS	EQ 300MG BASE	A090625	001	May 17, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844	001	May 17, 2012	Apr	NEWA
AB	WOCKHARDT LTD	EQ 75MG BASE	A202266	001	Aug 14, 2012	Jul	NEWA
	PLAVIX						
AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997	Mar	CTEC
AB	+	EQ 300MG BASE	N020839	002	Sep 20, 2007	Apr	CTEC

CLORAZEPATE DIPOTASSIUM

## CAPSULE; ORAL

	TRANXENE						
	@ LUNDBECK LLC	3.75MG	N017105	001		Mar	CAHN
	@	7.5MG	N017105	002		Mar	CAHN
	@	15MG	N017105	003		Mar	CAHN
	TABLET; ORAL						
	TRANXENE						
AB	LUNDBECK LLC	3.75MG	N017105	006		Mar	CAHN
AB		7.5MG	N017105	007		Mar	CAHN
AB	+	15MG	N017105	008		Mar	CAHN
	TRANXENE SD						
	@ LUNDBECK LLC	11.25MG	N017105	005		Mar	CAHN
	@	22.5MG	N017105	004		Mar	CAHN



CLOTRIMAZOLE

CREAM; TOPICAL  
 CLOTRIMAZOLE  
 AB FOUGERA PHARMS 1% A078338 001 Sep 02, 2008 Jan CAHN

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT  
 JAZZ 12.5MG N021590 004 May 30, 2007 Apr CAHN  
 25MG N021590 001 Feb 10, 2004 Apr CAHN  
 @ 50MG N021590 003 Jun 03, 2005 Apr CAHN  
 + 100MG N021590 002 Feb 10, 2004 Apr CAHN  
 150MG N021590 005 Jul 09, 2010 Apr CAHN  
 200MG N021590 006 Jul 09, 2010 Apr CAHN  
 JAZZ PHARMS III 12.5MG N021590 004 May 30, 2007 Jun CAHN  
 25MG N021590 001 Feb 10, 2004 Jun CAHN  
 @ 50MG N021590 003 Jun 03, 2005 Jun CAHN  
 + 100MG N021590 002 Feb 10, 2004 Jun CAHN  
 150MG N021590 005 Jul 09, 2010 Jun CAHN  
 200MG N021590 006 Jul 09, 2010 Jun CAHN

>A> COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

>A> TABLET; ORAL  
 >A> STRIBILD  
 >A> + GILEAD SCIENCES INC 150MG;150MG;200MG;300MG N203100 001 Aug 27, 2012 Aug NEWA

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL  
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE  
 AA TRIS PHARMA INC 10MG/5ML;6.25MG/5ML A200386 001 Jun 29, 2012 Jun NEWA

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE  
 PARAGARD T 380A  
 + TEVA WOMENS 309MG/COPPER N018680 001 Nov 15, 1984 May CAHN

COSYNTROPIN

INJECTABLE; INJECTION  
 COSYNTROPIN  
 AP INNOPHARMA INC 0.25MG/VIAL A202147 001 Jun 29, 2012 Jun NEWA

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION  
 INTAL  
 @ KING PFIZER 0.8MG/INH N018887 001 Dec 05, 1985 Jun DISC  
 CONCENTRATE; ORAL  
 GASTROCROM  
 AA + JAZZ PHARMS COMMERCL 100MG/5ML N020479 001 Feb 29, 1996 Mar CAHN  
 AA + JAZZ PHARMS INTL 100MG/5ML N020479 001 Feb 29, 1996 Jun CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL  
 CYCLOBENZAPRINE HYDROCHLORIDE  
 AB + MYLAN PHARMS INC 10MG A073144 001 May 30, 1991 Jul CRLD  
 AB PROSAM LABS 5MG A077291 001 Feb 03, 2006 Feb CAHN

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE  
 AB            PROSAM LABS            10MG            A077209 001    Oct 04, 2005    Feb    CAHN  
                  FLEXERIL  
                  @ JANSSEN RES AND DEV    5MG            N017821 001                            Jul    DISC  
                  @                            10MG            N017821 002                            Jul    DISC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION  
 CYTOXAN  
 AP    +    BAXTER HLTHCARE            500MG/VIAL            N012142 003                            Apr    CRLD  
 AP    +                            1GM/VIAL            N012142 004    Aug 30, 1982    Apr    CRLD  
 AP    +                            2GM/VIAL            N012142 005    Aug 30, 1982    Apr    CRLD

CYCLOSPORINE

CAPSULE; ORAL  
 CYCLOSPORINE  
 AB1            WATSON LABS INC            25MG            A065044 002    Dec 20, 2000    May    CAHN  
 AB1    100MG            A065044 001    Dec 20, 2000    May    CAHN

CYTARABINE

INJECTABLE; INJECTION  
 CYTARABINE  
 AP            ONCO THERAPIES LTD        100MG/ML            A201784 001    Jan 30, 2012    Jan    NEWA

DACTINOMYCIN

INJECTABLE; INJECTION  
 COSMEGEN  
 AP    +    LUNDBECK LLC            0.5MG/VIAL            N050682 001                            Mar    CAHN

DANTROLENE SODIUM

CAPSULE; ORAL  
 DANTROLENE SODIUM  
                  @ MIKAH PHARMA            25MG            A076686 001    Oct 24, 2005    Jul    CAHN  
                  @                            50MG            A076686 002    Oct 24, 2005    Jul    CAHN  
                  @                            100MG            A076686 003    Oct 24, 2005    Jul    CAHN

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
 DAPIPRAZOLE HYDROCHLORIDE  
                  @ FERA PHARMS            0.5%            N019849 001    Dec 31, 1990    Jul    CTNA

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL  
 PREZISTA  
 +    JANSSEN PRODS            EQ 100MG BASE/ML            N202895 001    Dec 16, 2011    Feb    CAHN  
 TABLET; ORAL  
 PREZISTA  
                  JANSSEN PRODS            EQ 75MG BASE            N021976 004    Dec 18, 2008    Feb    CAHN  
                                             EQ 150MG BASE            N021976 005    Dec 18, 2008    Feb    CAHN  
                  @                            EQ 300MG BASE            N021976 001    Jun 23, 2006    Feb    CAHN  
                                             EQ 400MG BASE            N021976 003    Oct 21, 2008    Feb    CAHN  
 +                            EQ 600MG BASE            N021976 002    Feb 25, 2008    Feb    CAHN

DEMECLOCYCLINE HYDROCHLORIDE

	TABLET; ORAL						
	DECLOMYCIN						
	@ COREPHARMA	150MG		N050261 002		Jul	DISC
	@	300MG		N050261 003		Jul	DISC
	DEMECLOCYCLINE HYDROCHLORIDE						
AB	+ AMNEAL PHARM	300MG		A065425 002	Feb 27, 2008	Jul	CRLD

DESFLURANE

LIQUID; INHALATION  
SUPRANE

	+ BAXTER HLTHCARE	99.9%		N020118 001	Sep 18, 1992	Jul	CAHN
--	-------------------	-------	--	-------------	--------------	-----	------

DESLORATADINE

TABLET; ORAL

	DESLORATADINE						
AB	BELCHER PHARMS	5MG		A078355 001	Apr 19, 2012	Apr	NEWA
AB	MYLAN PHARMS INC	5MG		A078351 001	Feb 10, 2012	Jan	NEWA

DESMOPRESSIN ACETATE

SOLUTION; NASAL  
DDAVP

AB	+ SANOFI AVENTIS US	0.01%		N017922 001		Mar	CFTG
	DESMOPRESSIN ACETATE						
AB	SUN PHARM INDS	0.01%		A077212 001	Apr 12, 2012	Mar	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

	MIRCETTE						
AB	+ TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG		N020713 001	Apr 22, 1998	Jun	CAHN
	VIORELE						
AB	GLENMARK GENERICS	.15MG,N/A; 0.02MG,0.01MG		A091346 001	Apr 02, 2012	Mar	NEWA

DESONIDE

LOTION; TOPICAL

	DESONIDE						
AB	FOUGERA PHARMS	0.05%		A075860 001	Mar 19, 2002	Jan	CAHN

OINTMENT; TOPICAL

	DESONIDE						
AB	FOUGERA PHARMS	0.05%		A075751 001	Mar 12, 2001	Jan	CAHN

DESOXIMETASONE

CREAM; TOPICAL

	DESOXIMETASONE						
AB	FOUGERA PHARMS	0.25%		A078369 001	Jun 29, 2010	Jan	CAHN
	TOPICORT						
	+ TARO	0.05%		A073210 001	Nov 30, 1990	Apr	CTNA
	+	0.25%		A073193 001	Nov 30, 1990	Apr	CTNA
	@ TARO PHARMS NORTH	0.25%		N017856 001		Apr	DISC
	TOPICORT LP						
	@ TARO PHARMS NORTH	0.05%		N018309 001		Apr	DISC
	GEL; TOPICAL						
	TOPICORT						
AB	+ TARO	0.05%		A074904 001	Jul 14, 1998	Apr	CTNA
	@ TARO PHARMS NORTH	0.05%		N018586 001	Mar 29, 1982	Apr	DISC

OINTMENT; TOPICAL

	DESOXIMETASONE								
AB	+ TARO	0.25%	A074286	001	Jun 07, 1996	Mar	CRLD		
	TOPICORT								
	+ TARO	0.25%	A074286	001	Jun 07, 1996	Apr	CTNA		
	@ TARO PHARMS NORTH	0.25%	N018763	001	Sep 30, 1983	Mar	DISC		

DEXAMETHASONE SODIUM PHOSPHATE

## INJECTABLE; INJECTION

	DEXAMETHASONE SODIUM PHOSPHATE								
AP	+ APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572	001	Apr 22, 2005	Feb	CRLD		

DEXRAZOXANE HYDROCHLORIDE

## INJECTABLE; INJECTION

	TOTECT								
	+ APRICUS PHARMS	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Jun	CAHN		

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

## SYRUP; ORAL

	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE								
AA	TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	Jun	NEWA		

DIAZEPAM

## INJECTABLE; INJECTION

	DIAZEPAM								
	@ HIKMA MAPLE	5MG/ML	A071310	001	Jul 17, 1987	Jul	CAHN		
	@	5MG/ML	A071308	001	Jul 17, 1987	Jul	CAHN		
	@	5MG/ML	A070312	001	Dec 16, 1985	Jul	CAHN		
	@	5MG/ML	A071309	001	Jul 17, 1987	Jul	CAHN		
	@	5MG/ML	A070313	001	Dec 16, 1985	Jul	CAHN		
	@	5MG/ML	A070311	001	Dec 16, 1985	Jul	CAHN		
	@ HOSPIRA	5MG/ML	A071584	001	Oct 13, 1987	Apr	DISC		

DICLOFENAC POTASSIUM

## CAPSULE; ORAL

	ZIPSOR								
	+ DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Jun	CAHN		

DICLOFENAC SODIUM; MISOPROSTOL

## TABLET, DELAYED RELEASE; ORAL

	ARTHROTEC								
AB	GD SEARLE LLC	50MG;0.2MG	N020607	001	Dec 24, 1997	Jun	CFTG		
AB	+	75MG;0.2MG	N020607	002	Dec 24, 1997	Jun	CFTG		
	DICLOFENAC SODIUM AND MISOPROSTOL								
AB	WATSON LABS INC	50MG;0.2MG	A201089	001	Jul 09, 2012	Jun	NEWA		
AB		75MG;0.2MG	A201089	002	Jul 09, 2012	Jun	NEWA		

DIDANOSINE

## TABLET, CHEWABLE; ORAL

	DIDANOSINE								
	AUROBINDO	100MG	A077275	001	Aug 14, 2012	Jul	NEWA		
		150MG	A077275	002	Aug 14, 2012	Jul	NEWA		
		200MG	A077275	003	Aug 14, 2012	Jul	NEWA		

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002	Jan	CAHN
AB1	+		0.05%	A075187	001	Mar 30, 1998	Jan	CAHN

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB		FOUGERA PHARMS	0.05%	A075374	001	Apr 27, 1999	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB		EMCURE PHARMS USA	500MG	A202845	001	Mar 08, 2012	Feb	NEWA
AB	+	TEVA	500MG	A073673	001	Jul 31, 1992	Feb	CTEC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP		HIKMA MAPLE	0.25MG/ML	A083391	001		Jul	CAHN
		@ HOSPIRA	0.25MG/ML	A040093	001	May 16, 1996	Jun	DISC

TABLET; ORAL

DIGOXIN

		@ MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jul	CAHN
		@	0.25MG	A040282	002	Dec 23, 1999	Jul	CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

AP		HIKMA FARMACEUTICA	5MG/ML	A202651	001	Aug 09, 2012	Jul	NEWA
AP		HIKMA MAPLE	5MG/ML	A078538	001	Dec 17, 2008	Jul	CAHN
		@ TEVA PARENTERAL	5MG/ML	A074894	001	Aug 26, 1997	Jan	DISC

DINOPROSTONEINSERT, EXTENDED RELEASE; VAGINAL  
CERVIDIL

+	FERRING CONTROLLED	10MG	N020411	001	Mar 30, 1995	Jul	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

@	MCNEIL CONS	50MG/ML	N006146	002		Mar	DISC
---	-------------	---------	---------	-----	--	-----	------

BENADRYL PRESERVATIVE FREE

@	MCNEIL CONS	50MG/ML	N009486	001		Mar	DISC
---	-------------	---------	---------	-----	--	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	BAXTER HLTHCARE	50MG/ML	A080817	002		Apr	CRLD
		@ HIKMA MAPLE	50MG/ML	A083183	001		Jul	CAHN
AP	+		50MG/ML	A080817	002		Jul	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP		HIKMA MAPLE	5MG/ML	A074521	001	Oct 18, 1996	Jul	CAHN
		@ TEVA PARENTERAL	5MG/ML	A074952	001	Nov 26, 1997	Jan	DISC

TABLET; ORALDIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB		75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISOPYRAMIDE PHOSPHATE

## CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

@	NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987	Jun	DISC
---	---------------	---------------	-------------	--------------	-----	------

DIVALPROEX SODIUM

## TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB	DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161 001	Mar 15, 2012	Feb	NEWA
AB	REDDYS	EQ 500MG VALPROIC ACID	A090070 001	Mar 12, 2012	Feb	NEWA

DOCETAXEL

## INJECTABLE; INJECTION

DOCETAXEL

AP	ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195 003	Apr 20, 2012	Apr	NEWA
AP		20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jan	CTEC
AP		80MG/4ML (20MG/ML)	N201195 004	Apr 20, 2012	Apr	NEWA
AP		80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jan	CTEC
		160MG/8ML (20MG/ML)	N201195 005	Apr 20, 2012	Apr	NEWA
AP	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	Jan	NEWA
AP		80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	Jan	NEWA
AP	+ SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449 003	Aug 03, 2010	Apr	CTEC
AP	+	80MG/4ML (20MG/ML)	N020449 004	Aug 02, 2010	Apr	CTEC

DONEPEZIL HYDROCHLORIDE

## TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	INDICUS PHARMA	5MG	A201634 001	Jun 13, 2012	Jul	NEWA	
AB		10MG	A201634 002	Jun 13, 2012	Jul	NEWA	
>A>	AB	MACLEODS PHARMS LTD	5MG	A201146 001	Aug 17, 2012	Aug	NEWA
>A>	AB		10MG	A201146 002	Aug 17, 2012	Aug	NEWA
AB	PRINSTON INC	5MG	A200292 001	May 31, 2011	Jun	CAHN	
AB		10MG	A200292 002	May 31, 2011	Jun	CAHN	

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

## SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667 001	Feb 01, 2012	Feb	NEWA
---	-------------------	-------------------------	-------------	--------------	-----	------

DOXAZOSIN MESYLATE

## TABLET; ORAL

DOXAZOSIN MESYLATE

@	NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000	Feb	DISC
@		EQ 2MG BASE	A075609 002	Oct 18, 2000	Feb	DISC
@		EQ 4MG BASE	A075609 003	Oct 18, 2000	Feb	DISC
@		EQ 8MG BASE	A075609 004	Oct 18, 2000	Feb	DISC

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+	FOUGERA PHARMS	5%	N020126 001	Apr 01, 1994	Jan	CAHN
---	----------------	----	-------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	2MG/ML	A200901 001	Feb 14, 2012	Jan	NEWA
AP	SANDOZ INC	2MG/ML	A200146 001	Jul 18, 2012	Jul	NEWA
AP	SUN PHARM INDS	2MG/ML	A091418 001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CAHN
+		50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	MYLAN PHARMS INC	EQ 150MG BASE	A202778 001	Jun 08, 2012	May	NEWA
	@ SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
	@	EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC
	MONODOX					
AB	AQUA PHARMS	EQ 50MG BASE	N050641 002	Feb 10, 1992	Jul	CAHN
AB		EQ 75MG BASE	N050641 003	Oct 18, 2006	Jul	CAHN
AB	+	EQ 100MG BASE	N050641 001	Dec 29, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE

@	SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
@		EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
@		EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXYCYCLINE

@	HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983	Jul	CAHN
@		EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983	Jul	CAHN
>A> AP	PFIZER	EQ 100MG BASE/VIAL	A091406 001	Aug 21, 2012	Aug	NEWA
	DOXYCYCLINE HYCLATE					
@	HIKMA MAPLE	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989	Jul	CAHN
@		EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	LARKEN LABS	EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CMFD
----	-------------	--------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DORYX

AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795 003	Jun 20, 2008	Jan	CTEC
		DOXYCYCLINE HYCLATE					
AB		MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012	Jan	NEWA

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

	BAYER HLTHCARE	0.25MG;0.5MG	N021355 001	Feb 29, 2012	Feb	NEWA
--	----------------	--------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL  
 ECONAZOLE NITRATE  
 AB + FOUGERA PHARMS 1% A076075 001 Nov 26, 2002 Jan CAHN

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL  
 COMPLERA  
 + GILEAD SCIENCES INC 200MG;EQ 25MG BASE;300MG N202123 001 Aug 10, 2011 Apr CAIN

ENALAPRIL MALEATE

TABLET; ORAL  
 ENALAPRIL MALEATE  
 @ SANDOZ INC 2.5MG A075621 001 Aug 22, 2000 Feb DISC  
 @ 2.5MG A075496 001 Aug 22, 2000 Jan DISC  
 @ 5MG A075621 002 Aug 22, 2000 Feb DISC  
 @ 5MG A075496 002 Aug 22, 2000 Jan DISC  
 @ 10MG A075621 003 Aug 22, 2000 Feb DISC  
 @ 10MG A075459 001 Aug 22, 2000 Jan DISC  
 @ 20MG A075621 004 Aug 22, 2000 Feb DISC  
 @ 20MG A075459 002 Aug 22, 2000 Jan DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL  
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE  
 @ SANDOZ INC 5MG;12.5MG A076116 001 Sep 19, 2001 Mar DISC  
 @ 10MG;25MG A076116 002 Sep 19, 2001 Mar DISC

ENFLURANE

LIQUID; INHALATION  
 ETHRANE  
 AN + BAXTER HLTHCARE 99.9% N017087 001 Jul CAHN

ENTACAPONE

TABLET; ORAL  
 COMTAN  
 AB + ORION PHARMA 200MG N020796 001 Oct 19, 1999 Jul CFTG  
 + 200MG N020796 001 Oct 19, 1999 May CAHN  
 ENTACAPONE  
 AB SUN PHARMA GLOBAL 200MG A090690 001 Jul 16, 2012 Jul NEWA  
 AB WOCKHARDT LTD 200MG A078941 001 Aug 16, 2012 Jul NEWA

>A> ENZALUTAMIDE

>A> CAPSULE; ORAL  
 >A> XTANDI  
 >A> + MEDIVATION 40MG N203415 001 Aug 31, 2012 Aug NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
 EPINASTINE HYDROCHLORIDE  
 AT LUITPOLD 0.05% A090951 001 Oct 31, 2011 Mar CAHN



EPINEPHRINE

INJECTABLE; IM-SC

ADRENACLICK

BX	+	COREPHARMA	EQ 0.15MG/DELIVERY	N020800 003	Nov 25, 2009	Mar	CAHN
BX	+		EQ 0.3MG/DELIVERY	N020800 004	Nov 25, 2009	Mar	CAHN
>A>		AUVI-Q					
>A>	BX	+	INTELLIJECT	EQ 0.15MG/DELIVERY	N201739 002	Aug 10, 2012	Aug NEWA
>A>	BX			EQ 0.3MG/DELIVERY	N201739 001	Aug 10, 2012	Aug NEWA
			TWINJECT 0.15				
BX	+	COREPHARMA	EQ 0.15MG/DELIVERY	N020800 002	May 28, 2004	Mar	CAHN
			TWINJECT 0.3				
BX	+	COREPHARMA	EQ 0.3MG/DELIVERY	N020800 001	May 30, 2003	Mar	CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

OCTOCAINE

AP	+	SEPTODONT	0.01MG/ML;2%	A084048 001		May	CRLD
			XYLOCAINE DENTAL WITH EPINEPHRINE				
		@ DENTSPLY PHARM	0.01MG/ML;2%	N021381 001		May	DISC
		@	0.02MG/ML;2%	N021381 002		May	DISC

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		CIPLA LTD	200MG/100ML (2MG/ML)	A065361 002	Oct 22, 2007	Mar	CAHN
AP			50MG/25ML (2MG/ML)	A065361 001	Oct 22, 2007	Mar	CAHN
AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075 001	Mar 25, 2010	Mar	CAHN
AP			200MG/100ML (2MG/ML)	A090075 002	Mar 25, 2010	Mar	CAHN
AP		ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599 001	Mar 12, 2012	Mar	NEWA
AP			200MG/100ML (2MG/ML)	A091599 002	Mar 12, 2012	Mar	NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

		ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260 002	Jun 28, 2012	Jun	NEWA
	+		EQ 1.5MG BASE/VIAL	N022260 001	Jun 27, 2008	May	CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB		WARNER CHILCOTT LLC	250MG	A062338 001		Jun	CAHN
----	--	---------------------	-------	-------------	--	-----	------

GEL; TOPICAL

E-GLADES

>D>		@ COREPHARMA	2%	A065009 001	Mar 18, 2002	Aug	CAHN
		@	2%	A065009 001	Mar 18, 2002	Jul	DISC
>A>		@ RENAISSANCE PHARMA	2%	A065009 001	Mar 18, 2002	Aug	CAHN

ERYTHROMYCIN

AT		FOUGERA PHARMS	2%	A064184 001	Sep 30, 1997	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

C-SOLVE-2

AT		FOUGERA PHARMS	2%	A062468 001	Jul 03, 1985	Jan	CMFD
----	--	----------------	----	-------------	--------------	-----	------

ERYTHROMYCIN

>D>		@ COREPHARMA	2%	A064127 001	Feb 14, 1997	Aug	CAHN
>A>		@ RENAISSANCE PHARMA	2%	A064127 001	Feb 14, 1997	Aug	CAHN

## SWAB; TOPICAL

## ERYCETE

@ JOHNSON AND JOHNSON 2%

N050594 001 Feb 15, 1985 Apr CAHN

## ERYTHROMYCIN

AT + FOUGERA PHARMS 2%

A065320 001 Jul 25, 2006 Jan CAHN

ESCITALOPRAM OXALATE

## SOLUTION; ORAL

## ESCITALOPRAM OXALATE

AA AMNEAL PHARMS EQ 5MG BASE/5ML A202227 001 Mar 14, 2012 Feb NEWA

AA AUROBINDO PHARMA LTD EQ 5MG BASE/5ML A079062 001 Apr 02, 2012 Mar NEWA

AA HETERO LABS LTD III EQ 5MG BASE/5ML A202221 001 Jun 12, 2012 May NEWA

AA TARO EQ 5MG BASE/5ML A079121 001 May 03, 2012 Apr NEWA

## LEXAPRO

AA + FOREST LABS EQ 5MG BASE/5ML N021365 001 Nov 27, 2002 Feb CFTG

## TABLET; ORAL

## ESCITALOPRAM OXALATE

&gt;A&gt; AB ACCORD HLTHCARE EQ 5MG BASE A202389 001 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A202389 002 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A202389 003 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB APOTEX INC EQ 5MG BASE A078777 001 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A078777 002 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A078777 003 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB AUROBINDO PHARMA LTD EQ 5MG BASE A090432 001 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A090432 002 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A090432 003 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB HIKMA PHARMS EQ 5MG BASE A078766 001 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A078766 002 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A078766 003 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB INVAGEN PHARMS EQ 5MG BASE A078604 001 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A078604 002 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A078604 003 Sep 11, 2012 Aug NEWA

AB IVAX SUB TEVA PHARMS EQ 5MG BASE A076765 001 Mar 14, 2012 Feb NEWA

AB EQ 10MG BASE A076765 002 Mar 14, 2012 Feb NEWA

AB EQ 20MG BASE A076765 003 Mar 14, 2012 Feb NEWA

&gt;A&gt; AB JUBILANT ORGANOSYS EQ 5MG BASE A202280 001 Sep 12, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A202280 002 Sep 12, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A202280 003 Sep 12, 2012 Aug NEWA

&gt;A&gt; AB LUPIN LTD EQ 5MG BASE A078169 001 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A078169 002 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A078169 003 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB MACLEODS PHARMS LTD EQ 5MG BASE A202210 001 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A202210 002 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A202210 003 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB STI PHARMA LLC EQ 5MG BASE A077512 001 Sep 12, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A077512 002 Sep 12, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A077512 003 Sep 12, 2012 Aug NEWA

&gt;A&gt; AB TORRENT PHARMS LTD EQ 5MG BASE A090939 001 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A090939 002 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A090939 003 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB ZYDUS PHARMS USA INC EQ 5MG BASE A077734 001 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 10MG BASE A077734 002 Sep 11, 2012 Aug NEWA

&gt;A&gt; AB EQ 20MG BASE A077734 003 Sep 11, 2012 Aug NEWA

## LEXAPRO

AB FOREST LABS EQ 5MG BASE N021323 001 Aug 14, 2002 Feb CFTG

AB EQ 10MG BASE N021323 002 Aug 14, 2002 Feb CFTG

	TABLET; ORAL								
	LEXAPRO								
AB	+	FOREST LABS	EQ 20MG BASE	N021323	003	Aug 14, 2002	Feb	CFTG	
	<u>ESMOLOL HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	BREVIBLOC								
AP	+	BAXTER HLTHCARE	10MG/ML	N019386	006	Feb 25, 2003	Jun	CAHN	
		@	10MG/ML	N019386	003	Aug 15, 1988	Jun	CAHN	
		@	20MG/ML	N019386	007	May 28, 2003	Jun	CAHN	
	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER								
+		BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003	Jun	CAHN	
	BREVIBLOC IN PLASTIC CONTAINER								
+		BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001	Jun	CAHN	
	<u>ESOMEPRAZOLE MAGNESIUM</u>								
	FOR SUSPENSION, DELAYED RELEASE; ORAL								
	NEXIUM								
		ASTRAZENECA	EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011	Jun	NEWA	
			EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011	Jun	NEWA	
	<u>ESTRADIOL</u>								
	CREAM; VAGINAL								
	ESTRACE								
+		WARNER CHILCOTT US	0.01%	A086069	001	Jan 31, 1984	Jun	CAHN	
	GEL, METERED; TRANSDERMAL								
	ELESTRIN								
+		JAZZ PHARMS COMMERCL	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Jun	CAHN	
	<u>ESTRADIOL ACETATE</u>								
	INSERT, EXTENDED RELEASE; VAGINAL								
	FEMRING								
		WARNER IRELAND	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	May	CAHN	
+			EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	May	CAHN	
	TABLET; ORAL								
	FEMTRACE								
		WARNER CHILCOTT LLC	0.45MG	N021633	001	Aug 20, 2004	Jun	CAHN	
			0.9MG	N021633	002	Aug 20, 2004	Jun	CAHN	
+			1.8MG	N021633	003	Aug 20, 2004	Jun	CAHN	
	<u>ESTRADIOL; NORETHINDRONE ACETATE</u>								
	TABLET; ORAL								
	ESTRADIOL AND NORETHINDRONE ACETATE								
AB		TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012	Feb	NEWA	
	<u>ESTROGENS, CONJUGATED SYNTHETIC A</u>								
	TABLET; ORAL								
	CENESTIN								
		TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Jun	CAHN	
			0.45MG	N020992	005	Feb 05, 2004	Jun	CAHN	
			0.625MG	N020992	002	Mar 24, 1999	Jun	CAHN	
			0.9MG	N020992	003	Mar 24, 1999	Jun	CAHN	
+			1.25MG	N020992	004	Mar 13, 2000	Jun	CAHN	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL		LEVONORGESTREL AND ETHINYL ESTRADIOL							
	+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	May	CRLD	
LOSEASONIQUE									
AB		TEVA BRANDED PHARM	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Jun	CAHN	
LYBREL									
	@	WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May	DISC	
PREVEN EMERGENCY CONTRACEPTIVE KIT									
	@	TEVA BRANDED PHARM	0.05MG;0.25MG	N020946	001	Sep 01, 1998	Jun	CAHN	
SEASONALE									
AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N021544	001	Sep 05, 2003	Jul	CAHN	
SEASONIQUE									
AB	+	TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	Jun	CAHN	
TABLET; ORAL-21		NORDETTE-21							
	@	TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982	Jun	CAHN	
TABLET; ORAL-28		FALMINA							
AB1		NOVAST LABS LTD	0.02MG;0.1MG	A090721	001	Mar 28, 2012	Mar	NEWA	
MARLISSA									
AB		GLENMARK GENERICS	0.03MG;0.15MG	A091452	001	Feb 29, 2012	Feb	NEWA	
MYZILRA									
AB		VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502	001	Nov 23, 2011	May	CDFR	
NORDETTE-28									
AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N018782	001	Jul 21, 1982	Jun	CAHN	

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL		ORTHO EVRA							
	+	JANSSEN PHARMS	0.75MG;6MG	N021180	001	Nov 20, 2001	Jun	CPOT	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28		ALYACEN 1/35							
AB		GLENMARK GENERICS	0.035MG;1MG	A091634	001	Jan 19, 2012	Jan	NEWA	
ALYACEN 7/7/7									
AB		GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636	001	Jan 19, 2012	Jan	NEWA	
OVCON-35									
AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001		Jun	CAHN	
OVCON-50									
	+	WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001		Jun	CAHN	
WERA									
AB		NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Mar	NEWA	
TABLET, CHEWABLE; ORAL		FEMCON FE							
AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jun	CAHN	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL		FEMHRT							
	+	WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jun	CAHN	
AB	+		0.005MG;1MG	N021065	002	Oct 15, 1999	Jun	CAHN	

## TABLET; ORAL

LO LOESTRIN FE

	+	WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501 001	Oct 21, 2010	Jun	CAHN
--	---	---------------------	-----------------------	-------------	--------------	-----	------

## TABLET; ORAL-21

ESTROSTEP 21

	@	WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 001	Oct 09, 1996	Jun	CAHN
--	---	---------------------	-----------------------------------	-------------	--------------	-----	------

LOESTRIN 21 1.5/30

AB		WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875 001		Jun	CAHN
----	--	---------------------	--------------	-------------	--	-----	------

LOESTRIN 21 1/20

AB		WARNER CHILCOTT LLC	0.02MG;1MG	N017876 001		Jun	CAHN
----	--	---------------------	------------	-------------	--	-----	------

## TABLET; ORAL-28

ESTROSTEP FE

AB	+	WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 002	Oct 09, 1996	Jun	CAHN
----	---	---------------------	-----------------------------------	-------------	--------------	-----	------

LOESTRIN FE 1.5/30

AB	+	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355 001		Jun	CAHN
----	---	---------------------	--------------	-------------	--	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

## TABLET; ORAL-28

MONO-LINYAH

AB		NOVAST LABS LTD	0.035MG;0.25MG	A090523 001	May 23, 2012	May	NEWA
----	--	-----------------	----------------	-------------	--------------	-----	------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB		GLENMARK GENERICS	0.035MG;0.25MG	A200538 001	Apr 05, 2012	Mar	NEWA
----	--	-------------------	----------------	-------------	--------------	-----	------

AB		LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541 001	Jun 25, 2012	Jun	NEWA
----	--	--------------	---	-------------	--------------	-----	------

TRI-LINYAH

AB		NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524 001	May 30, 2012	May	NEWA
----	--	-----------------	---	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

## TABLET; ORAL-28

ELINEST

AB		NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012	Mar	NEWA
----	--	-----------------	--------------	-------------	--------------	-----	------

ETHOTOIN

## TABLET; ORAL

PEGANONE

>D>	+	LUNDBECK INC	250MG	N010841 001		Aug	CAHN
-----	---	--------------	-------	-------------	--	-----	------

>D>	@		500MG	N010841 003		Aug	CAHN
-----	---	--	-------	-------------	--	-----	------

>A>	+	LUNDBECK LLC	250MG	N010841 001		Aug	CAHN
-----	---	--------------	-------	-------------	--	-----	------

>A>	@		500MG	N010841 003		Aug	CAHN
-----	---	--	-------	-------------	--	-----	------

ETODOLAC

## TABLET; ORAL

ETODOLAC

AB		PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Feb	CMFD
----	--	-------------	-------	-------------	--------------	-----	------

AB			500MG	A074819 002	Apr 28, 1998	Feb	CMFD
----	--	--	-------	-------------	--------------	-----	------

ETOMIDATE

## INJECTABLE; INJECTION

ETOMIDATE

AP		MYLAN INSTITUTIONAL	2MG/ML	A091297 001	Jun 20, 2012	Jun	NEWA
----	--	---------------------	--------	-------------	--------------	-----	------

ETOPOSIDE

## CAPSULE; ORAL

VEPESID

	@	CORDEN PHARMA	50MG	N019557 001	Dec 30, 1986	Feb	CAHN
--	---	---------------	------	-------------	--------------	-----	------

## CAPSULE; ORAL

VEPESID

@	CORDEN PHARMA	100MG	N019557 002	Dec 30, 1986	Feb	CAHN
---	---------------	-------	-------------	--------------	-----	------

## INJECTABLE; INJECTION

ETOPOSIDE

AP	+	APP PHARMS LLC	20MG/ML	A074983 001	Sep 30, 1998	Mar	CRLD
----	---	----------------	---------	-------------	--------------	-----	------

AP		BEDFORD	20MG/ML	A074290 001	Jul 17, 1995	Mar	CRLD
----	--	---------	---------	-------------	--------------	-----	------

VEPESID

@	CORDEN PHARMA	20MG/ML	N018768 001	Nov 10, 1983	Feb	CAHN
---	---------------	---------	-------------	--------------	-----	------

ETRAVIRINE

TABLET; ORAL

INTELENCE

JANSSEN R AND D	25MG	N022187 003	Mar 26, 2012	Mar	NEWA
-----------------	------	-------------	--------------	-----	------

	100MG	N022187 001	Jan 18, 2008	Feb	CAHN
--	-------	-------------	--------------	-----	------

+	200MG	N022187 002	Dec 22, 2010	Feb	CAHN
---	-------	-------------	--------------	-----	------

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS	7.5MG	N022334 004	Mar 30, 2012	Apr	NEWA
----------	-------	-------------	--------------	-----	------

&gt;A&gt; TABLET, FOR SUSPENSION; ORAL

&gt;A&gt; AFINITOR DISPERZ

>A>		NOVARTIS PHARM	2MG	N203985 001	Aug 29, 2012	Aug	NEWA
-----	--	----------------	-----	-------------	--------------	-----	------

>A>			3MG	N203985 002	Aug 29, 2012	Aug	NEWA
-----	--	--	-----	-------------	--------------	-----	------

>A>	+		5MG	N203985 003	Aug 29, 2012	Aug	NEWA
-----	---	--	-----	-------------	--------------	-----	------

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+	AMYLIN	2MG/VIAL	N022200 001	Jan 27, 2012	Jan	NEWA
---	--------	----------	-------------	--------------	-----	------

EZETIMIBE

TABLET; ORAL

ZETIA

+	MSD INTL GMBH	10MG	N021445 001	Oct 25, 2002	Feb	CAHN
---	---------------	------	-------------	--------------	-----	------

+	MSP SINGAPORE	10MG	N021445 001	Oct 25, 2002	Jan	CAHN
---	---------------	------	-------------	--------------	-----	------

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL	10MG;10MG	N021687 001	Jul 23, 2004	Jan	CAHN
----------	-----------	-------------	--------------	-----	------

	10MG;20MG	N021687 002	Jul 23, 2004	Jan	CAHN
--	-----------	-------------	--------------	-----	------

	10MG;40MG	N021687 003	Jul 23, 2004	Jan	CAHN
--	-----------	-------------	--------------	-----	------

+	10MG;80MG	N021687 004	Jul 23, 2004	Jan	CAHN
---	-----------	-------------	--------------	-----	------

EZOGABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE	50MG	N022345 001	Jun 10, 2011	May	CAHN
-----------------	------	-------------	--------------	-----	------

	200MG	N022345 002	Jun 10, 2011	May	CAHN
--	-------	-------------	--------------	-----	------

	300MG	N022345 003	Jun 10, 2011	May	CAHN
--	-------	-------------	--------------	-----	------

+	400MG	N022345 004	Jun 10, 2011	May	CAHN
---	-------	-------------	--------------	-----	------

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	MACLEODS PHARMS LTD	125MG	A201022 001	Jan 12, 2012	Jan	NEWA
AB		250MG	A201022 002	Jan 12, 2012	Jan	NEWA
AB		500MG	A201022 003	Jan 12, 2012	Jan	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	+ HIKMA MAPLE	10MG/ML	A075799 001	Apr 30, 2002	Jul	CAHN
AP	+	10MG/ML	A075488 001	Apr 16, 2001	Jul	CAHN
FAMOTIDINE PRESERVATIVE FREE						
AP	+ HIKMA MAPLE	10MG/ML	A075486 001	Apr 16, 2001	Jul	CAHN
AP	+	10MG/ML	A075789 001	Apr 30, 2002	Jul	CAHN

TABLET; ORAL

PEPCID

AB	MARATHON PHARMS	20MG	N019462 001	Oct 15, 1986	Jan	CAHN
AB	+	40MG	N019462 002	Oct 15, 1986	Jan	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

	@ UCB INC	20MG	N021712 001	Sep 24, 2004	Jan	CAHN
	@	40MG	N021712 002	Sep 24, 2004	Jan	CAHN

FEBUXOSTAT

TABLET; ORAL

ULORIC

	TAKEDA PHARMS USA	40MG	N021856 001	Feb 13, 2009	Apr	CAHN
	+	80MG	N021856 002	Feb 13, 2009	Apr	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

AB	WOCKHARDT LTD	2.5MG	A091484 001	Aug 15, 2012	Jul	NEWA
AB		5MG	A091484 002	Aug 15, 2012	Jul	NEWA
AB		10MG	A091484 003	Aug 15, 2012	Jul	NEWA

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB	LUPIN ATLANTIS	43MG	N021695 001	Nov 30, 2004	Feb	CFTG
AB	+	130MG	N021695 003	Nov 30, 2004	Feb	CFTG

FENOFIBRATE (MICRONIZED)

AB	DR REDDYS LABS SA	43MG	A090859 001	Mar 01, 2012	Feb	NEWA
AB		130MG	A090859 002	Mar 01, 2012	Feb	NEWA

TABLET; ORAL

FENOFIBRATE

AB	IMPAX LABS	160MG	A076509 002	Mar 26, 2008	May	CRLD
AB	+	160MG	A076509 002	Mar 26, 2008	Mar	CRLD
AB	TEVA	54MG	A076433 001	May 13, 2005	May	CMFD
	@	54MG	A076433 001	May 13, 2005	Mar	DISC
AB	+	160MG	A076433 002	May 13, 2005	May	CMFD
	@	160MG	A076433 002	May 13, 2005	Mar	DISC
AB	VALEANT INTL	48MG	A090715 001	Apr 05, 2012	Mar	NEWA
AB		145MG	A090715 002	Apr 05, 2012	Mar	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

>D>	+	PEDINOL	EQ 200MG BASE	N017604 003		Aug	CAHN
>D>		@	EQ 300MG BASE	N017604 002		Aug	CAHN
>D>			EQ 400MG BASE	N017604 004	Jul 21, 2009	Aug	CAHN
>A>	+	XSPIRE	EQ 200MG BASE	N017604 003		Aug	CAHN
>A>		@	EQ 300MG BASE	N017604 002		Aug	CAHN
>A>			EQ 400MG BASE	N017604 004	Jul 21, 2009	Aug	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB		AVEVA	100MCG/HR	A077449 004	Oct 20, 2008	Jun	CAHN
		FENTANYL-25					
AB		AVEVA	25MCG/HR	A077449 001	Oct 20, 2008	Jun	CAHN
		FENTANYL-50					
AB		AVEVA	50MCG/HR	A077449 002	Oct 20, 2008	Jun	CAHN
		FENTANYL-75					
AB		AVEVA	75MCG/HR	A077449 003	Oct 20, 2008	Jun	CAHN

SPRAY; SUBLINGUAL

SUBSYS

INSYS THERAP

			0.1MG	N202788 001	Jan 04, 2012	Mar	CPOT
			0.1MCG	N202788 001	Jan 04, 2012	Jan	NEWA
			0.2MG	N202788 002	Jan 04, 2012	Mar	CPOT
			0.2MCG	N202788 002	Jan 04, 2012	Jan	NEWA
	+		0.4MG	N202788 003	Jan 04, 2012	Mar	CPOT
	+		0.4MCG	N202788 003	Jan 04, 2012	Jan	NEWA
			0.6MG	N202788 004	Jan 04, 2012	Mar	CPOT
			0.6MCG	N202788 004	Jan 04, 2012	Jan	NEWA
			0.8MG	N202788 005	Jan 04, 2012	Mar	CPOT
			0.8MCG	N202788 005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

ARCHIMEDES

			EQ 0.1MG BASE	N022569 001	Jun 30, 2011	Jan	CPOT
	+		EQ 0.4MG BASE	N022569 002	Jun 30, 2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB		PAR PHARM	EQ 0.2MG BASE	A077312 001	Oct 30, 2009	Feb	CAHN
AB			EQ 0.4MG BASE	A077312 002	Oct 30, 2009	Feb	CAHN
AB			EQ 0.6MG BASE	A077312 003	Oct 30, 2009	Feb	CAHN
AB			EQ 0.8MG BASE	A077312 004	Oct 30, 2009	Feb	CAHN
AB			EQ 1.2MG BASE	A077312 005	Oct 30, 2009	Feb	CAHN
AB			EQ 1.6MG BASE	A077312 006	Oct 30, 2009	Feb	CAHN

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

@ AMAG PHARMS INC

EQ 11.2MG IRON/ML

N020416 001 Aug 30, 1996 Jun DISC



FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

AB	+	SANOFI AVENTIS US	30MG/5ML	N021963 001	Oct 16, 2006	Jul	CFTG
FEXOFENADINE HYDROCHLORIDE							
AB		ACTAVIS MID ATLANTIC	30MG/5ML	A201311 001	Jul 25, 2012	Jul	NEWA

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008 003	Apr 06, 2012	Jun	CPOT
+		10-30ML (13.5-51MCI/ML)	N202008 002	Apr 06, 2012	Apr	NEWA
+		10-50ML (13.5-51CMI/ML)	N202008 003	Apr 06, 2012	Apr	NEWA
+		10ML (13.5-51MCI/ML)	N202008 001	Apr 06, 2012	Apr	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>	AP	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005	Aug	CAHN
>A>	AP		400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005	Aug	CAHN
>D>	AP	APOTEX INC	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005	Aug	CAHN
>D>	AP		400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005	Aug	CAHN
	AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764 001	Jan 30, 2012	Jan	NEWA
	AP		400MG/200ML (2MG/ML)	A078764 002	Jan 30, 2012	Jan	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A>	@	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005	Aug	CAHN
>A>	@		400MG/200ML (2MG/ML)	A076889 002	Mar 25, 2005	Aug	CAHN
>D>	@	APOTEX INC	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005	Aug	CAHN
>D>	@		400MG/200ML (2MG/ML)	A076889 002	Mar 25, 2005	Aug	CAHN
	AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698 001	Jan 30, 2012	Jan	NEWA
	AP		400MG/200ML (2MG/ML)	A078698 002	Jan 30, 2012	Jan	NEWA

TABLET; ORAL

FLUCONAZOLE

AB		HARRIS PHARM	50MG	A078423 001	Mar 07, 2011	Jul	CAHN
AB			100MG	A078423 002	Mar 07, 2011	Jul	CAHN
AB			150MG	A078423 003	Mar 07, 2011	Jul	CAHN
AB			200MG	A078423 004	Mar 07, 2011	Jul	CAHN
	@	PLIVA	50MG	A076424 001	Jul 29, 2004	Feb	DISC
	@		100MG	A076424 002	Jul 29, 2004	Feb	DISC
	@		150MG	A076424 003	Jul 29, 2004	Feb	DISC
	@		200MG	A076424 004	Jul 29, 2004	Feb	DISC
	@	RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004	Apr	DISC
	@		100MG	A076386 002	Jul 29, 2004	Apr	DISC
	@		150MG	A076386 003	Jul 29, 2004	Apr	DISC
	@		200MG	A076386 004	Jul 29, 2004	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

	@	GENZYME CORP	50MG/VIAL	N020038 001	Apr 18, 1991	Mar	DISC
FLUDARABINE PHOSPHATE							
AP	+	HOSPIRA	50MG/VIAL	A077790 001	Apr 06, 2007	Mar	CRLD

TABLET; ORAL

OFORTA

	@	SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008	May	DISC
--	---	-------------------	------	-------------	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	HIKMA MAPLE	0.5MG/5ML (0.1MG/ML)	A076787 002	Oct 12, 2004	Jul	CAHN
AP		1MG/10ML (0.1MG/ML)	A076787 001	Oct 12, 2004	Jul	CAHN
>A>	AP	SAGENT PHARMS	0.5MG/5ML (0.1MG/ML)	A090584 001	Aug 28, 2012	Aug NEWA
>A>	AP		1MG/10ML (0.1MG/ML)	A090584 002	Aug 28, 2012	Aug NEWA
	@	TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589 002	Oct 12, 2004	Jan DISC
	@		1MG/10ML (0.1MG/ML)	A076589 001	Oct 12, 2004	Jan DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+	ACTON PHARMS	EQ 78MG BASE/INH	N021247 001	Jan 27, 2006	Jul	CPOT
---	--------------	------------------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

FLUNISOLIDE

>D>	AB	HH AND P	0.025MG/SPRAY	A077704 001	Aug 03, 2006	Aug CAHN
>A>	AB	HI TECH PHARMA CO	0.025MG/SPRAY	A077704 001	Aug 03, 2006	Aug CAHN

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	IDENTI PHARMS INC	0.01%	A091306 001	Oct 17, 2011	Jan	CPOT
----	-------------------	-------	-------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

AB2	FOUGERA PHARMS	0.05%	A076586 001	Jun 23, 2004	Jan	CAHN
	@	G AND W LABS INC	0.05%	A074204 001	Jun 13, 1995	May CAHN

OINTMENT; TOPICAL

FLUOCINONIDE

AB	FOUGERA PHARMS	0.05%	A074905 001	Aug 26, 1997	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

FLUOROURACIL

CREAM; TOPICAL

CARAC

+	VALEANT INTL	0.5%	N020985 001	Oct 27, 2000	Jul	CAHN
---	--------------	------	-------------	--------------	-----	------

FLUOROPLEX

+	AQUA PHARMS	1%	N016988 001		Jan	CAHN
---	-------------	----	-------------	--	-----	------

INJECTABLE; INJECTION

FLUOROURACIL

AP	ONCO THERAPIES LTD	500MG/10ML (50MG/ML)	A202668 001	Jul 17, 2012	Jul	NEWA
AP		1GM/20ML (50MG/ML)	A202668 002	Jul 17, 2012	Jul	NEWA
AP		2.5GM/50ML (50MG/ML)	A202669 001	Jul 17, 2012	Jul	NEWA
AP		5GM/100ML (50MG/ML)	A202669 002	Jul 17, 2012	Jul	NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

PROZAC

AB1	ELI LILLY AND CO	EQ 10MG BASE	N018936 006	Dec 23, 1992	Apr	CAHN
AB1		EQ 20MG BASE	N018936 001	Dec 29, 1987	Apr	CAHN
AB	+	EQ 40MG BASE	N018936 003	Jun 15, 1999	Apr	CAHN
	@	EQ 60MG BASE	N018936 004	Jun 15, 1999	Apr	CAHN
	SARAFEM					
AB2	ELI LILLY AND CO	EQ 10MG BASE	N018936 007	Jul 06, 2000	Apr	CAHN

CAPSULE; ORAL

SARAFEM							
AB2	+ ELI LILLY AND CO	EQ 20MG BASE	N018936	008	Jul 06, 2000	Apr	CAHN
TABLET; ORAL							
SARAFEM							
	WARNER CHILCOTT LLC	EQ 10MG BASE	N021860	001	May 19, 2006	Jun	CAHN
		EQ 15MG BASE	N021860	002	May 19, 2006	Jun	CAHN
	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jun	CAHN

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE							
AB	TEVA PHARMS	EQ 25MG BASE;EQ 6MG BASE	A077528	001	Jun 19, 2012	Jun	NEWA
AB		EQ 25MG BASE;EQ 12MG BASE	A077528	002	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE;EQ 6MG BASE	A077528	003	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE;EQ 12MG BASE	A077528	004	Jun 19, 2012	Jun	NEWA
SYMBYAX							
AB	LILLY	EQ 25MG BASE;EQ 6MG BASE	N021520	002	Dec 24, 2003	Jun	CFTG
AB		EQ 25MG BASE;EQ 12MG BASE	N021520	004	Dec 24, 2003	Jun	CFTG
AB	+	EQ 50MG BASE;EQ 6MG BASE	N021520	003	Dec 24, 2003	Jun	CFTG
AB		EQ 50MG BASE;EQ 12MG BASE	N021520	005	Dec 24, 2003	Jun	CFTG

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP							
>D>	AQUA PHARMS	0.025%	N012806	003		Aug	CRLD
>A>	+	0.025%	N012806	003		Aug	CRLD
		0.025%	N012806	003		Jul	CAHN
>D>		0.05%	N012806	002		Aug	CRLD
>A>	+	0.05%	N012806	002		Aug	CRLD
		0.05%	N012806	002		Jul	CAHN
	WATSON PHARMS	0.05%	N012806	002		Apr	CMFD

LOTION; TOPICAL

CORDRAN

+	AQUA PHARMS	0.05%	N013790	001		Jul	CAHN
---	-------------	-------	---------	-----	--	-----	------

OINTMENT; TOPICAL

CORDRAN

@	AQUA PHARMS	0.025%	N012806	004		Jul	CAHN
@		0.05%	N012806	001		Jul	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	+ IVAX SUB TEVA PHARMS	125MG	A075780	001	Sep 19, 2001	Mar	CRLD
AB	SANDOZ INC	125MG	A075818	001	Sep 18, 2001	Mar	CRLD

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+ FOUGERA PHARMS	0.05%	N019958	001	Dec 18, 1990	Jan	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	0.05%	A076451	001	May 14, 2004	Jan	CAHN
	@ NESHER PHARMS	0.05%	A076865	001	Sep 10, 2004	Jun	DISC

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	0.005%	A076300	001	May 14, 2004	Jan	CAHN
----	----------------	--------	---------	-----	--------------	-----	------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595 001	Apr 11, 2012	Mar	NEWA
AB		EQ 40MG BASE	A090595 002	Apr 11, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 20MG BASE	A078407 001	Jun 12, 2012	May	NEWA
AB		EQ 40MG BASE	A078407 002	Jun 12, 2012	May	NEWA
	LESCOL					
AB	NOVARTIS	EQ 20MG BASE	N020261 001	Dec 31, 1993	Mar	CFTG
AB	+	EQ 40MG BASE	N020261 002	Dec 31, 1993	Mar	CFTG

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

	JAZZ PHARMS	100MG	N022033 001	Feb 28, 2008	Jun	CAHN
+		150MG	N022033 002	Feb 28, 2008	Jun	CAHN

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518 001	Jun 22, 2010	Jun	CAHN
+		0.005MG/INH;0.2MG/INH	N022518 002	Jun 22, 2010	Jun	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

	@ RANBAXY LABS LTD	10MG	A076580 001	Apr 23, 2004	Apr	DISC
	@	20MG	A076580 002	Apr 23, 2004	Apr	DISC
	@	40MG	A076580 003	Apr 23, 2004	Apr	DISC
	MONOPRIL					
	@ BRISTOL MYERS SQUIBB	10MG	N019915 002	May 16, 1991	Mar	DISC
	@	20MG	N019915 003	May 16, 1991	Mar	DISC
	@	40MG	N019915 004	Mar 28, 1995	Mar	DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	HIKMA MAPLE	EQ 50MG PHENYTOIN NA/ML	A077989 001	Aug 06, 2007	Jul	CAHN
	@ TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007	Mar	DISC

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

	@ EISAI INC	1050MG/30ML (35MG/ML)	N022244 001	Dec 12, 2008	Jul	DISC
--	-------------	-----------------------	-------------	--------------	-----	------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

	@ HOSPIRA	10MG/ML	A070578 001	Jul 08, 1987	Jun	DISC
--	-----------	---------	-------------	--------------	-----	------

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

AA	ACELLA PHARMS LLC	250MG/5ML	A076403 001	May 01, 2012	Jun	CAHN
AA	AMNEAL PHARMS	250MG/5ML	A202024 001	Mar 23, 2012	Mar	NEWA

## SOLUTION; ORAL

## GABAPENTIN

AA	KIEL	250MG/5ML	A076403 001	May 01, 2012	Apr	NEWA
----	------	-----------	-------------	--------------	-----	------

GANCICLOVIR

## CAPSULE; ORAL

## GANCICLOVIR

	@ RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003	Apr	DISC
--	--------------------	-------	-------------	--------------	-----	------

	@	500MG	A076457 002	Jun 27, 2003	Apr	DISC
--	---	-------	-------------	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## GEMCITABINE HYDROCHLORIDE

>A>	AP	EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A202063 001	Sep 11, 2012	Aug	NEWA
-----	----	-------------------	--------------------	-------------	--------------	-----	------

>A>	AP		EQ 1GM BASE/VIAL	A202063 002	Sep 11, 2012	Aug	NEWA
-----	----	--	------------------	-------------	--------------	-----	------

>A>	AP	HAMEIN RDS GMBH	EQ 200MG BASE/VIAL	A090663 001	Sep 10, 2012	Aug	NEWA
-----	----	-----------------	--------------------	-------------	--------------	-----	------

>A>	AP		EQ 1GM BASE/VIAL	A090663 002	Sep 10, 2012	Aug	NEWA
-----	----	--	------------------	-------------	--------------	-----	------

	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795 001	Aug 04, 2011	Apr	CTNA
--	---	-------------	------------------------	-------------	--------------	-----	------

	+		1GM/26.3ML (38MG/ML)	N200795 002	Aug 04, 2011	Apr	CTNA
--	---	--	----------------------	-------------	--------------	-----	------

	+		2GM/52.6ML (38MG/ML)	N200795 003	Aug 04, 2011	Apr	CTNA
--	---	--	----------------------	-------------	--------------	-----	------

GLIMEPIRIDE

## TABLET; ORAL

## GLIMEPIRIDE

AB	AUROBINDO PHARMA LTD	1MG	A202759 001	Jun 29, 2012	Jun	NEWA
----	----------------------	-----	-------------	--------------	-----	------

AB		2MG	A202759 002	Jun 29, 2012	Jun	NEWA
----	--	-----	-------------	--------------	-----	------

AB		4MG	A202759 003	Jun 29, 2012	Jun	NEWA
----	--	-----	-------------	--------------	-----	------

AB	MICRO LABS USA	1MG	A091220 001	Jun 29, 2012	Jun	NEWA
----	----------------	-----	-------------	--------------	-----	------

AB		2MG	A091220 002	Jun 29, 2012	Jun	NEWA
----	--	-----	-------------	--------------	-----	------

		3MG	A091220 003	Jun 29, 2012	Jun	NEWA
--	--	-----	-------------	--------------	-----	------

AB		4MG	A091220 004	Jun 29, 2012	Jun	NEWA
----	--	-----	-------------	--------------	-----	------

		6MG	A091220 005	Jun 29, 2012	Jun	NEWA
--	--	-----	-------------	--------------	-----	------

AB		8MG	A091220 006	Jun 29, 2012	Jun	NEWA
----	--	-----	-------------	--------------	-----	------

	@ RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005	Apr	DISC
--	--------------------	-----	-------------	--------------	-----	------

	@	2MG	A076875 002	Oct 06, 2005	Apr	DISC
--	---	-----	-------------	--------------	-----	------

	@	4MG	A076875 003	Oct 06, 2005	Apr	DISC
--	---	-----	-------------	--------------	-----	------

	@	8MG	A076875 004	Oct 06, 2005	Apr	DISC
--	---	-----	-------------	--------------	-----	------

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

## TABLET; ORAL

## DUETACT

>D>	+	TAKEDA GLOBAL	2MG;30MG	N021925 001	Jul 28, 2006	Aug	CAHN
-----	---	---------------	----------	-------------	--------------	-----	------

>D>			4MG;30MG	N021925 002	Jul 28, 2006	Aug	CAHN
-----	--	--	----------	-------------	--------------	-----	------

>A>	+	TAKEDA PHARMS USA	2MG;30MG	N021925 001	Jul 28, 2006	Aug	CAHN
-----	---	-------------------	----------	-------------	--------------	-----	------

>A>			4MG;30MG	N021925 002	Jul 28, 2006	Aug	CAHN
-----	--	--	----------	-------------	--------------	-----	------

GLYCOPYRROLATE

## SOLUTION; ORAL

## CUVPOSA

>A>	+	MERZ PHARMS	1MG/5ML	N022571 001	Jul 28, 2010	Aug	CAHN
-----	---	-------------	---------	-------------	--------------	-----	------

>D>	+	SHIONOGI INC	1MG/5ML	N022571 001	Jul 28, 2010	Aug	CAHN
-----	---	--------------	---------	-------------	--------------	-----	------

## TABLET; ORAL

## GLYCOPYRROLATE

AA	NEXGEN PHARMA	1.5MG	A091522 001	Mar 12, 2012	Feb	NEWA
----	---------------	-------	-------------	--------------	-----	------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262 001	Dec 31, 2007	Mar	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258 001	Jun 30, 2008	Mar	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258 002	Jun 30, 2008	Mar	CAHN
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	+ APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096 001	Jun 30, 2008	Apr	CRLD
	@ TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007	Apr	DISC

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+ VALEANT PHARM NORTH	125MG/5ML	A062483 001	Jan 26, 1984	Feb	CAHN
TABLET; ORAL						
GRIFULVIN V						
	@ VALEANT INTL	125MG	A062279 001		Jul	CAHN
	@	250MG	A062279 002		Jul	CAHN
	+	500MG	A062279 003		Jul	CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004	Jan	CAHN
OINTMENT; TOPICAL						
HALOBETASOL PROPIONATE						
AB	FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004	Jan	CAHN
	@ VENUS PHARMS	0.05%	A077109 001	Jun 14, 2005	Jun	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+ B BRAUN	200 UNITS/100ML	N019953 001	Jul 20, 1992	Jul	CRLD
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985	Mar	DISC
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983	Mar	DISC
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+ B BRAUN	4,000 UNITS/100ML	N019952 001	Jul 20, 1992	Jul	CRLD
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985	Mar	DISC
	@	10,000 UNITS/100ML	N018814 004	Jul 02, 1987	Mar	DISC
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+ B BRAUN	5,000 UNITS/100ML	N019952 004	Jul 20, 1992	Jul	CRLD
AP	+	10,000 UNITS/100ML	N019952 005	Jul 20, 1992	Jul	CRLD

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

	+ PHOTOCURE ASA	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
--	-----------------	------------	-------------	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

@ AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005	Jun	DISC
-------------	--------------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	LANNETT HOLDINGS INC	12.5MG	A091662 001	Jan 27, 2012	Jan	NEWA
----	----------------------	--------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB	+	SANOFI AVENTIS	12.5MG;150MG	N020758 002	Sep 30, 1997	Mar	CFTG
AB	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Mar	CFTG
	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Feb	CRLD

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		TEVA	12.5MG;150MG	A077369 001	Mar 30, 2012	Mar	NEWA
AB			12.5MG;300MG	A077369 002	Mar 30, 2012	Mar	NEWA
	@		25MG;300MG	A077369 003	Mar 30, 2012	Apr	DISC
			25MG;300MG	A077369 003	Mar 30, 2012	Mar	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC LTD	12.5MG;50MG	A091617 001	Feb 17, 2012	Feb	NEWA
AB			12.5MG;100MG	A091617 002	Feb 17, 2012	Feb	NEWA
AB			25MG;100MG	A091617 003	Feb 17, 2012	Feb	NEWA
AB		MACLEODS PHARMS LTD	12.5MG;50MG	A202289 001	Aug 09, 2012	Jul	NEWA
AB			12.5MG;100MG	A202289 002	Aug 09, 2012	Jul	NEWA
AB			25MG;100MG	A202289 003	Aug 09, 2012	Jul	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

ASTRAZENECA

			12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006	Jan	CMFD
			12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006	Jan	CMFD
	+		12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Apr	CRLD
			12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	50MG;100MG	A076792 003	Aug 20, 2004	Jan	CTEC
AB		SUN PHARM INDS	25MG;50MG	A090654 001	Jan 19, 2012	Jan	NEWA
AB			25MG;100MG	A090654 002	Jan 19, 2012	Jan	NEWA
AB			50MG;100MG	A090654 003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ PADDOCK LLC

@

@

			12.5MG;7.5MG	A090096 001	Sep 25, 2008	Jan	DISC
			12.5MG;15MG	A090096 002	Sep 25, 2008	Jan	DISC
			25MG;15MG	A090096 003	Sep 25, 2008	Jan	DISC

HYDROCORTISONE

	CREAM; TOPICAL						
	NUTRACORT						
	@ DOW PHARM	0.5%	A080442	002		Jun	CAHN
	@	1%	A080442	003		Jun	CAHN
	LOTION; TOPICAL						
	CETACORT						
	@ DOW PHARM	0.5%	A080426	002		Jun	CAHN
	@	1%	A080426	001		Jun	CAHN
	HYDROCORTISONE						
AT	+ FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000	Jan	CAHN
	NUTRACORT						
	@ DOW PHARM	0.5%	A080443	002		Jun	CAHN
AT		1%	A080443	003		Jun	CAHN
AT		2.5%	A087644	001	Aug 24, 1982	Jun	CAHN
	OINTMENT; TOPICAL						
	HYDROCORTISONE						
AT	+ FOUGERA PHARMS	1%	A080692	001		Jan	CAHN

HYDROCORTISONE ACETATE; UREA

	CREAM; TOPICAL						
	CARMOL HC						
AT	FOUGERA PHARMS	1%;10%	A080505	001		Jan	CAHN

HYDROCORTISONE BUTYRATE

	CREAM; TOPICAL						
	LOCOID						
AB	+ PRECISION DERMAT	0.1%	N018514	001	Mar 31, 1982	Jun	CAHN
	LOCOID LIPOCREAM						
	+ PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997	Jun	CAHN
	LOTION; TOPICAL						
	LOCOID						
	+ PRECISION DERMAT	0.1%	N022076	001	May 18, 2007	May	CAHN
	OINTMENT; TOPICAL						
	LOCOID						
AB	+ PRECISION DERMAT	0.1%	N018652	001	Oct 29, 1982	May	CAHN
	SOLUTION; TOPICAL						
	LOCOID						
AT	+ PRECISION DERMAT	0.1%	N019116	001	Feb 25, 1987	Jun	CAHN

HYDROCORTISONE VALERATE

	CREAM; TOPICAL						
	HYDROCORTISONE VALERATE						
AB	+ TARO	0.2%	A075042	001	Aug 25, 1998	Mar	CRLD
	WESTCORT						
	@ RANBAXY	0.2%	N017950	001		Mar	DISC
	OINTMENT; TOPICAL						
	HYDROCORTISONE VALERATE						
AB	FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Jan	CAHN

HYDROFLUMETHIAZIDE

	TABLET; ORAL						
	SALURON						
AB	+ SHIRE LLC	50MG	N011949	001		Jan	CAHN



HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ NESHER PHARMS	2MG	A077311 001	Nov 09, 2005	Jun	DISC
@	4MG	A077311 002	Nov 09, 2005	Jun	DISC
@	8MG	A077311 003	Nov 09, 2005	Jun	DISC

TABLET, EXTENDED RELEASE; ORAL

EXALGO

>A>	MALLINCKRODT INC	32MG	N021217 004	Aug 24, 2012	Aug	NEWA
-----	------------------	------	-------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@ STI PHARMA LLC	10MG/5ML	A086880 001		Feb	CAHN
------------------	----------	-------------	--	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ MIKAH PHARMA	10MG	A040600 001	Dec 28, 2004	Jul	CAHN
@	25MG	A040602 001	Dec 28, 2004	Jul	CAHN
@	50MG	A040604 001	Dec 28, 2004	Jul	CAHN

HYDROXYZINE PAMOATE

SUSPENSION; ORAL

VISTARIL

@ PFIZER	EQ 25MG HCL/5ML	N011795 001		Jul	DISC
----------	-----------------	-------------	--	-----	------

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005	Mar	CFTG
----	---	-------------------	---------------	-------------	--------------	-----	------

IBANDRONATE SODIUM

AB		APOTEX INC	EQ 150MG BASE	A078948 001	Mar 19, 2012	Mar	NEWA
AB		DR REDDYS LABS LTD	EQ 150MG BASE	A078997 001	Apr 30, 2012	Apr	NEWA
AB		MUTUAL PHARM CO INC	EQ 150MG BASE	A078996 001	Aug 15, 2012	Jul	NEWA
AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012	Mar	NEWA
AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998 001	Mar 19, 2012	Mar	NEWA
AB		WATSON LABS INC	EQ 150MG BASE	A079003 001	Mar 20, 2012	Mar	NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

@ NORTHSTAR HLTHCARE	400MG	A078132 001	Sep 10, 2007	Jun	DISC
@	600MG	A078132 002	Sep 10, 2007	Jun	DISC
@	800MG	A078132 003	Sep 10, 2007	Jun	DISC
@ OHM LABS	400MG	A070818 001	Dec 26, 1985	Jun	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN
---	--------------	------------------------------------	-------------	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+	AMARIN PHARMA INC	1GM	N202057 001	Jul 26, 2012	Jul	NEWA
---	-------------------	-----	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

@	TEVA PARENTERAL	5MG/VIAL	A065037 003	May 01, 2002	Mar	DISC
@		10MG/VIAL	A065037 002	May 01, 2002	Mar	DISC
@		20MG/VIAL	A065037 001	May 01, 2002	Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB	PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Feb	CMFD
AB		25MG	A040752 001	Feb 28, 2008	Feb	CMFD
AB		50MG	A040751 001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	APOTEX INC	5%	A091308 001	Apr 06, 2012	Mar	NEWA
AB	FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
AB	GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+ LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985	Mar	CAHN
----	----------------	------------------	-------------	--------------	-----	------

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

	LEO PHARMA AS	0.015%	N202833 001	Jan 23, 2012	Jan	NEWA
+		0.05%	N202833 002	Jan 23, 2012	Jan	NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50 PEN

@	LILLY	50 UNITS/ML;50 UNITS/ML	N021018 003	Dec 22, 1999	Jun	DISC
---	-------	-------------------------	-------------	--------------	-----	------

HUMALOG MIX 75/25 PEN

@	LILLY	75 UNITS/ML;25 UNITS/ML	N021017 003	Dec 22, 1999	Jun	DISC
---	-------	-------------------------	-------------	--------------	-----	------

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG PEN

@	LILLY	100 UNITS/ML	N020563 002	Aug 06, 1998	Jun	DISC
---	-------	--------------	-------------	--------------	-----	------

IRBESARTAN

TABLET; ORAL

AVAPRO

AB	SANOFI AVENTIS US	75MG	N020757 001	Sep 30, 1997	Mar	CFTG
AB		150MG	N020757 002	Sep 30, 1997	Mar	CFTG
AB	+	300MG	N020757 003	Sep 30, 1997	Mar	CFTG

IRBESARTAN

AB	TEVA PHARMS	75MG	A077159 001	Mar 30, 2012	Mar	NEWA
AB		150MG	A077159 002	Mar 30, 2012	Mar	NEWA
AB		300MG	A077159 003	Mar 30, 2012	Mar	NEWA

IRINOTECAN HYDROCHLORIDE

## INJECTABLE; INJECTION

## IRINOTECAN HYDROCHLORIDE

AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012	Jan	NEWA
AP		100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012	Jan	NEWA
AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN
AP	TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101 002	Feb 27, 2008	Jun	NEWA
AP		100MG/5ML (20MG/ML)	A090101 003	Feb 27, 2008	Jun	NEWA
AP		500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Jun	CMFD
	@	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC

ISOFLURANE

## LIQUID; INHALATION

## FORANE

AN	+ BAXTER HLTHCARE	99.9%	N017624 001		Jul	CAHN
----	-------------------	-------	-------------	--	-----	------

ISOSORBIDE MONONITRATE

## TABLET, EXTENDED RELEASE; ORAL

## ISOSORBIDE MONONITRATE

AB	ALKERMES GAINESVILLE	60MG	A075041 001	Sep 22, 1998	Jun	CAHN
	@ SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999	Jan	DISC

ISOTRETINOIN

## CAPSULE; ORAL

## ABSORICA

## CIPHER

		10MG	N021951 001	May 25, 2012	May	NEWA
		20MG	N021951 002	May 25, 2012	May	NEWA
		30MG	N021951 003	May 25, 2012	May	NEWA
		40MG	N021951 004	May 25, 2012	May	NEWA
	MYORISAN					
AB	DOUGLAS PHARMS	10MG	A076485 001	Jan 19, 2012	Jan	NEWA
AB		20MG	A076485 002	Jan 19, 2012	Jan	NEWA
AB		40MG	A076485 003	Jan 19, 2012	Jan	NEWA

ITRACONAZOLE

## CAPSULE; ORAL

## ITRACONAZOLE

AB	MYLAN PHARMS INC	100MG	A200463 001	Jul 20, 2012	Jul	NEWA
----	------------------	-------	-------------	--------------	-----	------

IVACAFTOR

## TABLET; ORAL

## KALYDECO

+	VERTEX PHARMS	150MG	N203188 001	Jan 31, 2012	Jan	NEWA
---	---------------	-------	-------------	--------------	-----	------

IVERMECTIN

## LOTION; TOPICAL

## SKLICE

+	SANOFI PASTEUR	0.5%	N202736 001	Feb 07, 2012	Feb	NEWA
---	----------------	------	-------------	--------------	-----	------

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB	FOUGERA PHARMS	2%	A076294 001	Apr 28, 2004	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

	DORADO PHARMA	25MG	A074014 001	Jan 29, 1993	Jul	CAHN
AB		50MG	A074014 002	Jan 29, 1993	Jul	CAHN
AB		75MG	A074014 003	Jan 29, 1993	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

AB	ALKERMES GAINESVILLE	200MG	A074879 001	Dec 10, 1997	Jun	CAHN
----	----------------------	-------	-------------	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699 001	Apr 03, 2012	Mar	NEWA
----	------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	PAR FORM	100MG	A200908 001	Jul 10, 2012	Jun	NEWA
AB		200MG	A200908 002	Jul 10, 2012	Jun	NEWA
AB		300MG	A200908 003	Jul 10, 2012	Jun	NEWA

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+	CUMBERLAND PHARMS	10GM/PACKET	A074712 001	Dec 10, 1997	Jun	CAHN
+		20GM/PACKET	A074712 002	Dec 10, 1997	Jun	CAHN

SOLUTION; ORAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418 001	May 15, 2012	Apr	NEWA
AB	LUPIN LTD	150MG;300MG	A090246 001	May 15, 2012	Apr	NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	25MG	A090169 001	May 12, 2012	Apr	NEWA	
AB		100MG	A090169 002	May 12, 2012	Apr	NEWA	
AB		150MG	A090169 003	May 12, 2012	Apr	NEWA	
AB		200MG	A090169 004	May 12, 2012	Apr	NEWA	
>D>	AB	UPSHER SMITH	25MG	A078310 001	Feb 04, 2009	Aug	CTEC
>A>	BX		25MG	A078310 001	Feb 04, 2009	Aug	CTEC
>D>	AB		100MG	A078310 002	Feb 04, 2009	Aug	CTEC
>A>	BX		100MG	A078310 002	Feb 04, 2009	Aug	CTEC
>D>	AB		150MG	A078310 003	Feb 04, 2009	Aug	CTEC

TABLET; ORALLAMOTRIGINE

>A>	BX	UPSHER SMITH	150MG	A078310 003	Feb 04, 2009	Aug	CTEC
>D>	AB		200MG	A078310 004	Feb 04, 2009	Aug	CTEC
>A>	BX		200MG	A078310 004	Feb 04, 2009	Aug	CTEC

LANREOTIDE ACETATE

## INJECTABLE; SUBCUTANEOUS

## SOMATULINE DEPOT

+		IPSEN INC	EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
+			EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
+			EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN
+		IPSEN PHARMA	EQ 60MG BASE	N022074 001	Aug 30, 2007	May	CAHN
+			EQ 90MG BASE	N022074 002	Aug 30, 2007	May	CAHN
+			EQ 120MG BASE	N022074 003	Aug 30, 2007	May	CAHN

LANSOPRAZOLE

## CAPSULE, DELAYED REL PELLETS; ORAL

## LANSOPRAZOLE

>A>	AB	WOCKHARDT USA	15MG	A202176 001	Sep 14, 2012	Aug	NEWA
>A>	AB		30MG	A202176 002	Sep 14, 2012	Aug	NEWA

## PREVACID

AB		TAKEDA PHARMS USA	15MG	N020406 001	May 10, 1995	Mar	CAHN
AB	+		30MG	N020406 002	May 10, 1995	Mar	CAHN

## TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

## LANSOPRAZOLE

		@ TEVA PHARMS	15MG	A078730 001	Oct 15, 2010	Mar	DISC
		@	30MG	A078730 002	Oct 15, 2010	Mar	DISC
		PREVACID					
		TAKEDA PHARMS USA	15MG	N021428 001	Aug 30, 2002	Mar	CTEC
		+	30MG	N021428 002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

## TABLET, CHEWABLE; ORAL

## FOSRENOL

		@ SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004	Feb	CAHN
			EQ 500MG BASE	N021468 002	Oct 26, 2004	Feb	CAHN
			EQ 750MG BASE	N021468 003	Nov 23, 2005	Feb	CAHN
		+	EQ 1GM BASE	N021468 004	Nov 23, 2005	Feb	CAHN

LETROZOLE

## TABLET; ORAL

## LETROZOLE

AB		APOTEX INC	2.5MG	A091303 001	Apr 19, 2012	Apr	NEWA
----	--	------------	-------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM

## INJECTABLE; INJECTION

## LEUCOVORIN CALCIUM

		@ TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278 001	Sep 28, 1993	Mar	DISC
		LEUCOVORIN CALCIUM PRESERVATIVE FREE					
>A>	AP	SAGENT PHARMS	EQ 50MG BASE/VIAL	A200753 001	Sep 06, 2012	Aug	NEWA
>A>	AP		EQ 100MG BASE/VIAL	A200753 002	Sep 06, 2012	Aug	NEWA
>A>	AP		EQ 200MG BASE/VIAL	A200753 003	Sep 06, 2012	Aug	NEWA
>A>	AP		EQ 350MG BASE/VIAL	A200855 001	Sep 06, 2012	Aug	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+	ABBOTT ENDOCRINE	3.75MG/VIAL	N020011 001	Oct 22, 1990	May	CAHN
+		7.5MG/VIAL	N019732 001	Jan 26, 1989	May	CAHN
+		11.25MG/VIAL	N020708 001	Mar 07, 1997	May	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	APP PHARMS LLC	500MG/5ML (100MG/ML)	A090813 001	May 26, 2010	May	CAHN	
AP	HOSPIRA INC	500MG/ML (100MG/ML)	A202869 001	Apr 06, 2012	Mar	NEWA	
>A>	AP	LUITPOLD	500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012	Aug	CAHN
>D>	AP	PHARMAFORCE	500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012	Aug	CAHN
AP		500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012	Jan	NEWA	
AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A091485 001	Aug 05, 2011	Jul	CAHN	

SOLUTION; ORAL

LEVETIRACETAM

AA	HI-TECH PHARMACAL	100MG/ML	A090601 001	Feb 28, 2012	Feb	NEWA
AA	VINTAGE PHARMS	100MG/ML	A090079 001	Apr 11, 2012	Mar	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	LOTUS PHARM CO LTD	500MG	A090906 001	Nov 05, 2010	Jul	CAHN
AB	WATSON LABS INC	250MG	A078797 002	Jan 15, 2009	Apr	NEWA
AB		500MG	A078797 003	Jan 15, 2009	Apr	NEWA
AB		750MG	A078797 004	Jan 15, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	BOCA PHARMA	500MG	A201464 001	May 25, 2012	May	NEWA	
AB		750MG	A201464 002	May 25, 2012	May	NEWA	
>A>	AB	ROUSES POINT PHARMS	500MG	A202524 001	Aug 27, 2012	Aug	NEWA
>A>	AB		750MG	A202524 002	Aug 27, 2012	Aug	NEWA
AB	TORRENT PHARMS LTD	500MG	A091338 001	May 29, 2012	May	NEWA	
AB		750MG	A091338 002	May 29, 2012	May	NEWA	

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	HETERO LABS LTD III	5MG	A091264 001	Jun 29, 2012	Jun	NEWA
----	---------------------	-----	-------------	--------------	-----	------

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

AB	CIPLA LTD	250MG	A076890 001	Mar 30, 2012	Mar	NEWA	
AB		500MG	A076890 002	Mar 30, 2012	Mar	NEWA	
AB		750MG	A076890 003	Mar 30, 2012	Mar	NEWA	
AB	MACLEODS PHARMS LTD	250MG	A200839 001	Mar 22, 2012	Mar	NEWA	
AB		500MG	A200839 002	Mar 22, 2012	Mar	NEWA	
AB		750MG	A200839 003	Mar 22, 2012	Mar	NEWA	
AB	ORCHID HLTHCARE	250MG	A202200 001	Jan 30, 2012	Jan	NEWA	
AB		500MG	A202200 002	Jan 30, 2012	Jan	NEWA	
AB		750MG	A202200 003	Jan 30, 2012	Jan	NEWA	
>A>	AB	ZYDUS PHARMS USA INC	250MG	A077652 001	Sep 07, 2012	Aug	NEWA
>A>	AB		500MG	A077652 002	Sep 07, 2012	Aug	NEWA
>A>	AB		750MG	A077652 003	Sep 07, 2012	Aug	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

@ SPECTRUM PHARMS EQ 250MG BASE/25ML (EQ 10MG BASE/ML) N020140 003 Apr 29, 2011 Jun DISC

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

AB WATSON LABS INC 1.5MG A200670 001 Jul 12, 2012 Jun NEWA

PLAN B

AB + TEVA BRANDED PHARM 0.75MG N021045 002 Aug 24, 2006 May CAHN

@ 0.75MG N021045 001 Jul 28, 1999 May CAHN

PLAN B ONE-STEP

AB + DURAMED 1.5MG N021998 001 Jul 10, 2009 Jun CFTG

LIDOCAINE

PATCH; TOPICAL

>A> LIDOCAINE

>A> AB WATSON LABS INC 5% A200675 001 Aug 23, 2012 Aug NEWA

LIDODERM

>D> + TEIKOKU PHARMA USA 5% N020612 001 Mar 19, 1999 Aug CFTG

>A> AB + 5% N020612 001 Mar 19, 1999 Aug CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE DENTAL

@ DENTSPLY PHARM 2% N021380 001 May DISC

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB FOUGERA PHARMS 2.5%;2.5% A076453 001 Aug 18, 2003 Jan CAHN

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+ GALDERMA LABS LP 7%;7% N021717 001 Jun 29, 2006 Jun CTNA

>A> LINACLOTIDE

>A> CAPSULE; ORAL

>A> LINZESS

>A> FOREST LABS INC 145MCG N202811 001 Aug 30, 2012 Aug NEWA

>A> + 290MCG N202811 002 Aug 30, 2012 Aug NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

BOEHRINGER INGELHEIM 2.5MG;500MG N201281 001 Jan 30, 2012 Jan NEWA

2.5MG;850MG N201281 002 Jan 30, 2012 Jan NEWA

+ 2.5MG;1GM N201281 003 Jan 30, 2012 Jan NEWA

LINEZOLID

INJECTABLE; INJECTION

LINEZOLID

AP	TEVA PHARMS	200MG/100ML	A200222 001	Jun 22, 2012	Jun	NEWA
AP	+ ZYVOX PHARMACIA AND UPJOHN	200MG/100ML	N021131 001	Apr 18, 2000	Jun	CFTG

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	MYLAN PHARMS INC	300MG	A202288 001	Jun 29, 2012	Jun	NEWA
AB		450MG	A202219 001	Aug 08, 2012	Jul	NEWA

LOMUSTINE

CAPSULE; ORAL

CEENU

	BRISTOL MYERS SQUIBB	10MG	N017588 001		Jun	CMFD
	@	10MG	N017588 001		May	DISC
		40MG	N017588 002		Jun	CMFD
	@	40MG	N017588 002		May	DISC
	+	100MG	N017588 003		Jun	CMFD
	@	100MG	N017588 003		May	DISC

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	HI-TECH PHARMA CO	2MG/ML	A200169 001	Jan 30, 2012	Jan	NEWA
	INJECTABLE; INJECTION					
	LORAZEPAM					
	@ BEDFORD	2MG/ML	A077076 001	Jul 13, 2005	Jun	DISC
	@	4MG/ML	A077076 002	Jul 13, 2005	Jun	DISC
	@ HOSPIRA	2MG/ML	A074300 001	Apr 12, 1994	Jun	DISC

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

	+ ARENA PHARMS INC	10MG	N022529 001	Jun 27, 2012	Jun	NEWA
	+ EISAI INC	10MG	N022529 001	Jun 27, 2012	Jul	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	MACLEODS PHARMS LTD	25MG	A202230 001	May 30, 2012	May	NEWA
AB		50MG	A202230 002	May 30, 2012	May	NEWA
AB		100MG	A202230 003	May 30, 2012	May	NEWA

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

	@ MIKAH PHARMA	EQ 5MG BASE	A076868 001	Aug 04, 2005	Jul	CAHN
	@	EQ 10MG BASE	A076868 002	Aug 04, 2005	Jul	CAHN
	@	EQ 25MG BASE	A076868 003	Aug 04, 2005	Jul	CAHN
	@	EQ 50MG BASE	A076868 004	Aug 04, 2005	Jul	CAHN



LUCINACTANT

SUSPENSION; INTRATRACHEAL  
SURFAXIN

+ DISCOVERY LABS 8.5ML N021746 001 Mar 06, 2012 Apr NEWA

LURASIDONE HYDROCHLORIDE

TABLET; ORAL  
LATUDA

>D>	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011	Aug	CRLD
>A>	+	20MG	N200603 003	Dec 07, 2011	Aug	CRLD
		20MG	N200603 003	Dec 07, 2011	Apr	NEWA
>D>	+	40MG	N200603 001	Oct 28, 2010	Aug	CRLD
>A>		40MG	N200603 001	Oct 28, 2010	Aug	CRLD
	+	40MG	N200603 001	Oct 28, 2010	Apr	CRLD
		80MG	N200603 002	Oct 28, 2010	Apr	CRLD
		120MG	N200603 004	Apr 26, 2012	Apr	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS  
LUVERIS

@ EMD SERONO 75 IU/VIAL N021322 001 Oct 08, 2004 Jun DISC

MAFENIDE ACETATE

CREAM; TOPICAL  
SULFAMYLON

+ MYLAN LLC EQ 85MG BASE/GM N016763 001 Jun CAHN

FOR SOLUTION; TOPICAL  
SULFAMYLON

+ MYLAN LLC 5% N019832 003 Jun 05, 1998 Jun CAHN

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

@ SANTARUS 343MG;20MG;750MG N022456 001 Dec 04, 2009 Jun DISC

@ 343MG;40MG;750MG N022456 002 Dec 04, 2009 Jun DISC

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA 20GM/500ML (40MG/ML) N020309 004 Jan 18, 1995 Jan NEWA

40GM/1000ML(40MG/ML) N020309 005 Jan 18, 1995 Jan NEWA

MALATHION

LOTION; TOPICAL

MALATHION

AT MYLAN PHARMS INC 0.5% A078743 001 Mar 06, 2009 Feb CAHN

AT SUVEN LIFE 0.5% A091559 001 May 23, 2012 May NEWA

MANNITOL

POWDER; INHALATION

ARIDOL KIT

+ PHARMAXIS LTD N/A, 5MG, 10MG, 20MG, 40MG N022368 001 Oct 05, 2010 May CAHN

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	IPSEN INC	40MG/4ML (10MG/ML)	N021839 001	Aug 30, 2005	May	CAHN
---	-----------	--------------------	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294 001	Apr 13, 2012	Mar	NEWA
AA		25MG	A200294 002	Apr 13, 2012	Mar	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

@	TEVA PARENTERAL	150MG/ML	A076552 001	Oct 27, 2004	Apr	DISC
---	-----------------	----------	-------------	--------------	-----	------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

	@	ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012	Mar	DISC
AB			5MG	A090044 001	Mar 12, 2012	Feb	NEWA
	@		10MG	A090044 002	Mar 12, 2012	Mar	DISC
AB			10MG	A090044 002	Mar 12, 2012	Feb	NEWA
		NAMENDA					
		FOREST LABS	5MG	N021487 001	Oct 16, 2003	Mar	CTEC
AB			5MG	N021487 001	Oct 16, 2003	Feb	CTEC
	+		10MG	N021487 002	Oct 16, 2003	Mar	CTEC
AB	+		10MG	N021487 002	Oct 16, 2003	Feb	CTEC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

@	DENTSPLY PHARM	3%	A088653 001	Aug 21, 1984	May	DISC
---	----------------	----	-------------	--------------	-----	------

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

@	AQUA PHARMS	2%;0.01%	N020922 001	Dec 10, 1999	Jun	DISC
---	-------------	----------	-------------	--------------	-----	------

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

@	APTALIS PHARMA US	500MG	N021252 001	Jan 05, 2001	Jul	CAHN
		1GM	N021252 002	Nov 05, 2004	Jul	CAHN

ROWASA

@	MEDA PHARMS	500MG	N019919 001	Dec 18, 1990	Jan	CAHN
---	-------------	-------	-------------	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	MYLAN INSTITUTIONAL	100MG/ML	A076488 001	Mar 08, 2012	Feb	NEWA
----	---------------------	----------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MARKSANS PHARMA	500MG	A090888 001	Mar 12, 2012	Feb	NEWA
AB		850MG	A090888 002	Mar 12, 2012	Feb	NEWA
AB		1GM	A090888 003	Mar 12, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1	AUROBINDO PHARMA LTD	500MG	A079118 001	Jul 20, 2012	Jul	NEWA
AB		750MG	A079118 002	Jul 20, 2012	Jul	NEWA
AB1	INVENTIA HLTHCARE	500MG	A201991 001	Jan 18, 2012	Jan	NEWA
AB2	MYLAN PHARMS INC	500MG	A200690 001	Aug 01, 2012	Jul	NEWA
AB		1GM	A200690 002	Aug 01, 2012	Jul	NEWA
	@ RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004	Apr	DISC
	@	750MG	A077211 001	Jun 29, 2005	Apr	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

>D>	AB	TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Aug	CAHN
>D>	AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Aug	CAHN
>A>	AB	TAKEDA PHARMS USA	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Aug	CAHN
>A>	AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

>D>		TAKEDA GLOBAL	1GM;EQ 15MG BASE	N022024 001	May 12, 2009	Aug	CAHN
>D>		+	1GM;EQ 30MG BASE	N022024 002	May 12, 2009	Aug	CAHN
>A>		TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024 001	May 12, 2009	Aug	CAHN
>A>		+	1GM;EQ 30MG BASE	N022024 002	May 12, 2009	Aug	CAHN

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

		BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE	N200678 001	Nov 05, 2010	Apr	CAIN
			1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010	Apr	CAIN
		+	1GM;EQ 5MG BASE	N200678 002	Nov 05, 2010	Apr	CAIN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

		MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044 001	Mar 30, 2007	May	CAHN
		+	1GM;EQ 50MG BASE	N022044 002	Mar 30, 2007	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

		MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012	Feb	NEWA
			1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012	Feb	NEWA
		+	1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	5MG	A202068 001	Mar 07, 2012	Feb	NEWA
AB		10MG	A202068 002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989 001	Mar	CMFD
AA		750MG	A086988 001	Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266 001	Feb 26, 1999	Jan	CMFD
AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171 001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+ BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001	Sep 16, 1986	Feb	CTEC
----	-----------	-------------------------------------	-------------	--------------	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+ MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767 001	Apr 30, 2007	Feb	CAHN
AP	ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529 001	Mar 29, 2012	Mar	NEWA
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529 002	Mar 29, 2012	Mar	NEWA
AP		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529 003	Mar 29, 2012	Mar	NEWA
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004	Mar 29, 2012	Mar	NEWA
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001	Mar 29, 2012	Mar	NEWA

METHYLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM

2.5MG

N012524 001

Mar DISC

@

5MG

N012524 004

Mar DISC

METHYLOTHIAZIDE

AB	+ MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Mar	CRLD
----	--------------------	-----	-------------	--------------	-----	------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL

50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS

8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

+

12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008 Jun NEWA

SOLUTION; SUBCUTANEOUS

RELISTOR

+

SALIX PHARMS

12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008 May CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

AB	UCB INC	10MG	N021259 003	May 27, 2003	Jul	CFTG
AB2		20MG	N021259 001	Apr 03, 2001	Jul	CFTG
AB2		30MG	N021259 002	Jun 19, 2003	Jul	CFTG
AB2		40MG	N021259 004	Feb 19, 2006	Jul	CFTG

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

AB	UCB INC	50MG	N021259 005	Feb 19, 2006	Jul	CFTG
AB	+	60MG	N021259 006	Feb 19, 2006	Jul	CFTG

METHYLPHENIDATE HYDROCHLORIDE

AB1	ACTAVIS	20MG	A078458 001	Dec 01, 2011	Jul	CTEC
AB1		30MG	A078458 002	Dec 01, 2011	Jul	CTEC
AB1		40MG	A078458 003	Dec 01, 2011	Jul	CTEC
AB1	BARR LABS INC	20MG	A079031 001	Jul 13, 2012	Jul	CTEC
AB		20MG	A079031 001	Jul 13, 2012	Jun	NEWA
AB1		30MG	A079031 002	Jul 13, 2012	Jul	CTEC
AB		30MG	A079031 002	Jul 13, 2012	Jun	NEWA
AB1		40MG	A079031 003	Jul 13, 2012	Jul	CTEC
AB		40MG	A079031 003	Jul 13, 2012	Jun	NEWA
AB	TEVA PHARMS	10MG	A077707 001	Jul 19, 2012	Jul	NEWA
AB2		20MG	A077707 002	Jul 19, 2012	Jul	NEWA
AB2		30MG	A077707 003	Jul 19, 2012	Jul	NEWA
AB2		40MG	A078873 001	Jul 19, 2012	Jul	NEWA
AB		50MG	A078873 002	Jul 19, 2012	Jul	NEWA
AB		60MG	A078873 003	Jul 19, 2012	Jul	NEWA

RITALIN LA

AB1	NOVARTIS	20MG	N021284 001	Jun 05, 2002	Jul	CTEC
AB1		30MG	N021284 002	Jun 05, 2002	Jul	CTEC
AB1	+	40MG	N021284 003	Jun 05, 2002	Jul	CTEC

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	A090710 001	Mar 15, 2012	Feb	NEWA
AB		10MG	A090710 002	Mar 15, 2012	Feb	NEWA
AB		20MG	A090710 003	Mar 15, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

@	UCB INC	10MG	A040306 001	Oct 20, 1999	Jul	DISC
---	---------	------	-------------	--------------	-----	------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

>D>	AP	HEMOPARM	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Aug	CAHN
>D>	AP		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Aug	CAHN
>A>	AP	HOSPIRA INC	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Aug	CAHN
>A>	AP		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Aug	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

@	BEDFORD LABS	EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007	Jun	DISC
@		EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007	Jun	DISC
@	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@	TEVA PARENTERAL	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Jan	DISC
---	-----------------	----------------	-------------	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617 001	Aug 01, 2012	Jul	NEWA
AB		EQ 50MG TARTRATE	A090617 002	Aug 01, 2012	Jul	NEWA
	@ NESHER PHARMS	EQ 100MG TARTRATE	A076640 002	May 18, 2007	Jun	DISC
	@	EQ 200MG TARTRATE	A076640 001	May 18, 2007	Jun	DISC
AB	REDDYS	EQ 100MG BASE	A078889 001	Aug 15, 2012	Jul	NEWA
AB		EQ 200MG BASE	A078889 002	Aug 15, 2012	Jul	NEWA
>D>	AB SANDOZ	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006	Aug	DISC
>A>	@	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006	Aug	DISC
>D>	AB	EQ 50MG TARTRATE	A076969 002	May 18, 2007	Aug	DISC
>A>	@	EQ 50MG TARTRATE	A076969 002	May 18, 2007	Aug	DISC
>D>	AB	EQ 100MG TARTRATE	A076969 003	Mar 20, 2008	Aug	DISC
>A>	@	EQ 100MG TARTRATE	A076969 003	Mar 20, 2008	Aug	DISC
>D>	AB	EQ 200MG TARTRATE	A076969 004	Mar 20, 2008	Aug	DISC
>A>	@	EQ 200MG TARTRATE	A076969 004	Mar 20, 2008	Aug	DISC

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004	Jan	CAHN
	NORITATE					
+	VALEANT INTL	1%	N020743 001	Sep 26, 1997	Apr	CAHN

GEL; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

LOTION; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+	HRA PHARMA	250MG	N012911 002	Aug 09, 1996	Jun	CAHN
---	------------	-------	-------------	--------------	-----	------

TABLET; ORAL

METOPIRONE

	@ HRA PHARMA	250MG	N012911 001		Jun	CAHN
--	--------------	-------	-------------	--	-----	------

METYROSINE

CAPSULE; ORAL

DEMSEER

+	BIOVAIL TECHNOLOGIES	250MG	N017871 001		May	CAHN
---	----------------------	-------	-------------	--	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
AP		EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

AB	SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
AB	+	5MG	N019815 002	Sep 06, 1996	Jan	CAHN

TABLET; ORAL							
PROAMATINE							
AB	SHIRE LLC	10MG	N019815 003	Mar 20, 2002	Jan	CAHN	
<u>MIFEPRISTONE</u>							
TABLET; ORAL							
KORLYM							
+	CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012	Feb	NEWA	
<u>MINOCYCLINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
MINOCIN							
AB	PRECISION DERMAT	EQ 50MG BASE	N050649 001	May 31, 1990	May	CAHN	
	@	EQ 75MG BASE	N050649 003	Feb 12, 2001	May	CAHN	
AB		EQ 100MG BASE	N050649 002	May 31, 1990	May	CAHN	
CAPSULE, EXTENDED RELEASE; ORAL							
XIMINO							
	RANBAXY LABS LTD	EQ 45MG BASE	N201922 001	Jul 11, 2012	Jul	NEWA	
		EQ 67.5MG BASE	N201922 002	Jul 11, 2012	Jul	NEWA	
		EQ 90MG BASE	N201922 003	Jul 11, 2012	Jul	NEWA	
		EQ 112.5MG BASE	N201922 004	Jul 11, 2012	Jul	NEWA	
+		EQ 135MG BASE	N201922 005	Jul 11, 2012	Jul	NEWA	
INJECTABLE; INJECTION							
MINOCIN							
+	PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444 001		May	CAHN	
SUSPENSION; ORAL							
MINOCIN							
	@ PRECISION DERMAT	EQ 50MG BASE/5ML	N050445 001		May	CAHN	
<u>MIRABEGRON</u>							
TABLET, EXTENDED RELEASE; ORAL							
MYRBETRIQ							
	APGDI	25MG	N202611 001	Jun 28, 2012	Jun	NEWA	
+		50MG	N202611 002	Jun 28, 2012	Jun	NEWA	
<u>MISOPROSTOL</u>							
TABLET; ORAL							
MISOPROSTOL							
AB	NOVEL LABS INC	0.1MG	A091667 001	Jul 25, 2012	Jul	NEWA	
AB		0.2MG	A091667 002	Jul 25, 2012	Jul	NEWA	
<u>MITOMYCIN</u>							
FOR SOLUTION; TOPICAL							
MITOSOL							
+	MOBIUS THERAP	0.2MG/VIAL	N022572 001	Feb 07, 2012	Feb	NEWA	
<u>MITOXANTRONE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
MITOXANTRONE HYDROCHLORIDE							
@	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008	Jun	DISC	
@		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008	Jun	DISC	
@		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008	Jun	DISC	

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

@ STRIDES ARCOLAB LTD EQ 2MG BASE/ML A078562 001 Apr 30, 2009 Jun CAHN

MODAFINIL

TABLET; ORAL

MODAFINIL

AB MYLAN PHARMS INC 100MG A076594 001 Jul 16, 2012 Jun NEWA

AB 200MG A076594 002 Jul 16, 2012 Jun NEWA

PROVIGIL

AB CEPHALON 100MG N020717 001 Dec 24, 1998 Jun CFTG

AB + 200MG N020717 002 Dec 24, 1998 Jun CFTG

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB + MERCK SHARP DOHME 0.1% N019625 001 May 06, 1987 Jun CAHN

MOMETASONE FUROATE

AB FOUGERA PHARMS 0.1% A076171 001 Apr 08, 2005 Jan CAHN

LOTION; TOPICAL

ELOCON

AB + MERCK SHARP DOHME 0.1% N019796 001 Mar 30, 1989 Jul CAHN

MOMETASONE FUROATE

AB FOUGERA PHARMS 0.1% A075919 001 Nov 29, 2007 Jan CAHN

OINTMENT; TOPICAL

ELOCON

AB + MERCK SHARP DOHME 0.1% N019543 001 Apr 30, 1987 May CAHN

MOMETASONE FUROATE

AB FOUGERA PHARMS 0.1% A077061 001 Mar 28, 2005 Jan CAHN

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB TEVA PHARMS EQ 4MG BASE/PACKET A090955 001 Aug 03, 2012 Jul NEWA

SINGULAIR

AB + MERCK EQ 4MG BASE/PACKET N021409 001 Jul 26, 2002 Jul CFTG

TABLET; ORAL

MONTELUKAST SODIUM

AB APOTEX CORP EQ 10MG BASE A201294 001 Aug 03, 2012 Jul NEWA

AB AUROBINDO PHARMA LTD EQ 10MG BASE A202468 001 Aug 03, 2012 Jul NEWA

AB DR REDDYS LABS LTD EQ 10MG BASE A201582 001 Aug 06, 2012 Jul NEWA

AB ENDO PHARMS EQ 10MG BASE A091576 001 Aug 03, 2012 Jul NEWA

AB GLENMARK GENERICS EQ 10MG BASE A090926 001 Aug 03, 2012 Jul NEWA

AB KUDCO IRELAND EQ 10MG BASE A201522 001 Aug 03, 2012 Jul NEWA

AB MYLAN PHARMS INC EQ 10MG BASE A079103 001 Aug 03, 2012 Jul NEWA

AB ROXANE EQ 10MG BASE A090655 001 Aug 03, 2012 Jul NEWA

AB SANDOZ INC EQ 10MG BASE A200889 001 Aug 03, 2012 Jul NEWA

AB TEVA PHARMS EQ 10MG BASE A078605 001 Aug 03, 2012 Jul NEWA

AB TORRENT PHARMS LTD EQ 10MG BASE A201515 001 Aug 03, 2012 Jul NEWA

SINGULAIR

AB + MERCK EQ 10MG BASE N020829 002 Feb 20, 1998 Jul CFTG

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB APOTEX INC EQ 4MG BASE A201508 001 Aug 03, 2012 Jul NEWA



## TABLET, CHEWABLE; ORAL

## MONTELUKAST SODIUM

AB	APOTEX INC	EQ 5MG BASE	A201508 002	Aug 03, 2012	Jul	NEWA
AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A202096 002	Aug 03, 2012	Jul	NEWA
AB	DR REDDYS LABS LTD	EQ 4MG BASE	A201581 001	Aug 06, 2012	Jul	NEWA
AB		EQ 5MG BASE	A201581 002	Aug 06, 2012	Jul	NEWA
AB	ENDO PHARMS	EQ 4MG BASE	A091588 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091588 002	Aug 03, 2012	Jul	NEWA
AB	KUDCO IRELAND	EQ 4MG BASE	A200405 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A200405 002	Aug 03, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 4MG BASE	A079142 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A079142 002	Aug 03, 2012	Jul	NEWA
AB	ROXANE	EQ 4MG BASE	A091128 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091128 002	Aug 03, 2012	Jul	NEWA
AB	SANDOZ INC	EQ 4MG BASE	A091414 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091414 002	Aug 03, 2012	Jul	NEWA
AB	TEVA PHARMS	EQ 4MG BASE	A078723 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A078723 002	Aug 03, 2012	Jul	NEWA
AB	TORRENT PHARMS LTD	EQ 4MG BASE	A090984 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A090984 002	Aug 03, 2012	Jul	NEWA
	SINGULAIR					
AB	MERCK	EQ 4MG BASE	N020830 002	Mar 03, 2000	Jul	CFTG
AB	+	EQ 5MG BASE	N020830 001	Feb 20, 1998	Jul	CFTG

MORPHINE SULFATE

## CAPSULE, EXTENDED RELEASE; ORAL

## KADIAN

	ACTAVIS ELIZABETH	40MG	N020616 009	Jul 09, 2012	Jul	NEWA
		70MG	N020616 010	Jul 09, 2012	Jul	NEWA
		130MG	N020616 011	Jul 09, 2012	Jul	NEWA
		150MG	N020616 012	Jul 09, 2012	Jul	NEWA

## INJECTABLE; INJECTION

## DURAMORPH PF

AP	+	HIKMA MAPLE	0.5MG/ML	N018565 001	Sep 18, 1984	Jun	CAHN
AP	+		1MG/ML	N018565 002	Sep 18, 1984	Jun	CAHN
	INFUMORPH						
+		HIKMA MAPLE	10MG/ML	N018565 003	Jul 19, 1991	Jun	CAHN
+			25MG/ML	N018565 004	Jul 19, 1991	Jun	CAHN

## INJECTABLE, LIPOSOMAL; EPIDURAL

## DEPODUR

	@	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CAHN
	@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	CAHN
	@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	May	CAHN

## SOLUTION; ORAL

## MORPHINE SULFATE

AA		PADDOCK LLC	100MG/5ML	A201574 001	Aug 06, 2012	Jul	NEWA
----	--	-------------	-----------	-------------	--------------	-----	------

## TABLET, EXTENDED RELEASE; ORAL

## MORPHINE SULFATE

AB		RANBAXY LABS LTD	15MG	A078761 001	May 11, 2012	Apr	NEWA
AB			30MG	A078761 002	May 11, 2012	Apr	NEWA
AB			60MG	A078761 003	May 11, 2012	Apr	NEWA
AB			100MG	A078761 004	May 11, 2012	Apr	NEWA
AB			200MG	A078761 005	May 11, 2012	Apr	NEWA
	ORAMORPH SR						
	@	XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994	May	DISC

## TABLET, EXTENDED RELEASE; ORAL

## ORAMORPH SR

@	XANODYNE PHARMS INC	30MG	N019977 001	Aug 15, 1991	May	DISC
@		60MG	N019977 002	Aug 15, 1991	May	DISC
@		100MG	N019977 003	Aug 15, 1991	May	DISC

MUPIROCIN

## OINTMENT; TOPICAL

## MUPIROCIN

AB	FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

MYCOPHENOLIC ACID

## TABLET, DELAYED RELEASE; ORAL

## &gt;A&gt; MYCOPHENOLIC ACID

>A>	AB	APOTEX INC	180MG	A091558 001	Aug 21, 2012	Aug	NEWA
-----	----	------------	-------	-------------	--------------	-----	------

## MYFORTIC

>D>		NOVARTIS	180MG	N050791 001	Feb 27, 2004	Aug	CFTG
-----	--	----------	-------	-------------	--------------	-----	------

>A>	AB		180MG	N050791 001	Feb 27, 2004	Aug	CFTG
-----	----	--	-------	-------------	--------------	-----	------

NABUMETONE

## TABLET; ORAL

## NABUMETONE

AB	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Feb	CMFD
----	-------------	-------	-------------	--------------	-----	------

AB		750MG	A079093 002	Feb 27, 2009	Feb	CMFD
----	--	-------	-------------	--------------	-----	------

NAFCILLIN SODIUM

## INJECTABLE; INJECTION

## NAFCILLIN SODIUM

>D>	AP	ACIC FINE CHEMS	EQ 1GM BASE	A090560 001	Oct 03, 2011	Aug	CAHN
-----	----	-----------------	-------------	-------------	--------------	-----	------

>D>	AP		EQ 2GM BASE	A090560 002	Oct 03, 2011	Aug	CAHN
-----	----	--	-------------	-------------	--------------	-----	------

>A>	AP	ANTIBIOTICE	EQ 1GM BASE	A090560 001	Oct 03, 2011	Aug	CAHN
-----	----	-------------	-------------	-------------	--------------	-----	------

>A>	AP		EQ 2GM BASE	A090560 002	Oct 03, 2011	Aug	CAHN
-----	----	--	-------------	-------------	--------------	-----	------

>A>	AP	ASTRAL PHARM INDS	EQ 1GM BASE/VIAL	A090582 001	Aug 24, 2012	Aug	NEWA
-----	----	-------------------	------------------	-------------	--------------	-----	------

>A>	AP		EQ 2GM BASE/VIAL	A090582 002	Aug 24, 2012	Aug	NEWA
-----	----	--	------------------	-------------	--------------	-----	------

>A>	AP		EQ 10GM BASE/VIAL	A090580 001	Aug 24, 2012	Aug	NEWA
-----	----	--	-------------------	-------------	--------------	-----	------

NAFTIFINE HYDROCHLORIDE

## CREAM; TOPICAL

## NAFTIN

+	MERZ PHARMS	2%	N019599 002	Jan 13, 2012	Jan	NEWA
---	-------------	----	-------------	--------------	-----	------

NALOXONE HYDROCHLORIDE

## INJECTABLE; INJECTION

## NALOXONE

@	HIKMA MAPLE	0.4MG/ML	A070298 001	Sep 24, 1986	Jun	CAHN
---	-------------	----------	-------------	--------------	-----	------

@		0.4MG/ML	A070299 001	Sep 24, 1986	Jun	CAHN
---	--	----------	-------------	--------------	-----	------

@		0.4MG/ML	A070496 001	Sep 24, 1986	Jun	CAHN
---	--	----------	-------------	--------------	-----	------

## NALOXONE HYDROCHLORIDE

@	HIKMA MAPLE	0.02MG/ML	A071272 001	May 24, 1988	Jun	CAHN
---	-------------	-----------	-------------	--------------	-----	------

@		1MG/ML	A071287 001	May 24, 1988	Jun	CAHN
---	--	--------	-------------	--------------	-----	------

@		1MG/ML	A071274 001	May 24, 1988	Jun	CAHN
---	--	--------	-------------	--------------	-----	------

@		1MG/ML	A071273 001	May 24, 1988	Jun	CAHN
---	--	--------	-------------	--------------	-----	------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356 001	Feb 24, 2012	Feb	NEWA
----	-------------------	------	-------------	--------------	-----	------

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	HOFFMANN LA ROCHE	EQ 250MG BASE	N018164 001		May	CAHN
----	-------------------	---------------	-------------	--	-----	------

ANAPROX DS

AB	+ HOFFMANN LA ROCHE	EQ 500MG BASE	N018164 003	Sep 30, 1987	May	CAHN
----	---------------------	---------------	-------------	--------------	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+	SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008	May	CAHN
---	--------------------	--------------------	-------------	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	MYLAN PHARMS INC	EQ 1MG BASE	A202431 001	May 31, 2012	May	NEWA
----	------------------	-------------	-------------	--------------	-----	------

AB		EQ 2.5MG BASE	A202431 002	May 31, 2012	May	NEWA
----	--	---------------	-------------	--------------	-----	------

AB	ORCHID HLTHCARE	EQ 1MG BASE	A091441 001	Apr 30, 2012	Apr	NEWA
----	-----------------	-------------	-------------	--------------	-----	------

AB		EQ 2.5MG BASE	A091441 002	Apr 30, 2012	Apr	NEWA
----	--	---------------	-------------	--------------	-----	------

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

@	TEVA PHARMS	60MG	A077467 001	Sep 09, 2009	Jul	DISC
---	-------------	------	-------------	--------------	-----	------

@		120MG	A077467 002	Sep 09, 2009	Jul	DISC
---	--	-------	-------------	--------------	-----	------

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIL

>D>	+	ALLERGAN	2%	N021009 001	Dec 08, 1999	Aug	CFTG
-----	---	----------	----	-------------	--------------	-----	------

>A>	AT	+	2%	N021009 001	Dec 08, 1999	Aug	CFTG
-----	----	---	----	-------------	--------------	-----	------

>A>		NEDOCROMIL SODIUM					
-----	--	-------------------	--	--	--	--	--

>A>	AT	AKORN	2%	A090638 001	Aug 22, 2012	Aug	NEWA
-----	----	-------	----	-------------	--------------	-----	------

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA	AUROBINDO	50MG/5ML	A077702 001	May 22, 2012	May	NEWA
----	-----------	----------	-------------	--------------	-----	------

VIRAMUNE

AA	+ BOEHRINGER INGELHEIM	50MG/5ML	N020933 001	Sep 11, 1998	May	CFTG
----	------------------------	----------	-------------	--------------	-----	------

TABLET; ORAL

NEVIRAPINE

AB	APOTEX INC	200MG	A203021 001	May 22, 2012	May	NEWA
----	------------	-------	-------------	--------------	-----	------

AB	AUROBINDO	200MG	A077521 001	May 22, 2012	May	NEWA
----	-----------	-------	-------------	--------------	-----	------

AB	CIPLA	200MG	A077956 001	May 22, 2012	May	NEWA
----	-------	-------	-------------	--------------	-----	------

AB	HETERO LABS LTD III	200MG	A078584 001	May 22, 2012	May	NEWA
----	---------------------	-------	-------------	--------------	-----	------

AB	MICRO LABS LTD	200MG	A203080 001	May 22, 2012	May	NEWA
----	----------------	-------	-------------	--------------	-----	------

AB	MYLAN LABS	200MG	A078864 001	May 22, 2012	May	NEWA
----	------------	-------	-------------	--------------	-----	------

AB	MYLAN PHARMS INC	200MG	A202523 001	May 22, 2012	May	NEWA
----	------------------	-------	-------------	--------------	-----	------

AB	PRINSTON INC	200MG	A078644 001	May 22, 2012	May	NEWA
----	--------------	-------	-------------	--------------	-----	------

TABLET; ORAL

## NEVIRAPINE

AB	SCIEGEN PHARMS INC	200MG	A203176 001	May 22, 2012	May	NEWA
AB	STRIDES	200MG	A078195 001	May 22, 2012	May	NEWA
<u>VIRAMUNE</u>						
AB	+ BOEHRINGER INGELHEIM	200MG	N020636 001	Jun 21, 1996	May	CFTG

NIFEDIPINE

## TABLET, EXTENDED RELEASE; ORAL

## NIFEDIPINE

AB1	ACTAVIS	90MG	A077899 003	May 25, 2012	May	NEWA
-----	---------	------	-------------	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

## CAPSULE; ORAL

## MACRODANTIN

AB	ALMATICA	25MG	N016620 003		Jul	CAHN
AB		50MG	N016620 001		Jul	CAHN
AB	+	100MG	N016620 002		Jul	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

## CAPSULE; ORAL

## MACROBID

AB	+ ALMATICA	75MG;25MG	N020064 001	Dec 24, 1991	Jul	CAHN
	NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)					
	@ RANBAXY LABS LTD	75MG;25MG	A076951 001	Mar 30, 2005	Apr	DISC

NITROGLYCERIN

## FILM, EXTENDED RELEASE; TRANSDERMAL

## MINITRAN

AB1	MEDICIS	0.1MG/HR	A089771 001	Aug 30, 1996	Jul	CAHN
AB1		0.2MG/HR	A089772 001	Aug 30, 1996	Jul	CAHN
AB1		0.4MG/HR	A089773 001	Aug 30, 1996	Jul	CAHN
AB1		0.6MG/HR	A089774 001	Aug 30, 1996	Jul	CAHN

## OINTMENT; INTRA-ANAL

## RECTIV

+	APTALIS PHARMA	0.4%	N021359 001	Jun 21, 2011	Jan	CAHN
---	----------------	------	-------------	--------------	-----	------

NIZATIDINE

## CAPSULE; ORAL

## AXID

@ SMITHKLINE BEECHAM 150MG

@ 300MG

## NIZATIDINE

@ MYLAN PHARMS INC 150MG

@ 300MG

AB	+	300MG	A075806 002	Jul 05, 2002	Apr	CRLD
----	---	-------	-------------	--------------	-----	------

NOREPINEPHRINE BITARTRATE

## INJECTABLE; INJECTION

## NOREPINEPHRINE BITARTRATE

AP	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012	May	CAHN
AP	SINETICA	EQ 1MG BASE/ML	A040859 001	Mar 27, 2012	Mar	NEWA

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB	AMNEAL PHARMS	5MG	A200275 001	Jul 30, 2012	Jul	NEWA
----	---------------	-----	-------------	--------------	-----	------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	FOUGERA PHARMS	100,000 UNITS/GM	A062129 001		Jan	CAHN
>D>	AT	TARO	A064022 001	Jan 29, 1993	Aug	CRLD
>A>	AT	+	A064022 001	Jan 29, 1993	Aug	CRLD

OINTMENT; TOPICAL

NYSTATIN

AT	+	FOUGERA PHARMS	100,000 UNITS/GM	A062124 002	Sep 23, 1982	Jan	CAHN
----	---	----------------	------------------	-------------	--------------	-----	------

POWDER; TOPICAL

NYSTATIN

@ NESHER PHARMS

		100,000 UNITS/GM	A065321 001	Aug 18, 2006	Jun	DISC
--	--	------------------	-------------	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@ G AND W LABS INC

		100,000 UNITS/GM;0.1%	A062367 001	May 28, 1985	Jun	CAHN
--	--	-----------------------	-------------	--------------	-----	------

OINTMENT; TOPICAL

MYKACET

@ G AND W LABS INC

		100,000 UNITS/GM;0.1%	A062733 001	Mar 09, 1987	Jun	CAHN
--	--	-----------------------	-------------	--------------	-----	------

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

>D>	AT	SANDOZ	0.3%	A076848 001	Nov 25, 2008	Aug	DISC
>A>		@	0.3%	A076848 001	Nov 25, 2008	Aug	DISC

TABLET; ORAL

OFLOXACIN

@ RANBAXY LABS LTD

		200MG	A076220 001	Sep 02, 2003	Apr	DISC
--	--	-------	-------------	--------------	-----	------

@

		300MG	A076220 002	Sep 02, 2003	Apr	DISC
--	--	-------	-------------	--------------	-----	------

@

		400MG	A076220 003	Sep 02, 2003	Apr	DISC
--	--	-------	-------------	--------------	-----	------

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP	PHARMAFORCE	10MG/VIAL	A201741 001	Mar 20, 2012	Mar	NEWA
AP	SANDOZ INC	10MG/VIAL	A201588 001	Oct 24, 2011	Mar	CAHN

TABLET; ORAL

OLANZAPINE

AB	APOTEX INC	2.5MG	A090798 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A090798 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A090798 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A090798 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A090798 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A090798 006	Apr 23, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A202050 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202050 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202050 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202050 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202050 005	Apr 23, 2012	Apr	NEWA

TABLET; ORAL

OLANZAPINE

AB	AUROBINDO PHARMA LTD	20MG	A202050 006	Apr 23, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A076255 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076255 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076255 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076255 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076133 001	Apr 23, 2012	Apr	NEWA
AB	MYLAN	2.5MG	A076866 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076866 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076866 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076866 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076866 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A076866 006	Apr 23, 2012	Apr	NEWA
AB	ORCHID HLTHCARE	2.5MG	A202287 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202287 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202287 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202287 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202287 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202287 006	Apr 23, 2012	Apr	NEWA
AB	SUN PHARM INDS	2.5MG	A091038 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091038 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091038 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091038 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091038 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091038 006	Apr 23, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	2.5MG	A091434 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091434 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091434 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091434 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091434 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091434 006	Apr 23, 2012	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA	
AB		10MG	A077243 002	Jan 30, 2012	Jan	NEWA	
AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA	
AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA	
>A>	AB	JUBILANT ORGANOSYS	5MG	A200221 001	Sep 12, 2012	Aug	NEWA
>A>	AB		10MG	A200221 002	Sep 12, 2012	Aug	NEWA
>A>	AB		15MG	A200221 003	Sep 12, 2012	Aug	NEWA
>A>	AB		20MG	A200221 004	Sep 12, 2012	Aug	NEWA
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA	
AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA	
AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA	
AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA	

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS LTD	10MG	A078490 002	Mar 16, 2009	Apr	NEWA	
AB		20MG	A078490 003	Mar 16, 2009	Apr	NEWA	
>D>	AB	LEK PHARMS	10MG	A075757 001	Jan 28, 2003	Aug	CAHN
>D>	AB		20MG	A075757 002	Jan 28, 2003	Aug	CAHN
>A>	AB	SANDOZ	10MG	A075757 001	Jan 28, 2003	Aug	CAHN
>A>	AB		20MG	A075757 002	Jan 28, 2003	Aug	CAHN

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

	@ NESHER PHARMS	4MG	A077717 001	Jun 25, 2007	Jun	DISC
	@	8MG	A077717 002	Jun 25, 2007	Jun	DISC
>D>	AB PAR PHARM	4MG	A076506 001	Dec 26, 2006	Aug	DISC
>A>	@	4MG	A076506 001	Dec 26, 2006	Aug	DISC
>D>	AB	8MG	A076506 002	Dec 26, 2006	Aug	DISC
>A>	@	8MG	A076506 002	Dec 26, 2006	Aug	DISC
>D>		16MG	A077406 001	Dec 26, 2006	Aug	DISC
>A>	@	16MG	A077406 001	Dec 26, 2006	Aug	DISC
>D>		24MG	A077406 002	Dec 26, 2006	Aug	DISC
>A>	@	24MG	A077406 002	Dec 26, 2006	Aug	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648 001	Jun 15, 2012	Jun	NEWA
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365 001	Dec 26, 2006	Jun	CAHN
>A>	@ SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007	Aug	DISC
>D>	AP SPECTRUM PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007	Aug	DISC
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541 001	Dec 26, 2006	Jun	CAHN

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

>D>	AB PAR PHARM	EQ 4MG BASE	A077303 001	Jun 25, 2007	Aug	DISC
>A>	@	EQ 4MG BASE	A077303 001	Jun 25, 2007	Aug	DISC
>D>	AB	EQ 8MG BASE	A077303 002	Jun 25, 2007	Aug	DISC
>A>	@	EQ 8MG BASE	A077303 002	Jun 25, 2007	Aug	DISC
>D>	AB	EQ 24MG BASE	A077303 004	Jun 25, 2007	Aug	DISC
>A>	@	EQ 24MG BASE	A077303 004	Jun 25, 2007	Aug	DISC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB	CNTY LINE PHARMS	100MG	A040249 001	Jan 29, 1999	Jul	CAHN
AB	INVAGEN PHARMS	100MG	A091158 001	Jul 27, 2012	Jul	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+	ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jan	CRLD
---	-------	----------------	-------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246 001	Mar 30, 2012	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A091246 002	Mar 30, 2012	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A091245 001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	ACTAVIS TOTOWA	50MG/VIAL	A078803 001	Aug 08, 2012	Jul	NEWA
AP		100MG/VIAL	A078803 002	Aug 08, 2012	Jul	NEWA

## INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	ONCO THERAPIES LTD	50MG/10ML (5MG/ML)	A091358 001	Aug 07, 2012	Jul	NEWA
AP		50MG/VIAL	A200979 001	Aug 08, 2012	Jul	NEWA
AP		100MG/20ML (5MG/ML)	A091358 002	Aug 07, 2012	Jul	NEWA
AP		100MG/VIAL	A200979 002	Aug 08, 2012	Jul	NEWA
AP	+ TEVA PHARMS	50MG/10ML (5MG/ML)	N022160 001	Aug 07, 2009	Mar	CRLD
AP	+	100MG/20ML (5MG/ML)	N022160 002	Aug 07, 2009	Mar	CRLD

OXCARBAZEPINE

## SUSPENSION; ORAL

OXCARBAZEPINE

>A>	AB	AMNEAL PHARMS	300MG/5ML	A202961 001	Sep 17, 2012	Aug	NEWA
-----	----	---------------	-----------	-------------	--------------	-----	------

OXICONAZOLE NITRATE

## CREAM; TOPICAL

OXISTAT

	+	FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
--	---	----------------	------------	-------------	--------------	-----	------

OXTRIPHYLLINE

## TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

	+	WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983	Jun	CAHN
	+		600MG	A086742 001		Jun	CAHN

OXYBUTYNIN

## GEL, METERED; TRANSDERMAL

ANTUROL

	+	ARROW INTL	3%	N202513 001	Dec 07, 2011	Apr	CAHN
	+	WATSON LABS INC	3%	N202513 001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

## TABLET; ORAL

DITROPAN

## @ JANSSEN PHARMS

5MG

N017577 001 Mar DISC

OXYBUTYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079 001	Oct 31, 1997	Mar	CRLD
----	---	----------------	-----	-------------	--------------	-----	------

## TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB		MYLAN PHARMS INC	15MG	A076644 002	May 10, 2007	Mar	NEWA
----	--	------------------	------	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

## CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB		COASTAL PHARMS	5MG	A203107 001	Jul 26, 2012	Jul	NEWA
AB	+	LEHIGH VALLEY	5MG	N200534 001	Oct 20, 2010	Jul	CFTG

## SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA	+	LEHIGH VALLEY	100MG/5ML	N200535 001	Oct 20, 2010	Jul	CFTG
	+	VISTAPHARM	5MG/5ML	N201194 001	Jan 12, 2012	Jan	NEWA
AA			100MG/5ML	A202537 001	Jul 30, 2012	Jul	NEWA

## TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB		MALLINCKRODT INC	5MG	A076758 003	Mar 19, 2007	Apr	NEWA
----	--	------------------	-----	-------------	--------------	-----	------



OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

	@ ENDO PHARMS	5MG	N021610 001	Jun 22, 2006	May	DISC
	@	10MG	N021610 002	Jun 22, 2006	May	DISC
	@	20MG	N021610 003	Jun 22, 2006	May	DISC
	@	30MG	N021610 007	Feb 29, 2008	May	DISC
>D>		40MG	N201655 007	Dec 09, 2011	Aug	CRLD
>A>	+	40MG	N201655 007	Dec 09, 2011	Aug	CRLD
	@	40MG	N021610 004	Jun 22, 2006	May	DISC

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS

5MG	A079087 001	Jun 14, 2010	May	CTEC
10MG	A079087 003	Jun 14, 2010	May	CTEC
20MG	A079087 005	Jun 14, 2010	May	CTEC
30MG	A079087 006	Jul 22, 2010	May	CTEC
40MG	A079087 007	Jun 14, 2010	May	CTEC

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

	@ TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008	Jan	DISC
	@	100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008	Mar	DISC
>A>	PITOCIN					
	JHP PHARMS	500USP UNITS/50ML (10USP UNITS/ML)	N018261 003	Sep 05, 2012	Aug	NEWA

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

@ CORDEN PHARMA	6MG/ML	N020262 001	Dec 29, 1992	Mar	CAHN
-----------------	--------	-------------	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

ARELIA

@ NOVARTIS	30MG/VIAL	N020036 001	Oct 31, 1991	Mar	DISC
------------	-----------	-------------	--------------	-----	------

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBOTT LABS

	15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725 004	Jul 12, 2011	Jun	NEWA
	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725 001	Apr 30, 2009	Feb	CAHN
	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725 002	Apr 30, 2009	Feb	CAHN
+	120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725 003	Apr 30, 2009	Feb	CAHN

PERTZYE

DIGESTIVE CARE INC

	30,250USP/UNITS;8,000USP/UNITS;28,750USP/UNITS	N022175 001	May 17, 2012	May	NEWA
+	60,500USP/UNITS;16,000USP/UNITS;57,500USP/UNITS	N022175 002	May 17, 2012	May	NEWA

ULTRESA

APTALIS PHARMA US

27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222 001	Mar 01, 2012	Mar	NEWA
41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222 002	Mar 01, 2012	Mar	NEWA

CAPSULE, DELAYED RELEASE; ORAL

ULTRESA

+ APTALIS PHARMA US 46,000USP UNITS;23,000USP UNITS;46,000USP UNITS N022222 003 Mar 01, 2012 Mar NEWA

ZENPEP

APTALIS PHARMA US 16,000USP UNITS;3,000USP UNITS;10,000USP UNITS N022210 005 Jun 15, 2011 Apr NEWA  
 109,000USP UNITS;20,000USP UNITS;68,000USP UNITS N022210 004 Aug 27, 2009 Apr CRLD  
 + 136,000USP UNITS;25,000USP UNITS;85,000USP UNITS N022210 006 Jul 13, 2011 Apr NEWA

TABLET; ORAL

VIOKACE

APTALIS PHARMA US 39,150USP UNITS;10,440USP UNITS;39,150USP UNITS N022542 001 Mar 01, 2012 Mar NEWA  
 + 78,300USP UNITS;20,880USP UNITS;78,300USP UNITS N022542 002 Mar 01, 2012 Mar NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB APOTEX INC EQ 20MG BASE A090807 001 May 02, 2012 Apr NEWA  
 AB EQ 40MG BASE A090807 002 May 02, 2012 Apr NEWA  
 AB MACLEODS PHARMS LTD EQ 20MG BASE A200821 001 Feb 16, 2012 Jan NEWA  
 AB EQ 40MG BASE A200821 002 Feb 16, 2012 Jan NEWA  
 AB RANBAXY LABS LTD EQ 20MG BASE A200794 001 May 02, 2012 Apr NEWA  
 AB EQ 40MG BASE A200794 002 May 02, 2012 Apr NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB ACTAVIS ELIZABETH EQ 10MG BASE A076968 001 Jun 21, 2010 Feb CMFD  
 AB EQ 20MG BASE A076968 002 Jun 21, 2010 Feb CMFD  
 AB EQ 30MG BASE A076968 003 Jun 21, 2010 Feb CMFD  
 AB EQ 40MG BASE A076968 004 Jun 21, 2010 Feb CMFD

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+ VALEANT PHARMS LLC EQ 0.3MG ACID/0.09ML N021756 001 Dec 17, 2004 May CAHN

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+ AFFYMAX EQ 10MG BASE/ML (EQ 10MG BASE/ML) N202799 007 Mar 27, 2012 Mar NEWA  
 + EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N202799 008 Mar 27, 2012 Mar NEWA

OMONTYS PRESERVATIVE FREE

+ AFFYMAX EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) N202799 001 Mar 27, 2012 Mar NEWA  
 + EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) N202799 002 Mar 27, 2012 Mar NEWA  
 + EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) N202799 003 Mar 27, 2012 Mar NEWA  
 + EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) N202799 004 Mar 27, 2012 Mar NEWA  
 + EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) N202799 005 Mar 27, 2012 Mar NEWA  
 + EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) N202799 006 Mar 27, 2012 Mar NEWA

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246 001		Feb	CAHN
---	------------	---------	-------------	--	-----	------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	XOMA	2MG	N020184 001	Dec 30, 1993	Jan	CAHN
AB		4MG	N020184 002	Dec 30, 1993	Jan	CAHN
AB	+	8MG	N020184 003	Dec 30, 1993	Jan	CAHN

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+	RENAISSANCE PHARMA	5%	N019855 001	Aug 25, 1989	May	CAHN
----	---	--------------------	----	-------------	--------------	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+	WELLSPRING PHARM	10MG	N008708 001		Jun	CFTG
----	---	------------------	------	-------------	--	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

AB		ROXANE	10MG	A201050 001	Jul 16, 2012	Jun	NEWA
----	--	--------	------	-------------	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA		LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA
	@	MIKAH PHARMA	15MG	A040460 001	Jan 14, 2003	Jul	CAHN
	@		30MG	A040448 001	Jan 22, 2003	Jul	CAHN
	@		30MG	A040227 001	Jun 18, 1997	Jul	CAHN
	@		37.5MG	A040228 001	Jun 19, 1997	Jul	CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

	@	MIKAH PHARMA	37.5MG	A040190 001	May 30, 1997	Jul	CAHN
--	---	--------------	--------	-------------	--------------	-----	------

	@	SANDOZ INC	30MG	A088605 001	Sep 28, 1987	Feb	DISC
--	---	------------	------	-------------	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

		CITIUS PHARMS	30MG	N202088 002	Jun 13, 2011	Apr	CRLD
+			37.5MG	N202088 003	Mar 27, 2012	Apr	CRLD
			37.5MG	N202088 003	Mar 27, 2012	Mar	NEWA

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

VIVUS

		EQ 3.75MG BASE;23MG	N022580 001	Jul 17, 2012	Jul	NEWA
		EQ 7.5MG BASE;46MG	N022580 002	Jul 17, 2012	Jul	NEWA
		EQ 11.25MG BASE;69MG	N022580 003	Jul 17, 2012	Jul	NEWA
+		EQ 15MG BASE;92MG	N022580 004	Jul 17, 2012	Jul	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011	Jan	CRLD
+		EQ 30MG BASE	A040872 002	Jul 28, 2011	Jan	CRLD

PHENYTOIN SODIUM

INJECTABLE; INJECTION  
 PHENYTOIN SODIUM  
 AP + HIKMA MAPLE 50MG/ML A084307 001 Jun CAHN

PHYTONADIONE

INJECTABLE; INJECTION  
 PHYTONADIONE  
 BP + INTL MEDICATION 1MG/0.5ML A083722 001 Feb CRLD  
 TABLET; ORAL  
 MEPHYTON  
 + VALEANT PHARMS 5MG N010104 003 Jun CAHN

PINDOLOL

TABLET; ORAL  
 PINDOLOL  
 @ MYLAN PHARMS INC 5MG A074013 001 Sep 24, 1992 May CAHN  
 @ 10MG A074018 001 Sep 24, 1992 May CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL  
 ACTOS  
 >D> TAKEDA PHARMS USA EQ 15MG BASE N021073 001 Jul 15, 1999 Aug CFTG  
 >A> AB EQ 15MG BASE N021073 001 Jul 15, 1999 Aug CFTG  
 EQ 15MG BASE N021073 001 Jul 15, 1999 Mar CAHN  
 >D> EQ 30MG BASE N021073 002 Jul 15, 1999 Aug CFTG  
 >A> AB EQ 30MG BASE N021073 002 Jul 15, 1999 Aug CFTG  
 EQ 30MG BASE N021073 002 Jul 15, 1999 Mar CAHN  
 >D> + EQ 45MG BASE N021073 003 Jul 15, 1999 Aug CFTG  
 >A> AB + EQ 45MG BASE N021073 003 Jul 15, 1999 Aug CFTG  
 + EQ 45MG BASE N021073 003 Jul 15, 1999 Mar CAHN  
 >A> PIOGLITAZONE HYDROCHLORIDE  
 >A> AB MYLAN PHARMS INC EQ 15MG BASE A076801 001 Aug 17, 2012 Aug NEWA  
 >A> AB EQ 30MG BASE A076801 002 Aug 17, 2012 Aug NEWA  
 >A> AB EQ 45MG BASE A076801 003 Aug 17, 2012 Aug NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
 K+10  
 @ FUTURE PAK 10MEQ A070999 001 Oct 22, 1987 Mar DISC  
 KAON CL-10  
 @ SAVAGE LABS 10MEQ N017046 002 Mar DISC  
 KLOR-CON M20  
 AB + UPSHER SMITH LABS 20MEQ A074726 001 Nov 20, 1998 Mar CRLD  
 KLOTRIX  
 @ APOTHECON 10MEQ N017850 001 Mar DISC  
 POTASSIUM CHLORIDE  
 @ NESHER PHARMS 20MEQ A076044 001 Apr 05, 2002 Mar DISC  
 @ SCHERING 10MEQ N019439 002 Jun 13, 1986 Mar DISC  
 @ 20MEQ N019439 001 Jun 13, 1986 Mar DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL  
 POTASSIUM CITRATE  
 @ NOVA K 10MEQ/PACKET N019647 002 Oct 13, 1988 Feb CAHN

## FOR SOLUTION; ORAL

POTASSIUM CITRATE

@ NOVA K

20MEQ/PACKET

N019647 001 Oct 13, 1988 Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

## TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	APOTEX INC	0.125MG	A090151 001	Apr 30, 2012	Apr	NEWA
AB		0.25MG	A090151 002	Apr 30, 2012	Apr	NEWA
AB		0.5MG	A090151 003	Apr 30, 2012	Apr	NEWA
AB		0.75MG	A090151 006	Apr 30, 2012	Apr	NEWA
AB		1MG	A090151 004	Apr 30, 2012	Apr	NEWA
AB		1.5MG	A090151 005	Apr 30, 2012	Apr	NEWA

PRAVASTATIN SODIUM

## TABLET; ORAL

PRAVASTATIN SODIUM

@ PLIVA HRVATSKA DOO

10MG

A077730 001 Nov 21, 2006 Jun DISC

@

20MG

A077730 002 Nov 21, 2006 Jun DISC

@

30MG

A077730 003 Nov 21, 2006 Jun DISC

@

40MG

A077730 005 Nov 21, 2006 Jun DISC

@ RANBAXY LABS LTD

10MG

A076445 001 Apr 23, 2007 Apr DISC

@

20MG

A076445 002 Apr 23, 2007 Apr DISC

@

40MG

A076445 003 Apr 23, 2007 Apr DISC

@

80MG

A076445 004 Apr 23, 2007 Apr DISC

PREDNICARBATE

## CREAM; TOPICAL

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077287 001	Sep 19, 2006	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

## OINTMENT; TOPICAL

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077236 001	Mar 09, 2007	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

PREDNISOLONE

## SYRUP; ORAL

PREDNISOLONE

AA	+ HI TECH PHARMA CO	15MG/5ML	A040401 001	Feb 27, 2003	Jul	CRLD
----	---------------------	----------	-------------	--------------	-----	------

@ NESHER PHARMS

5MG/5ML

A040423 001 Oct 22, 2001 Jun DISC

@

15MG/5ML

A040364 001 Apr 10, 2002 Jun DISC

PREDNISOLONE SODIUM PHOSPHATE

## SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

+ MISSION PHARMA

EQ 25MG BASE/5ML

A091396 001 Sep 13, 2010 Jul CAHN

@ NESHER PHARMS

EQ 5MG BASE/5ML

A076982 001 May 24, 2005 Jun DISC

PREDNISONE

## TABLET, DELAYED RELEASE; ORAL

RAYOS

HORIZON PHARMA

1MG

N202020 001 Jul 26, 2012 Jul NEWA

2MG

N202020 002 Jul 26, 2012 Jul NEWA

+

5MG

N202020 003 Jul 26, 2012 Jul NEWA

PREGABALIN

CAPSULE; ORAL

LYRICA

AB	PF PRISM	25MG	N021446 001	Dec 30, 2004	Jun	CFTG
		25MG	N021446 001	Dec 30, 2004	Jan	CAHN
AB		50MG	N021446 002	Dec 30, 2004	Jun	CFTG
		50MG	N021446 002	Dec 30, 2004	Jan	CAHN
AB		75MG	N021446 003	Dec 30, 2004	Jun	CFTG
		75MG	N021446 003	Dec 30, 2004	Jan	CAHN
		100MG	N021446 004	Dec 30, 2004	Jan	CAHN
AB		150MG	N021446 005	Dec 30, 2004	Jun	CFTG
		150MG	N021446 005	Dec 30, 2004	Jan	CAHN
AB		200MG	N021446 006	Dec 30, 2004	Jun	CFTG
		200MG	N021446 006	Dec 30, 2004	Jan	CAHN
AB		225MG	N021446 007	Dec 30, 2004	Jun	CFTG
		225MG	N021446 007	Dec 30, 2004	Jan	CAHN
AB	+	300MG	N021446 008	Dec 30, 2004	Jun	CFTG
	+	300MG	N021446 008	Dec 30, 2004	Jan	CAHN

PREGABALIN

AB	LUPIN LTD	25MG	A091040 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091040 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091040 003	Jul 03, 2012	Jun	NEWA
AB		100MG	A091040 004	Jul 03, 2012	Jun	NEWA
AB		150MG	A091040 005	Jul 03, 2012	Jun	NEWA
AB		200MG	A091040 006	Jul 03, 2012	Jun	NEWA
AB		225MG	A091040 007	Jul 03, 2012	Jun	NEWA
AB		300MG	A091040 008	Jul 03, 2012	Jun	NEWA
AB	TEVA PHARMS	25MG	A091219 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091219 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091224 001	Jul 03, 2012	Jun	NEWA
AB		100MG	A091224 002	Jul 03, 2012	Jun	NEWA
AB		150MG	A091224 003	Jul 03, 2012	Jun	NEWA
AB		200MG	A091224 004	Jul 03, 2012	Jun	NEWA
AB		225MG	A091224 005	Jul 03, 2012	Jun	NEWA
AB		300MG	A091224 006	Jul 03, 2012	Jun	NEWA
AB	WATSON LABS INC	25MG	A091221 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091221 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091221 003	Jul 03, 2012	Jun	NEWA
AB		100MG	A091221 004	Jul 03, 2012	Jun	NEWA
AB		150MG	A091221 005	Jul 03, 2012	Jun	NEWA
AB		200MG	A091221 006	Jul 03, 2012	Jun	NEWA
AB		225MG	A091221 007	Jul 03, 2012	Jun	NEWA
AB		300MG	A091221 008	Jul 03, 2012	Jun	NEWA

SOLUTION; ORAL

LYRICA

+	PF PRISM	20MG/ML	N022488 001	Jan 04, 2010	Jan	CAHN
---	----------	---------	-------------	--------------	-----	------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

@ DENTSPLY PHARM

4%

N021382 001

May DISC

PRILOCAINE HYDROCHLORIDE

+ SEPTODONT INC

4%

A079235 001 Sep 29, 2010 May CRLD

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

@ HIKMA MAPLE 100MG/ML

A089029 001 Apr 17, 1986 Jun CAHN

@ 500MG/ML

A089030 001 Apr 17, 1986 Jun CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

@ HIKMA MAPLE EQ 5MG BASE/ML

A089523 001 May 03, 1988 Jun CAHN

AP + EQ 5MG BASE/ML

A089903 001 Aug 29, 1989 Jun CAHN

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB TEVA PHARMS 100MG

A202121 001 Feb 29, 2012 Feb NEWA

AB 200MG

A202121 002 Feb 29, 2012 Feb NEWA

PROMETRIUM

AB ABBOTT LABS 100MG

N019781 001 May 14, 1998 Feb CFTG

AB + 200MG

N019781 002 Oct 15, 1999 Feb CFTG

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA TRIS PHARMA INC 6.25MG/5ML

A091675 001 Jun 28, 2012 Jun NEWA

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

@ NESHER PHARMS 150MG

A076193 001 Feb 07, 2002 Jun DISC

@ 225MG

A076193 002 Feb 07, 2002 Jun DISC

@ 300MG

A076193 003 Feb 07, 2002 Jun DISC

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

@ TEVA WOMENS R AND D 5MG

N016012 001 Jul CAHN

@ 10MG

N016012 002 Jul CAHN

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

MESTINON

AB + VALEANT PHARMS LLC 60MG

N009829 002 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

MESTINON

+ VALEANT PHARMS LLC 180MG

N011665 001 Jun CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB ACCORD HLTHCARE INC EQ 25MG BASE

A202152 001 Mar 27, 2012 Mar NEWA

AB EQ 50MG BASE

A202152 002 Mar 27, 2012 Mar NEWA

AB EQ 100MG BASE

A202152 003 Mar 27, 2012 Mar NEWA

AB EQ 200MG BASE

A202152 004 Mar 27, 2012 Mar NEWA

AB EQ 300MG BASE

A202152 005 Mar 27, 2012 Mar NEWA

## TABLET; ORAL

## QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE INC	EQ 400MG BASE	A202152 006	Mar 27, 2012	Mar	NEWA
AB	APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090960 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090960 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090960 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090960 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090960 006	Mar 27, 2012	Mar	NEWA
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A091388 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A091388 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A091388 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A091388 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A091388 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A091388 007	Mar 27, 2012	Mar	NEWA
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077380 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077380 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar	NEWA
AB	LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar	NEWA
AB	ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA



## TABLET; ORAL

## SEROQUEL

AB	+	ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB			EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB			EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
AB			EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+		EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB			EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

QUINAPRIL HYDROCHLORIDE

## TABLET; ORAL

## QUINAPRIL HYDROCHLORIDE

>D>	AB	SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005	Aug	DISC
>A>		@	EQ 5MG BASE	A076803 001	Mar 02, 2005	Aug	DISC
>D>	AB		EQ 10MG BASE	A076803 002	Mar 02, 2005	Aug	DISC
>A>		@	EQ 10MG BASE	A076803 002	Mar 02, 2005	Aug	DISC
>D>	AB		EQ 20MG BASE	A076803 003	Mar 02, 2005	Aug	DISC
>A>		@	EQ 20MG BASE	A076803 003	Mar 02, 2005	Aug	DISC
>D>	AB		EQ 40MG BASE	A076803 004	Mar 02, 2005	Aug	DISC
>A>		@	EQ 40MG BASE	A076803 004	Mar 02, 2005	Aug	DISC

RAMELTEON

## TABLET; ORAL

## ROZEREM

	+	TAKEDA PHARMS USA	8MG	N021782 001	Jul 22, 2005	Jul	CAHN
--	---	-------------------	-----	-------------	--------------	-----	------

RAMIPRIL

## CAPSULE; ORAL

## RAMIPRIL

	@	RANBAXY LABS LTD	5MG	A078849 001	Mar 06, 2009	Apr	DISC
	@		10MG	A078849 002	Mar 06, 2009	Apr	DISC

## TABLET; ORAL

## ALTACE

	@	KING PFIZER	1.25MG	N022021 001	Feb 27, 2007	Jan	DISC
	@		2.5MG	N022021 002	Feb 27, 2007	Jan	DISC
	@		5MG	N022021 003	Feb 27, 2007	Jan	DISC
	@		10MG	N022021 004	Feb 27, 2007	Jan	DISC

RANITIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
		ZANTAC IN PLASTIC CONTAINER					
	+	COVIS PHARMA	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Mar	CAHN
		@	EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986	Mar	CAHN

RIFAMPIN

## CAPSULE; ORAL

## RIMACTANE

AB		PROSAM LABS	300MG	N050429 001		Feb	CMFD
----	--	-------------	-------	-------------	--	-----	------

RILPIVIRINE HYDROCHLORIDE

## TABLET; ORAL

## EDURANT

	+	JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011	Feb	CAHN
--	---	---------------	--------------	-------------	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	WARNER CHILCOTT LLC	5MG	N020835 002	Apr 14, 2000	Jun	CAHN
AB		30MG	N020835 001	Mar 27, 1998	Jun	CAHN
AB	+	35MG	N020835 003	May 25, 2002	Jun	CAHN
	@	75MG	N020835 004	Apr 16, 2007	Jun	CAHN
	+	150MG	N020835 005	Apr 22, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

+	WARNER CHILCOTT LLC	35MG	N022560 001	Oct 08, 2010	Jun	CAHN
---	---------------------	------	-------------	--------------	-----	------

RISPERIDONE

TABLET; ORAL

RISPERIDONE

AB	PROSAM LABS	0.25MG	A078071 001	Jun 17, 2009	Feb	CMFD
AB		0.5MG	A078071 002	Jun 17, 2009	Feb	CMFD
AB		1MG	A078071 003	Jun 17, 2009	Feb	CMFD
AB		2MG	A078071 004	Jun 17, 2009	Feb	CMFD
AB		3MG	A078071 005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071 006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	TEVA	0.5MG	A076908 001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908 002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908 003	Mar 12, 2012	Feb	NEWA

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

>A>	NOVARTIS	13.3MG/24HR	N022083 005	Aug 31, 2012	Aug	NEWA
-----	----------	-------------	-------------	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB	ALEMBIC PHARMS LTD	EQ 1.5MG BASE	A091689 001	Jun 12, 2012	May	NEWA
AB		EQ 3MG BASE	A091689 002	Jun 12, 2012	May	NEWA
AB		EQ 4.5MG BASE	A091689 003	Jun 12, 2012	May	NEWA
AB		EQ 6MG BASE	A091689 004	Jun 12, 2012	May	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

>A>	AP	TAMARANG	50MG/5ML (10MG/ML)	A091115 001	Aug 27, 2012	Aug	NEWA
>A>	AP		100MG/10ML (10MG/ML)	A091115 002	Aug 27, 2012	Aug	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165 001	Feb 07, 2012	Jan	NEWA
AB		EQ 0.5MG BASE	A079165 002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165 003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165 004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165 005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165 006	Feb 07, 2012	Jan	NEWA

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB APOTEX EQ 5MG BASE A079165 007 Feb 07, 2012 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB + SMITHKLINE BEECHAM EQ 2MG BASE N022008 001 Jun 13, 2008 Apr CFTG  
 AB EQ 4MG BASE N022008 003 Jun 13, 2008 Apr CFTG  
 AB EQ 6MG BASE N022008 006 Apr 10, 2009 Apr CFTG  
 AB EQ 8MG BASE N022008 004 Jun 13, 2008 Apr CFTG  
 AB EQ 12MG BASE N022008 005 Oct 31, 2008 Apr CFTG

ROPINIROLE HYDROCHLORIDE

AB ACTAVIS EQ 2MG BASE A090869 001 May 17, 2012 Apr NEWA  
 AB EQ 4MG BASE A090869 002 May 17, 2012 Apr NEWA  
 AB EQ 6MG BASE A090869 003 May 17, 2012 Apr NEWA  
 AB EQ 8MG BASE A090869 004 May 17, 2012 Apr NEWA  
 AB EQ 12MG BASE A090869 005 May 17, 2012 Apr NEWA  
 AB DR REDDYS LABS LTD EQ 2MG BASE A201576 001 Jun 06, 2012 May NEWA  
 AB EQ 4MG BASE A201576 002 Jun 06, 2012 May NEWA  
 AB EQ 6MG BASE A201576 003 Jun 06, 2012 May NEWA  
 AB EQ 8MG BASE A201576 004 Jun 06, 2012 May NEWA  
 AB EQ 12MG BASE A201576 005 Jun 06, 2012 May NEWA  
 AB SANDOZ INC EQ 2MG BASE A201047 001 Jun 06, 2012 May NEWA  
 AB EQ 4MG BASE A201047 003 Jun 06, 2012 May NEWA  
 AB EQ 6MG BASE A201047 004 Jun 06, 2012 May NEWA  
 AB EQ 8MG BASE A201047 005 Jun 06, 2012 May NEWA  
 AB EQ 12MG BASE A201047 006 Jun 06, 2012 May NEWA  
 AB WATSON LABS INC EQ 2MG BASE A200431 001 Jun 06, 2012 May NEWA  
 AB EQ 4MG BASE A200431 002 Jun 06, 2012 May NEWA  
 AB EQ 6MG BASE A200431 003 Jun 06, 2012 May NEWA  
 AB EQ 8MG BASE A200431 004 Jun 06, 2012 May NEWA  
 AB EQ 12MG BASE A200431 005 Jun 06, 2012 May NEWA  
 >A> AB WOCKHARDT LTD EQ 2MG BASE A091395 001 Aug 27, 2012 Aug NEWA  
 >A> AB EQ 4MG BASE A091395 002 Aug 27, 2012 Aug NEWA  
 >A> AB EQ 6MG BASE A091395 003 Aug 27, 2012 Aug NEWA  
 >A> AB EQ 8MG BASE A091395 004 Aug 27, 2012 Aug NEWA  
 >A> AB EQ 12MG BASE A091395 005 Aug 27, 2012 Aug NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

UCB INC 1MG/24HR N021829 004 Apr 02, 2012 Apr NEWA  
 2MG/24HR N021829 001 May 09, 2007 Apr CMFD  
 3MG/24HR N021829 005 Apr 02, 2012 Apr NEWA  
 4MG/24HR N021829 002 May 09, 2007 Apr CMFD  
 6MG/24HR N021829 003 May 09, 2007 Apr CMFD  
 + 8MG/24HR N021829 006 Apr 02, 2012 Apr NEWA

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+ JAZZ EUSA PHARMA 50mCi/ML N020570 001 Mar 28, 1997 Jul CAHN

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+ VALEANT INTL 2% N021385 001 Dec 10, 2003 Jan CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AA	RANBAXY	EQ 20MG BASE/ML	A078053 001	Feb 05, 2007	Aug	DISC
>A>		@ RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053 001	Feb 05, 2007	Aug	DISC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB		PROSAM LABS	EQ 25MG BASE	A078175 001	Jul 21, 2010	Feb	CMFD
AB			EQ 50MG BASE	A078175 002	Jul 21, 2010	Feb	CMFD
AB			EQ 100MG BASE	A078175 003	Jul 21, 2010	Feb	CMFD

SILDENAFIL CITRATE

&gt;A&gt; FOR SUSPENSION; ORAL

&gt;A&gt; REVATIO

>A>	+	PFIZER	10MG/ML	N203109 001	Aug 30, 2012	Aug	NEWA
-----	---	--------	---------	-------------	--------------	-----	------

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

AB		THEPHARMANETWORK LLC	1%	N018810 001	Dec 23, 1985	Jun	CAHN
----	--	----------------------	----	-------------	--------------	-----	------

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB		PROSAM LABS	5MG	A078735 001	Aug 30, 2010	Feb	CMFD
AB			10MG	A078735 002	Aug 30, 2010	Feb	CMFD
AB			20MG	A078735 003	Aug 30, 2010	Feb	CMFD
AB			40MG	A078735 004	Aug 30, 2010	Feb	CMFD
AB			80MG	A078735 005	Aug 30, 2010	Feb	CMFD

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

		MERCK SHARP DOHME	EQ 25MG BASE	N021995 001	Oct 16, 2006	May	CAHN
			EQ 50MG BASE	N021995 002	Oct 16, 2006	May	CAHN
	+		EQ 100MG BASE	N021995 003	Oct 16, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

		@ MALLINCKRODT INC	460MG/GM; 420MG/GM	N018509 001	Aug 07, 1985	Jan	CAHN
--	--	--------------------	--------------------	-------------	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP		HIKMA (MAPLE)	9MG/ML	A201850 001	Jan 20, 2012	Jan	NEWA
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
		MEDEFIL	9MG/ML	N202832 001	Jan 06, 2012	Jan	NEWA

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

		@ BRACCO	200uCi/ML	N013993 001		Jun	DISC
--	--	----------	-----------	-------------	--	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB	HIKMA PHARMS	62.5MG/5ML	A078215 001	Mar 31, 2011	May	CAHN
----	--------------	------------	-------------	--------------	-----	------

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

@	GE HEALTHCARE	100uCi	N017630 001		May	DISC
---	---------------	--------	-------------	--	-----	------

SOLUTION; ORAL

SODIUM IODIDE I 123

@	GE HEALTHCARE	2mCi/ML	N017630 002		Jul	DISC
---	---------------	---------	-------------	--	-----	------

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE	9-100mCi	N021305 006	May 19, 2005	Feb	CAHN
--------------------	----------	-------------	--------------	-----	------

@		2-200mCi	N021305 004	Nov 18, 2004	Jan	DISC
---	--	----------	-------------	--------------	-----	------

SOLUTION; ORAL

HICON

@	JUBILANT DRAXIMAGE	1-1000mCi/ML	N021305 005	Apr 04, 2006	Feb	DISC
---	--------------------	--------------	-------------	--------------	-----	------

@		1-250mCi/0.25ML	N021305 002	Jan 24, 2003	Feb	DISC
---	--	-----------------	-------------	--------------	-----	------

@		1-500mCi/0.5ML	N021305 003	Jan 24, 2003	Feb	DISC
---	--	----------------	-------------	--------------	-----	------

+		250-1000mCi	N021305 007	Dec 05, 2011	Jan	NEWA
---	--	-------------	-------------	--------------	-----	------

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML (30MG/ML)	N203922 001	Feb 14, 2012	Feb	NEWA
---	-------------	----------------------	-------------	--------------	-----	------

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+	JAZZ PHARMS	500MG/ML	N021196 001	Jul 17, 2002	Jun	CAHN
---	-------------	----------	-------------	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@	CITRUSPHRMA	454GM/BOT	A040909 001	Dec 03, 2008	Jun	DISC
---	-------------	-----------	-------------	--------------	-----	------

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923 001	Feb 14, 2012	Feb	NEWA
---	-------------	------------------------	-------------	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

@	NOVO NORDISK INC	5MG/1.5ML	N021148 001	Jun 20, 2000	Jul	DISC
---	------------------	-----------	-------------	--------------	-----	------

@		10MG/1.5ML	N021148 002	Jun 20, 2000	Jul	DISC
---	--	------------	-------------	--------------	-----	------

@		15MG/1.5ML	N021148 003	Jun 20, 2000	Jul	DISC
---	--	------------	-------------	--------------	-----	------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB2	EPIC PHARMA INC	80MG	A077070 001	Nov 04, 2005	Jun	CAHN
AB2		120MG	A077070 002	Nov 04, 2005	Jun	CAHN
AB2		160MG	A077070 003	Nov 04, 2005	Jun	CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO LLC	0.9%	N022408 001	Jan 18, 2011	May	CAHN
---	-------------	------	-------------	--------------	-----	------

SUCCIMER

CAPSULE; ORAL

CHEMET

+	LUNDBECK LLC	100MG	N019998 002	Jan 30, 1991	Mar	CAHN
---	--------------	-------	-------------	--------------	-----	------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	FOUGERA PHARMS	10%	A077015 001	Nov 17, 2006	Jan	CAHN
----	----------------	-----	-------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFATRIM

>D>	@ ACTAVIS MID ATLANTIC	200MG/5ML;40MG/5ML	N018615 002	Jan 07, 1983	Aug	CAHN
>A>	@ STI PHARMA LLC	200MG/5ML;40MG/5ML	N018615 002	Jan 07, 1983	Aug	CAHN
	SULFATRIM PEDIATRIC					
>D>	AB ACTAVIS MID ATLANTIC	200MG/5ML;40MG/5ML	N018615 001	Jan 07, 1983	Aug	CAHN
>A>	AB STI PHARMA LLC	200MG/5ML;40MG/5ML	N018615 001	Jan 07, 1983	Aug	CAHN

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	JAZZ PHARMS COMMERCL	15%	N006530 003	Jan 27, 1987	Mar	CAHN
+	JAZZ PHARMS II	15%	N006530 003	Jan 27, 1987	Jul	CAHN
+	JAZZ PHARMS III	15%	N006530 003	Jan 27, 1987	Jun	CAHN

SUPPOSITORY; VAGINAL

AVC

@	JAZZ PHARMS COMMERCL	1.05GM	N006530 004	Jan 27, 1987	Mar	CAHN
@	JAZZ PHARMS II	1.05GM	N006530 004	Jan 27, 1987	Jul	CAHN
@	JAZZ PHARMS III	1.05GM	N006530 004	Jan 27, 1987	Jun	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

BX	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Jun	CRLD
	SUMATRIPTAN SUCCINATE					
AP	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310 001	Aug 11, 2010	Mar	CAHN
	SUMAVEL DOSEPRO					
BX	+ ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001	Jul 15, 2009	Jun	CTEC

TABLET; ORALSUMATRIPTAN SUCCINATE

AB	APOTEX INC	EQ 25MG BASE	A200263 001	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE	A200263 002	Jun 19, 2012	Jun	NEWA
AB		EQ 100MG BASE	A200263 003	Jun 19, 2012	Jun	NEWA

TAFLUPROSTSOLUTION/DROPS; OPHTHALMICZIOPTAN

+	MERCK SHARP DOHME	0.0015%	N202514 001	Feb 10, 2012	Feb	NEWA
---	-------------------	---------	-------------	--------------	-----	------

TALIGLUCERASE ALFAPOWDER; IV (INFUSION)ELELYSO

+	PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012	May	NEWA
---	--------	----------------	-------------	--------------	-----	------

TAMOXIFEN CITRATESOLUTION; ORALSOLTAMOX

>A>	ONCOGENERIX PHARMS	EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005	Aug	CMFD
>D>	@ ROSEMONT	EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005	Aug	CMFD

TABLET; ORALTAMOXIFEN CITRATE@ AEGIS PHARMS@

		EQ 10MG BASE	A076398 001	Mar 31, 2003	Jun	DISC
		EQ 20MG BASE	A076398 002	Mar 31, 2003	Jun	DISC

TAZAROTENEAEROSOL, FOAM; TOPICALFABIOR

+	STIEFEL LABS INC	0.1%	N202428 001	May 11, 2012	May	NEWA
---	------------------	------	-------------	--------------	-----	------

TECHNETIUM TC-99M MEDRONATEINJECTABLE; INJECTIONDRAXIMAGE MDP-10@ JUBILANT DRAXIMAGEDRAXIMAGE MDP-25

		N/A	N018035 001		May	CAHN
+	JUBILANT DRAXIMAGE	N/A	N018035 002	Feb 27, 2004	May	CAHN

TEMAZEPAMCAPSULE; ORALTEMAZEPAM

AB	NOVEL LABS INC	7.5MG	A071457 002	Jun 22, 2012	Jun	NEWA
AB		22.5MG	A071457 003	Jun 22, 2012	Jun	NEWA

TEMOZOLOMIDECAPSULE; ORALTEMODAR

AB	MERCK SHARP DOHME	5MG	N021029 001	Aug 11, 1999	Jun	CAHN
AB		20MG	N021029 002	Aug 11, 1999	Jun	CAHN
AB		100MG	N021029 003	Aug 11, 1999	Jun	CAHN
AB		140MG	N021029 005	Oct 19, 2006	Jun	CAHN
AB		180MG	N021029 006	Oct 19, 2006	Jun	CAHN
AB	+	250MG	N021029 004	Aug 11, 1999	Jun	CAHN

POWDER; INTRAVENOUSTEMODAR

+	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009	Jun	CAHN
---	-------------------	------------	-------------	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+ GILEAD SCIENCES INC 40MG/SCOOPFUL N022577 001 Jan 18, 2012 Jan NEWA

TABLET; ORAL

VIREAD

GILEAD SCIENCES INC	150MG	N021356 002	Jan 18, 2012	Apr	NEWA
	200MG	N021356 003	Jan 18, 2012	Apr	NEWA
	250MG	N021356 004	Jan 18, 2012	Apr	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

@ RANBAXY LABS LTD	EQ 1MG BASE	A076021 001	Aug 22, 2002	Apr	DISC
@	EQ 2MG BASE	A076021 002	Aug 22, 2002	Apr	DISC
@	EQ 5MG BASE	A076021 003	Aug 22, 2002	Apr	DISC
@	EQ 10MG BASE	A076021 004	Aug 22, 2002	Apr	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@ TEVA PARENTERAL 1MG/ML A076853 001 Jul 20, 2004 Jan DISC

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB FOUGERA PHARMS 0.4% A076712 001 Feb 18, 2005 Jan CAHN

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB FOUGERA PHARMS 80MG A076850 001 Jul 12, 2006 Jan CAHN

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

@ EMD SERONO	EQ 1MG BASE/VIAL	N022505 001	Nov 10, 2010	Jun	DISC
+	EQ 1MG BASE/VIAL	N022505 001	Nov 10, 2010	May	CAHN
+	EQ 2MG BASE/VIAL	N022505 002	Nov 29, 2011	Jun	NEWA

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

BX + ABBOTT LABS	1% (50MG/5GM PACKET)	N021015 002	Feb 28, 2000	Feb	CPOT
	1% (25MG/2.5GM PACKET)	N021015 001	Feb 28, 2000	Feb	CPOT

TESTIM

BX + AUXILIUM PHARMS 1% (50MG/5GM PACKET) N021454 001 Oct 31, 2002 Feb CPOT

TESTOSTERONE

TEVA PHARMS	25MG/2.5GM PACKET	N202763 001	Feb 14, 2012	Feb	NEWA
	50MG/5GM PACKET	N202763 002	Feb 14, 2012	Feb	NEWA

GEL, METERED; TRANSDERMAL

ANDROGEL

+ ABBOTT LABS 1% (1.25GM/ACTUATION) N021015 003 Sep 26, 2003 Jun CPOT

PELLET; IMPLANTATION

TESTOPEL

+ ACTIENT PHARMS 75MG A080911 001 May CAHN



TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION  
TESTOSTERONE CYPIONATE

AO	HIKMA FARMACEUTICA	200MG/ML	A091244 001	May 01, 2012	Apr	NEWA
AO	MYLAN INSTITUTIONAL	200MG/ML	A040652 001	Dec 11, 2006	Feb	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION  
TESTOSTERONE ENANTHATE

AO	MYLAN INSTITUTIONAL	200MG/ML	A040647 001	Oct 05, 2009	Feb	CAHN
----	---------------------	----------	-------------	--------------	-----	------

TETRABENAZINE

TABLET; ORAL  
XENAZINE

VALEANT PHARMS 12.5MG  
+ 25MG

N021894 001	Aug 15, 2008	Apr	CAHN
N021894 002	Aug 15, 2008	Apr	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL  
TYZINE

+ FOUGERA PHARMS 0.05%  
0.1%

A086576 002		Jan	CAHN
A086576 001		Jan	CAHN

SPRAY; NASAL  
TYZINE

+ FOUGERA PHARMS 0.1%

A086576 003		Jan	CAHN
-------------	--	-----	------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL  
THEO-24

UCB INC 100MG  
200MG  
300MG  
+ 400MG

A087942 001	Aug 22, 1983	May	CTEC
A087943 001	Aug 22, 1983	May	CTEC
A087944 001	Aug 22, 1983	May	CTEC
A081034 001	Feb 28, 1992	May	CRLD

THEOPHYLLINE

@ INWOOD LABS 100MG  
@ 125MG  
@ 200MG  
@ 300MG

A040052 001	Feb 14, 1994	May	DISC
A040052 002	Feb 14, 1994	May	DISC
A040052 003	Feb 14, 1994	May	DISC
A040052 004	Feb 14, 1994	May	DISC

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 4MG/ML  
@ 40MG/100ML  
@ 80MG/100ML  
@ 160MG/100ML  
@ 200MG/100ML  
@ 320MG/100ML  
@ 400MG/100ML

N018649 007	Jul 26, 1982	Mar	DISC
N018649 001	Jul 26, 1982	Mar	DISC
N018649 002	Jul 26, 1982	Mar	DISC
N018649 003	Jul 26, 1982	Mar	DISC
N018649 004	Jul 26, 1982	Mar	DISC
N018649 006	Nov 13, 1985	Mar	DISC
N018649 005	Jul 26, 1982	Mar	DISC

SOLUTION; ORAL

THEOPHYLLINE

AA	+ SILARX	80MG/15ML
AA	TRIS PHARMA INC	80MG/15ML

A091156 001	Apr 13, 2011	Jun	CTEC
A091586 001	Jun 15, 2012	Jun	NEWA

TABLET; ORAL

THEOLAIR

+ MEDICIS 125MG  
+ 250MG

A086399 001		Jul	CAHN
A086399 002		Jul	CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	100MG/ML	A091623 001	Jun 25, 2012	Jun	NEWA
----	---------------------	----------	-------------	--------------	-----	------

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

@ CEPHALON

6MG

N020646 006 Nov 29, 2005 Jan DISC

@

8MG

N020646 007 Nov 29, 2005 Jan DISC

@

10MG

N020646 008 Nov 29, 2005 Jan DISC

TINIDAZOLE

TABLET; ORAL

TINDAMAX

AB	MISSION PHARMA	250MG	N021618 001	May 17, 2004	Apr	CFTG
----	----------------	-------	-------------	--------------	-----	------

AB	+	500MG	N021618 002	May 17, 2004	Apr	CFTG
----	---	-------	-------------	--------------	-----	------

TINIDAZOLE

AB	NOVEL LABS INC	250MG	A202044 001	Apr 30, 2012	Apr	NEWA
----	----------------	-------	-------------	--------------	-----	------

AB		500MG	A202044 002	Apr 30, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

AB	ROXANE	250MG	A201172 001	Apr 30, 2012	Apr	NEWA
----	--------	-------	-------------	--------------	-----	------

AB		500MG	A201172 002	Apr 30, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

@ LEO PHARMA AS

20,000 IU/ML

N020484 001 Jul 14, 2000 Jun DISC

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	APOTEX INC	EQ 2MG BASE	A078868 001	Feb 03, 2012	Jan	NEWA
----	------------	-------------	-------------	--------------	-----	------

AB		EQ 4MG BASE	A078868 002	Feb 03, 2012	Jan	NEWA
----	--	-------------	-------------	--------------	-----	------

AB		EQ 6MG BASE	A078868 003	Feb 03, 2012	Jan	NEWA
----	--	-------------	-------------	--------------	-----	------

ZANAFLEX

AB	ACORDA	EQ 2MG BASE	N021447 001	Aug 29, 2002	Jan	CFTG
----	--------	-------------	-------------	--------------	-----	------

AB		EQ 4MG BASE	N021447 002	Aug 29, 2002	Jan	CFTG
----	--	-------------	-------------	--------------	-----	------

AB	+	EQ 6MG BASE	N021447 003	Aug 29, 2002	Jan	CFTG
----	---	-------------	-------------	--------------	-----	------

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 2MG BASE	A076281 001	Oct 20, 2003	Feb	CMFD
----	-------------	-------------	-------------	--------------	-----	------

AB		EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
----	--	-------------	-------------	--------------	-----	------

AB	SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA
----	------------	-------------	-------------	--------------	-----	------

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
---	------------------	-------	-------------	--	-----	------

	@ WATSON LABS	500MG	A087318 001		Mar	DISC
--	---------------	-------	-------------	--	-----	------

	@	500MG	A086109 001		Mar	DISC
--	---	-------	-------------	--	-----	------

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998	May	CAHN
---	--------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

TASMAR

@ VALEANT PHARMS LLC 200MG N020697 002 Jan 29, 1998 May CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP INNOPHARMA INC EQ 4MG BASE/VIAL A201166 001 Aug 08, 2012 Jul NEWA

>A> AP ONCO THERAPIES LTD EQ 4MG BASE/VIAL A091542 001 Aug 28, 2012 Aug NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>D> AB SANDOZ 50MG A075968 001 Jun 25, 2002 Aug DISC

>A> @ 50MG A075968 001 Jun 25, 2002 Aug DISC

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB2 ACTAVIS 100MG A091609 001 Jun 27, 2012 Jun NEWA

AB2 200MG A091609 002 Jun 27, 2012 Jun NEWA

AB2 300MG A091609 003 Jun 27, 2012 Jun NEWA

AB2 ANCHEN PHARMS 100MG A200491 001 Jun 27, 2012 Jun NEWA

AB2 200MG A200491 002 Jun 27, 2012 Jun NEWA

AB2 300MG A200491 003 Jun 27, 2012 Jun NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+ SHIONOGI INC 50MG N021693 001 May 05, 2005 Mar CTNA

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP APP PHARMS LLC 100MG/ML A091596 001 Mar 02, 2012 May CAHN

AP NEXUS PHARMS 100MG/ML A091596 001 Mar 02, 2012 Feb NEWA

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB + COVIS PHARMA EQ 10MG BASE N012342 003 Aug 16, 1985 Jan CAHN

TRETINOIN

CREAM; TOPICAL

AVITA

AB MYLAN PHARMS INC 0.025% N020404 003 Jan 14, 1997 Jun CAHN

RENOVA

+ VALEANT INTL 0.02% N021108 001 Aug 31, 2000 Jan CAHN

AB2 + 0.05% N019963 001 Dec 29, 1995 Jan CAHN

RETIN-A

AB + VALEANT INTL 0.025% N019049 001 Sep 16, 1988 Jan CAHN

AB1 + 0.05% N017522 001 Jan CAHN

AB + 0.1% N017340 001 Jan CAHN

TRETINOIN

AB PRECISION DERMAT 0.025% A075264 001 Dec 24, 1998 May CAHN

+ 0.0375% A090098 001 Mar 22, 2010 May CAHN

AB1 0.05% A075265 001 Dec 24, 1998 May CAHN

AB 0.1% A075213 001 Dec 24, 1998 May CAHN

AB2 SUNEVA MEDCL 0.05% A076498 001 Sep 15, 2005 May CAHN

GEL; TOPICAL						
RETIN-A						
AB	+	VALEANT INTL	0.01%	N017955 001		Jan CAHN
AB	+		0.025%	N017579 002		Jan CAHN
TRETINOIN						
AB		PRECISION DERMAT	0.01%	A075589 001	Jun 11, 2002	May CAHN
AB			0.025%	A075529 001	Feb 22, 2000	May CAHN
SOLUTION; TOPICAL						
RETIN-A						
AT	+	VALEANT INTL	0.05%	N016921 001		Jan CAHN
SWAB; TOPICAL						
RETIN-A						
		@ VALEANT INTL	0.05%	N016921 002		Jan CAHN
<u>TRIAMCINOLONE ACETONIDE</u>						
AEROSOL, METERED; INHALATION						
AZMACORT						
		@ ABBOTT	0.1MG/INH	N018117 001	Apr 23, 1982	May DISC
CREAM; TOPICAL						
TRIAMCINOLONE ACETONIDE						
AT		FOUGERA PHARMS	0.025%	A085692 001		Jan CAHN
AT			0.1%	A085692 003		Jan CAHN
AT	+		0.5%	A085692 002		Jan CAHN
LOTION; TOPICAL						
TRIAMCINOLONE ACETONIDE						
AT		FOUGERA PHARMS	0.025%	A040467 001	Apr 21, 2003	Jan CAHN
AT			0.1%	A040467 002	Apr 21, 2003	Jan CAHN
OINTMENT; TOPICAL						
TRIAMCINOLONE ACETONIDE						
AT		FOUGERA PHARMS	0.025%	A085691 001		Jan CAHN
AT			0.1%	A085691 003		Jan CAHN
AT			0.5%	A085691 002		Jan CAHN
SPRAY, METERED; NASAL						
TRIAMCINOLONE ACETONIDE						
AB		TEVA PHARMS	0.055MG/SPRAY	A078104 001	Jul 30, 2009	Mar CAHN
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
TRIMETHOBENZAMIDE HYDROCHLORIDE						
		@ HOSPIRA	100MG/ML	A088804 001	Apr 03, 1987	Jun DISC
<u>VALACYCLOVIR HYDROCHLORIDE</u>						
TABLET; ORAL						
VALACYCLOVIR HYDROCHLORIDE						
AB		JUBILANT ORGANOSYS	EQ 500MG BASE	A201506 001	Apr 03, 2012	Mar NEWA
AB			EQ 1GM BASE	A201506 002	Apr 03, 2012	Mar NEWA
<u>VALGANCICLOVIR HYDROCHLORIDE</u>						
FOR SOLUTION; ORAL						
VALCYTE						
	+	HOFFMANN LA ROCHE	50MG/ML	N022257 001	Aug 28, 2009	May CAHN
TABLET; ORAL						
VALCYTE						
	+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304 001	Mar 29, 2001	May CAHN

VANCOMYCIN HYDROCHLORIDE

## CAPSULE; ORAL

## VANCOCIN HYDROCHLORIDE

AB	VIROPHARMA	EQ 125MG BASE	N050606 001	Apr 15, 1986	Mar	CFTG
AB	+	EQ 250MG BASE	N050606 002	Apr 15, 1986	Mar	CFTG

## VANCOMYCIN HYDROCHLORIDE

AB	AKORN	EQ 125MG BASE	A065478 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065478 002	Apr 09, 2012	Mar	NEWA
AB	APP PHARMS LLC	EQ 125MG BASE	A065453 001	Jun 18, 2012	Jun	NEWA
AB		EQ 250MG BASE	A065453 002	Jun 18, 2012	Jun	NEWA
AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065490 002	Apr 09, 2012	Mar	NEWA
AB	WATSON LABS	EQ 125MG BASE	A065510 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065510 002	Apr 09, 2012	Mar	NEWA

## INJECTABLE; INJECTION

## VANCOMYCIN HYDROCHLORIDE

AP	SAGENT PHARMS	EQ 5GM BASE/VIAL	A200837 001	Aug 10, 2012	Jul	NEWA
AP	SANDOZ INC	EQ 5GM BASE/VIAL	A201048 001	Aug 10, 2012	Jul	NEWA
AP		EQ 10GM BASE/VIAL	A201048 002	Aug 10, 2012	Jul	NEWA

VANDETANIB

## TABLET; ORAL

## CAPRELSA

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb	CTNA
	+	300MG	N022405 002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

## TABLET; ORAL

## LEVITRA

AB	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG
AB		5MG	N021400 001	Aug 19, 2003	Apr	CFTG
AB		10MG	N021400 002	Aug 19, 2003	Apr	CFTG
AB	+	20MG	N021400 004	Aug 19, 2003	Apr	CFTG

## VARDENAFIL HYDROCHLORIDE

AB	TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
AB		5MG	A091347 002	May 03, 2012	Apr	NEWA
AB		10MG	A091347 003	May 03, 2012	Apr	NEWA
AB		20MG	A091347 004	May 03, 2012	Apr	NEWA

VECURONIUM BROMIDE

## INJECTABLE; INJECTION

## VECURONIUM BROMIDE

AP	BEDFORD	10MG/VIAL	A075549 001	Jun 13, 2000	Jun	CRLD
		20MG/VIAL	A075549 002	Jun 13, 2000	Jun	CRLD
AP	+	SUN PHARMA GLOBAL	A079001 001	Jun 17, 2009	Jun	CRLD
AP	+	20MG/VIAL	A079001 002	Jun 17, 2009	Jun	CRLD

VENLAFAXINE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

## TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

>D>	AB	ACTAVIS TOTOWA	EQ 25MG BASE	A078554 001	Jan 09, 2009	Aug	CAHN
>D>	AB		EQ 37.5MG BASE	A078554 002	Jan 09, 2009	Aug	CAHN
>D>	AB		EQ 50MG BASE	A078554 003	Jan 09, 2009	Aug	CAHN
>D>	AB		EQ 75MG BASE	A078554 004	Jan 09, 2009	Aug	CAHN
>D>	AB		EQ 100MG BASE	A078554 005	Jan 09, 2009	Aug	CAHN
>A>	AB	HERITAGE PHARMS INC	EQ 25MG BASE	A078554 001	Jan 09, 2009	Aug	CAHN
>A>	AB		EQ 37.5MG BASE	A078554 002	Jan 09, 2009	Aug	CAHN
>A>	AB		EQ 50MG BASE	A078554 003	Jan 09, 2009	Aug	CAHN
>A>	AB		EQ 75MG BASE	A078554 004	Jan 09, 2009	Aug	CAHN
>A>	AB		EQ 100MG BASE	A078554 005	Jan 09, 2009	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

VERAPAMIL HYDROCHLORIDE

AB		APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
AB			180MG	A200878 002	Apr 20, 2012	Apr	NEWA
AB			240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

## FOR SOLUTION; ORAL

## SABRIL

+	LUNDBECK LLC	500MG/PACKET	N022006 001	Aug 21, 2009	Apr	CAHN
---	--------------	--------------	-------------	--------------	-----	------

## TABLET; ORAL

## SABRIL

+	LUNDBECK LLC	500MG	N020427 001	Aug 21, 2009	Apr	CAHN
---	--------------	-------	-------------	--------------	-----	------

VILAZODONE HYDROCHLORIDE

## TABLET; ORAL

## VIIBRYD

+	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	Apr	CRLD
		40MG	N022567 003	Jan 21, 2011	Apr	CRLD

VINCRIStINE SULFATE

>A>		INJECTABLE, LIPOSOMAL; INTRAVENOUS					
>A>		MARQIBO KIT					
>A>	+	TALON THERAP	5MG/5ML (1MG/ML)	N202497 001	Aug 09, 2012	Aug	NEWA

VINORELBINE

## INJECTABLE; INJECTION

## VINORELBINE

>A>	AP	ONCO THERAPIES LTD	EQ 10MG BASE/ML	A200148 001	Aug 31, 2012	Aug	NEWA
-----	----	--------------------	-----------------	-------------	--------------	-----	------

VISMODEGIB

## CAPSULE; ORAL

## ERIVEDGE

+	GENENTECH	150MG	N203388 001	Jan 30, 2012	Jan	NEWA
---	-----------	-------	-------------	--------------	-----	------

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

AP	+	PFIZER	200MG/VIAL	N021267 001	May 24, 2002	May	CFTG
VORICONAZOLE							
AP		SANDOZ INC	200MG/VIAL	A090862 001	May 30, 2012	May	NEWA
TABLET; ORAL							
VORICONAZOLE							
AB		TEVA PHARMS	50MG	A091658 001	Apr 06, 2012	Mar	NEWA
AB			200MG	A091658 002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

		@ JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	Mar	CAHN
		@ JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	Jun	CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+		JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	Mar	CAHN
+			500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Mar	CAHN
+			500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Mar	CAHN
+		JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	Jun	CAHN
+			500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Jun	CAHN
+			500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Jun	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

		@ RANBAXY LABS LTD	300MG	A077327 001	Sep 19, 2005	Apr	DISC
--	--	--------------------	-------	-------------	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825 001	Feb 05, 2001	Feb	CFTG
AB			EQ 40MG BASE	N020825 002	Feb 05, 2001	Feb	CFTG
AB			EQ 60MG BASE	N020825 003	Feb 05, 2001	Feb	CFTG
AB			EQ 80MG BASE	N020825 004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077561 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077561 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077561 004	Mar 02, 2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077565 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077565 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077565 004	Mar 02, 2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077560 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077560 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077560 004	Mar 02, 2012	Feb	NEWA
AB		SANDOZ INC	EQ 20MG BASE	A077562 001	Jun 01, 2012	May	NEWA
AB			EQ 40MG BASE	A077562 002	Jun 01, 2012	May	NEWA
AB			EQ 60MG BASE	A077562 003	Jun 01, 2012	May	NEWA

## CAPSULE; ORAL

## ZIPRASIDONE HYDROCHLORIDE

AB	SANDOZ INC	EQ 80MG BASE	A077562 004	Jun 01, 2012	May	NEWA
>A>	WOCKHARDT LTD	EQ 20MG BASE	A090348 001	Sep 05, 2012	Aug	NEWA
>A>		EQ 40MG BASE	A090348 002	Sep 05, 2012	Aug	NEWA
>A>		EQ 60MG BASE	A090348 003	Sep 05, 2012	Aug	NEWA
>A>		EQ 80MG BASE	A090348 004	Sep 05, 2012	Aug	NEWA

ZOLPIDEM TARTRATE

## TABLET; ORAL

## ZOLPIDEM TARTRATE

AB	CIPLA LTD	5MG	A077388 001	Jul 30, 2012	Jul	NEWA
AB		10MG	A077388 002	Jul 30, 2012	Jul	NEWA



OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+ MCNEIL CONS 800MG;10MG;165MG N020958 001 Oct 16, 2000 Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@ RANBAXY LABS LTD 5MG/5ML A090183 002 Apr 24, 2008 Jul DISC

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ RANBAXY LABS LTD 5MG/5ML A090183 001 Apr 24, 2008 Jul DISC

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

>D> + CARDINAL HLTH 2%;70% (0.67ML) N021555 001 Oct 07, 2002 Aug CAHN

>A> + CAREFUSION 2%;70% (0.67ML) N021555 001 Oct 07, 2002 Aug CAHN

CHLORAPREP SINGLE SWABSTICK

>D> + CARDINAL HLTH 2%;70% (1.75ML) N021555 002 May 10, 2005 Aug CAHN

>A> + CAREFUSION 2%;70% (1.75ML) N021555 002 May 10, 2005 Aug CAHN

CHLORAPREP TRIPLE SWABSTICK

>D> + CARDINAL HLTH 2%;70% (5.25ML) N021555 003 Jun 10, 2009 Aug CAHN

>A> + CAREFUSION 2%;70% (5.25ML) N021555 003 Jun 10, 2009 Aug CAHN

CHLORASCUB MAXI SWABSTICK

+ PROF DSPLS 3.15%;70% (5.1ML) N021524 003 Jun 03, 2005 Mar CAHN

CHLORASCUB SWAB

+ PROF DSPLS 3.15%;70% (1ML) N021524 001 Jun 03, 2005 Mar CAHN

CHLORASCUB SWABSTICK

+ PROF DSPLS 3.15%;70% (1.6ML) N021524 002 Jun 03, 2005 Mar CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

TRIS PHARMA INC EQ 30MG HBR/5ML A091135 001 May 25, 2012 May NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES ARCOLAB LTD 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT A200888 001 Mar 05, 2012 Feb NEWA

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@ MCNEIL CONS 10MG N020801 001 Sep 24, 1998 Mar CAHN

+ 20MG N020801 002 Dec 17, 2007 Mar CAHN

TABLET; ORAL

PEPCID AC

MCNEIL CONS 10MG N020325 001 Apr 28, 1995 Mar CAHN

+ 20MG N020325 002 Sep 23, 2003 Mar CAHN

PEPCID AC (GELTAB)

MCNEIL CONS 10MG N020902 001 Aug 05, 1999 Mar CAHN

FEXOFENADINE HYDROCHLORIDE

## TABLET; ORAL

## CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	30MG	A091567 002	Feb 06, 2012	Jan	NEWA
WOCKHARDT LTD	30MG	A079112 002	Feb 08, 2012	Jan	NEWA

## CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	30MG	A091567 001	Feb 06, 2012	Jan	NEWA
WOCKHARDT LTD	30MG	A079112 001	Feb 08, 2012	Jan	NEWA

## FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	60MG	A091567 004	Feb 06, 2012	Jan	NEWA
	180MG	A091567 006	Feb 06, 2012	Jan	NEWA
WOCKHARDT LTD	60MG	A079112 004	Feb 08, 2012	Jan	NEWA
	180MG	A079112 006	Feb 08, 2012	Jan	NEWA

## FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	60MG	A091567 003	Feb 06, 2012	Jan	NEWA
	180MG	A091567 005	Feb 06, 2012	Jan	NEWA
WOCKHARDT LTD	60MG	A079112 003	Feb 08, 2012	Jan	NEWA
	180MG	A079112 005	Feb 08, 2012	Jan	NEWA

IBUPROFEN

## CAPSULE; ORAL

## IBUPROFEN

ACCUCAPS INDS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338 001	Jul 10, 2009	Jan	CAHN
---------------	---------------------------------------	-------------	--------------	-----	------

IBUPROFEN SODIUM

## TABLET; ORAL

## ADVIL

+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803 001	Jun 12, 2012	Jun	NEWA
------------------------	---------------	-------------	--------------	-----	------

LANSOPRAZOLE

## CAPSULE, DELAYED REL PELLETS; ORAL

## LANSOPRAZOLE

DR REDDYS LABS LTD	15MG	A202194 001	May 18, 2012	Apr	NEWA
PERRIGO R AND D	15MG	A202319 001	May 18, 2012	Apr	NEWA
WOCKHARDT LTD	15MG	A202727 001	May 18, 2012	Apr	NEWA
PREVACID 24 HR					
+ NOVARTIS	15MG	N022327 001	May 18, 2009	Apr	CFTG

LEVONORGESTREL

## TABLET; ORAL

## LEVONORGESTREL

WATSON LABS INC	1.5MG	A200670 001	Jul 12, 2012	Jun	NEWA
PLAN B					
+ TEVA BRANDED PHARM	0.75MG	N021045 002	Aug 24, 2006	May	CAHN
PLAN B ONE-STEP					
+ DURAMED	1.5MG	N021998 001	Jul 10, 2009	Jun	CFTG

LORATADINE

## SYRUP; ORAL

## LORATADINE

@ RANBAXY LABS LTD	1MG/ML	A076529 001	Aug 20, 2004	Jul	DISC
--------------------	--------	-------------	--------------	-----	------

NICOTINEFILM, EXTENDED RELEASE; TRANSDERMAL  
NICOTINE

AVEVA	7MG/24HR	A074612 002	Jul 28, 2003	Apr	NEWA
	14MG/24HR	A074612 003	Oct 20, 1997	Apr	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 150MG BASE	A200172 001	May 31, 2012	May	NEWA
SHASUN CHEMS	EQ 75MG BASE	A201745 001	Feb 29, 2012	Feb	NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 08 AUGUST 2012**

NO AUGUST 2012 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N202450 001	>A> 5840279	Jun 21, 2016	DP		NCE	Jul 23, 2017
	>A> 6071498	Jun 21, 2016	DP			
	>A> 6681768	Aug 07, 2022	DP			
	>A> 6750226	Sep 05, 2020	DS DP	U-1264		
	>A> 7078412	Jul 16, 2020	DS DP	U-1263		
	>A> 8051851	Apr 22, 2027	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022		U-1078		
	8129362	Jul 18, 2027		U-1078		
	>A> 8241649	Dec 23, 2022	DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N020899 001					>A> M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N020983 001	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001	8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002	8168616	Jul 05, 2025	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030		U-1225		
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 001	RE42462	Jul 29, 2018	DS			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 002	RE42462	Jul 29, 2018	DS			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	>A> 8216289	May 01, 2018		U-289		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASON PROPRIONATE - DYMISTA</u>						
N202236 001	8163723	Aug 29, 2023	U-81		NC	May 01, 2015
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-644			
	8168620	Feb 24, 2026	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			



## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					NCE ODE PED PED	Mar 20, 2013 Mar 20, 2015 Sep 20, 2015 Sep 20, 2013
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					NCE ODE PED PED	Mar 20, 2013 Mar 20, 2015 Sep 20, 2015 Sep 20, 2013
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N022258 001	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 003					>A> NDF	Aug 30, 2013
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 004					>A> NDF	Aug 30, 2013

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N202714 001	7232818	Apr 14, 2025	DS DP		NCE	Jul 20, 2017
	7417042	Jun 07, 2026	DS DP		>A> ODE	Jul 20, 2019
	7491704	Apr 14, 2025	U-1260			
	7737112	Dec 07, 2027	DP			
	8129346	Dec 25, 2026	U-1260			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7717889	Feb 27, 2025	DP U-1022			
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLOPIROX - LOPROX</u>						
N021159 001	8227490	Sep 16, 2017	U-1256			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535 001					NP	Jul 16, 2015
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5856346	Jan 05, 2021	DS DP U-893			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078223 001					PC	Jun 30, 2012
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078854 001					PC	Jun 30, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665 002					PC	Nov 13, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023 001					PC	Nov 13, 2012
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7964648	Oct 06, 2028	U-1161			
	8097655	Oct 06, 2028	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N202570 001	8217057	Nov 06, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	8217057	Nov 06, 2029	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N021313 001	8187630	Dec 19, 2020	DP U-1017			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N021879 001	8227484	Jul 17, 2023	U-1093			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001	8217078	Jul 10, 2029	U-1248			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001					I-653 ODE	Jun 13, 2015 Jun 13, 2019
<u>DORIPENEM - DORIBAX</u>						
N022106 001	>A> 8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	>A> 8247402	Mar 30, 2021	DS DP			
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	8206740	Dec 24, 2025	DP U-925			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	>A> 5223510	Jul 26, 2013	DS DP U-992			
	>A> 5223510	Jul 26, 2013	DS DP U-1261			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5811423	Aug 07, 2012	U-750			
	5811423	Aug 07, 2012	U-1170			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	>A> 7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	>A> 7160870	Nov 20, 2022	DS DP U-930			



## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	>A> 7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 004	>A> 7160870	Nov 20, 2022	DS DP U-930			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	8080551	Apr 11, 2023	DS DP		NCE	May 20, 2016
	8101629	Aug 09, 2022	DP			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5922695	Jul 25, 2017	DS U-1259			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	DP U-541			
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-1259			
	6043230	Jul 25, 2017	DP U-248			
<u>ENZALUTAMIDE - XTANDI</u>						
N203415 001					>A> NCE	Aug 31, 2017
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	>A> 8226610	Apr 10, 2029	DP			
	>A> 8231573	Nov 25, 2028	DP			
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 003	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 004	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ETONOGESTREL - NEXPLANON</u>						
N021529 002					NP	May 31, 2014
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
				PED	Apr 29, 2014	
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
				PED	Apr 29, 2014	
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
				PED	Apr 29, 2014	
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
				PED	Apr 29, 2014	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985	001				>A> I-630	Oct 29, 2013
					>A> NCE	Mar 30, 2014
					>A> ODE	Oct 29, 2017
					>A> PED	Apr 29, 2018
					>A> PED	Sep 30, 2014
					>A> PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985	002				>A> I-630	Oct 29, 2013
					>A> NCE	Mar 30, 2014
					>A> ODE	Oct 29, 2017
					>A> PED	Apr 29, 2018
					>A> PED	Sep 30, 2014
					>A> PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985	003				>A> I-630	Oct 29, 2013
					>A> NCE	Mar 30, 2014
					>A> ODE	Oct 29, 2017
					>A> PED	Apr 29, 2018
					>A> PED	Sep 30, 2014
					>A> PED	Apr 29, 2014
<u>EVEROLIMUS - ZORTRESS</u>						
N021560	001	5665772	Sep 09, 2019	DS DP U-1049	NP	Apr 20, 2013
		5665772*PED	Mar 09, 2020		NCE	Mar 30, 2014
		6004973	Jul 12, 2016	DP U-1049	PED	Sep 30, 2014
		6004973*PED	Jan 12, 2017		PED	Oct 20, 2013
		6239124	Aug 11, 2017	U-1049		
		6239124*PED	Feb 11, 2018			
		6440990	Sep 24, 2013	DP U-1049		
		6440990*PED	Mar 24, 2014			
		6455518	Jul 29, 2017	U-1049		
		6455518*PED	Jan 29, 2018			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560	002	5665772	Sep 09, 2019	DS DP U-1049	NP	Apr 20, 2013
		5665772*PED	Mar 09, 2020		NCE	Mar 30, 2014
		6004973	Jul 12, 2016	DP U-1049	PED	Sep 30, 2014
		6004973*PED	Jan 12, 2017		PED	Oct 20, 2013
		6239124	Aug 11, 2017	U-1049		
		6239124*PED	Feb 11, 2018			
		6440990	Sep 24, 2013	DP U-1049		
		6440990*PED	Mar 24, 2014			
		6455518	Jul 29, 2017	U-1049		
		6455518*PED	Jan 29, 2018			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004					M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-112	Feb 09, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 001	8124125	Oct 01, 2024	DP U-1234			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 002	8124125	Oct 01, 2024	DP U-1234			
<u>FENTANYL - SUBSYS</u>						
N202788 001					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 002					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 003					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 004					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 005					NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	7579019	Jan 22, 2020	U-767			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	>A> 6858650	Jul 03, 2022	DS U-913			
	8088398	Jun 07, 2027	DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	>A> 6858650	Jul 03, 2022	DS U-913			
	8088398	Jun 07, 2027	DP U-913			
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	6004565	Sep 23, 2017	U-1086			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	8232264	Mar 09, 2023	DP			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	>A> 8062264	Apr 05, 2026	DP			
	>A> 8147461	Mar 10, 2025	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 001	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 002	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 003	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 001	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 002	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 003	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					NPP PED	Apr 27, 2015 Oct 27, 2015



## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116	001				NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023	002	5512570	Mar 04, 2014	U-850		
		5538982	Jul 23, 2013	U-850		
		5716942	Feb 10, 2015	U-850		
		7214692	Sep 18, 2012	U-850		
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244	001	6204257	Jul 01, 2022	DS DP U-945		
<u>GABAPENTIN - GRALISE</u>						
N022544	001	8192756	Oct 25, 2022	DP U-1114		
<u>GABAPENTIN - GRALISE</u>						
N022544	002	8192756	Oct 25, 2022	DP U-1114		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399	001	8048917	Nov 06, 2022	DS DP U-1247	I-652	Jun 06, 2015
		8114909	Apr 11, 2026	U-1231		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399	002	8048917	Nov 06, 2022	DS DP U-1247	I-652	Jun 06, 2015
		8114909	Apr 11, 2026	U-1231		
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357	001				I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357	002				I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357	003				I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357	004				I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N021358	001				I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N021358	002				I-654	Jul 06, 2015
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711	001	6676929	May 04, 2020	DP		
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711	002	6676929	May 04, 2020	DP		
<u>GADOXETATE DISODIUM - EOVIIST</u>						
N022090	001	5798092	Aug 25, 2015	DS DP		
		6039931	Nov 13, 2021	U-1239		
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571	001				ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369	001				PC	Sep 26, 2012

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369	002				PC	Sep 26, 2012
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217	004	>A> 5702725	Jul 07, 2014	DP U-1043		
		>A> 5914131	Jul 07, 2014	DP U-1043		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057	001	8188146	Jan 27, 2020	DS DP		
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588	001				ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588	002				ODE	Dec 19, 2015
<u>IMIQUIMOD - ZYCLARA</u>						
N022483	001	8236816	Dec 11, 2029	U-68		
<u>IMIQUIMOD - ZYCLARA</u>						
N022483	002	8222270	Dec 11, 2029	U-68		
<u>INGENOL MEBUTATE - PICATO</u>						
N202833	001	6432452	Aug 19, 2018	DS U-68	NCE	Jan 23, 2017
		6844013	Aug 19, 2018	DS DP U-1221		
		7410656	Aug 19, 2018	DS U-1222		
<u>INGENOL MEBUTATE - PICATO</u>						
N202833	002	6432452	Aug 19, 2018	DS U-68	NCE	Jan 23, 2017
		6844013	Aug 19, 2018	DS DP U-1221		
		7410656	Aug 19, 2018	DS U-1222		
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536	001	5750497	Jun 16, 2019	DS DP U-668	M-117 M-115	May 18, 2015 Apr 06, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454	001	5310912	Feb 25, 2013	DS		
<u>IRBESARTAN - IRBESARTAN</u>						
A077159	001				PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159	002				PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159	003				PC	Sep 26, 2012
<u>ISOTRETINOIN - ABSORICA</u>						
N021951	001	7435427	Sep 21, 2021	DP	NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951	002	7435427	Sep 21, 2021	DP	NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951	003	7435427	Sep 21, 2021	DP	NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951	004	7435427	Sep 21, 2021	DP	NP	May 25, 2015

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N021946 001	>A> 8232276	Nov 24, 2020	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8008338*PED	Nov 24, 2027				
	8207215	May 28, 2024	U-1251			
	8207215*PED	Nov 28, 2024				
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 001					NPP >A> PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 002					NPP >A> PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 003					NPP >A> PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 004					NPP >A> PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021505 001					NPP >A> PED	Dec 16, 2014 Jun 16, 2015
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623 001	6465709	Jul 07, 2020	DP			
<u>LINACLOTIDE - LINZESS</u>						
N202811 001					>A> NCE	Aug 30, 2017
<u>LINACLOTIDE - LINZESS</u>						
N202811 002					>A> NCE	Aug 30, 2017

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	>A> 6303661	Apr 24, 2017	U-774		>A> M-121	Aug 13, 2015
	>A> 6303661	Apr 24, 2017	U-1270		>A> M-118	Aug 13, 2015
	>A> 6890898	Feb 02, 2019	U-493			
	>A> 6890898	Feb 02, 2019	U-1270			
	>A> 7078381	Feb 02, 2019	U-493			
	>A> 7078381	Feb 02, 2019	U-1270			
	>A> 7459428	Feb 02, 2019	U-493			
	>A> 7459428	Feb 02, 2019	U-1270			
	>A> 8119648	Aug 12, 2023	U-774			
	>A> 8119648	Aug 12, 2023	U-1270			
	>A> 8178541	Aug 12, 2023	U-775			
	>A> 8178541	Aug 12, 2023	U-1270			
	>A> 8178541	Aug 12, 2023	U-1245			
	>A> 8178541	Aug 12, 2023	U-1244			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	8114833	Aug 13, 2025	DP		M-115	Apr 06, 2015
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LORCASERIN HYDROCHLORIDE - BELVIQ</u>						
N022529 001	6953787	Apr 10, 2023	DS DP U-1253		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	6953787	Apr 10, 2023	DS DP U-1252			
	7514422	Apr 10, 2023	U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1255			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N021746 001	5407914	Nov 17, 2012	DS DP U-1242			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001					D-134	Apr 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	002				D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	003				D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	004				D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842	001				M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842	002				M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406	001				>A> PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406	002				>A> PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	001	>A> 8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	002	>A> 8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	003	>A> 8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	004	>A> 8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	005	>A> 8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270	001	6303661	Apr 24, 2017			U-1227
		6340475	Sep 19, 2016	DP		
		6635280	Sep 19, 2016	DP		
		6699871	Jul 26, 2022	DS DP		U-1227
		6890898	Feb 02, 2019			U-1228
		7078381	Feb 02, 2019			U-1227
		7125873	Jul 26, 2022	DP		U-1227
		7326708	Apr 11, 2026	DS DP		U-1227
		7459428	Feb 02, 2019			U-1227
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270	002	6303661	Apr 24, 2017			U-1227
		6340475	Sep 19, 2016	DP		
		6635280	Sep 19, 2016	DP		
		6699871	Jul 26, 2022	DS DP		U-1227
		6890898	Feb 02, 2019			U-1228
		7078381	Feb 02, 2019			U-1227
		7125873	Jul 26, 2022	DP		U-1227
		7326708	Apr 11, 2026	DS DP		U-1227
		7459428	Feb 02, 2019			U-1227



PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	>A> 8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	>A> 8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	>A> 8247425	Dec 31, 2030	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	6682348	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	>A> 8252776	Jun 24, 2025	U-124			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	>A> 8252776	Jun 24, 2025	U-124			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023			U-913	
	7982049	Nov 04, 2023	DP			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023			U-913	
	7982049	Nov 04, 2023	DP			
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001					NPP	Mar 26, 2015

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599 002					NS	Jan 13, 2015
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	8075911	May 22, 2021	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8163904	Aug 23, 2028	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8163904	Aug 23, 2028	DS DP			
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	>A> 8241662	Apr 26, 2020	U-318			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N022204 001	>A> 8241662	Apr 26, 2020	U-318			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	8114383	Oct 10, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	8138229	Dec 09, 2023	DP U-1092			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 001					>A> M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 002					>A> M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 003					>A> M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 004					>A> M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 005					>A> M-119	Aug 29, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 004					I-625 M-93 NCE	Apr 30, 2013 Jul 29, 2019 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 001					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 001	>A> 8221747	Feb 20, 2028	DP			
	>A> 8246950	Feb 20, 2028				U-1274

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 002	>A> 8221747	Feb 20, 2028	DP			
	>A> 8246950	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 003	>A> 8221747	Feb 20, 2028	DP			
	>A> 8246950	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 004	>A> 8221747	Feb 20, 2028	DP			
	>A> 8246950	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 005	>A> 8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 006	>A> 8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	7084245	May 12, 2024	DS DP	U-1238		
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	7084245	May 12, 2024	DS DP	U-1238		
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	6149938	Jul 23, 2018	DP U-1243			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 001	>A> 7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	>A> 7553818	Jun 14, 2020	U-1262			
	>A> 7659256	Jun 14, 2020	DP U-1262			
	>A> 7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 002	>A> 7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	>A> 7553818	Jun 14, 2020	U-1262			
	>A> 7659256	Jun 14, 2020	DP U-1262			
	>A> 7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 003	>A> 7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	>A> 7553818	Jun 14, 2020	U-1262			
	>A> 7659256	Jun 14, 2020	DP U-1262			
	>A> 7674776	Jun 14, 2020	DP U-1262			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 004	>A> 7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	>A> 7553818	Jun 14, 2020	U-1262			
	>A> 7659256	Jun 14, 2020	DP U-1262			
	>A> 7674776	Jun 14, 2020	DP U-1262			
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 001					>A> PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 002					>A> PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 003					>A> PC	Feb 13, 2013
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISONE - RAYOS</u>						
N202020 001	>A> 6488960	Mar 14, 2020	DP U-1267			
	>A> 6677326	Mar 14, 2020	DP U-1268			
<u>PREDNISONE - RAYOS</u>						
N202020 002	>A> 6488960	Mar 14, 2020	DP U-1267			
	>A> 6677326	Mar 14, 2020	DP U-1268			
<u>PREDNISONE - RAYOS</u>						
N202020 003	>A> 8168218	Jan 07, 2028	DP U-1269			
<u>PREGABALIN - LYRICA</u>						
N021446 001	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			



## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N021446 002	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 003	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 004	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 005	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 006	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 007	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 008	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N022488 001	6001876	Dec 30, 2018	U-819	Y		
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 001	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 002	6500454	Oct 04, 2021	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001					M-114	Mar 28, 2015
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N023045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 001	>A> 6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 002	>A> 6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 003	>A> 6677358	Jun 12, 2018	DS DP U-1265			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N022560 001	>A> 8246989	Jan 16, 2026	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Aug 22, 2013	DS DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	>A> 8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	>A> 8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	>A> 8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	>A> 8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	>A> 8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	>A> 8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	>A> 8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	>A> 8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	>A> 8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	>A> 8246979	Sep 01, 2027	DP U-1273			
	>A> 8246979	Sep 01, 2027	DP U-1272			
	>A> 8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	>A> 8246979	Sep 01, 2027	DP U-1273			
	>A> 8246979	Sep 01, 2027	DP U-1272			
	>A> 8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	>A> 8246979	Sep 01, 2027	DP U-1273			
	>A> 8246979	Sep 01, 2027	DP U-1272			
	>A> 8246980	Nov 27, 2025	DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Nov 14, 2022	DS DP			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			>A> M-61	Aug 30, 2015
					>A> PED	Mar 01, 2016
					PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		>A> M-61	Aug 30, 2015
	5250534*PED	Sep 27, 2012			NDF	Nov 20, 2012
					>A> PED	Mar 01, 2016
					PED	May 20, 2013

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - REVATIO</u>						
N203109	001				>A> NDF >A> PED	Aug 30, 2015 Mar 01, 2016
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895	001	5250534	Mar 27, 2012			
		5250534*PED	Sep 27, 2012			
		6469012	Oct 22, 2019	U-155		
		6469012*PED	Apr 22, 2020			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895	002	5250534	Mar 27, 2012			
		5250534*PED	Sep 27, 2012			
		6469012	Oct 22, 2019	U-155		
		6469012*PED	Apr 22, 2020			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895	003	5250534	Mar 27, 2012			
		5250534*PED	Sep 27, 2012			
		6469012	Oct 22, 2019	U-155		
		6469012*PED	Apr 22, 2020			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343	001	8168637	Jun 26, 2022	DP U-1188		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343	002	8168637	Jun 26, 2022	DP U-1188		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343	003	8168637	Jun 26, 2022	DP U-1188		
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922	001				ODE	Jan 14, 2018
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923	001				ODE	Jan 14, 2018
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239	001	>A> 7776007	Nov 22, 2026	DP		
		8118771	Aug 10, 2023	DP		
		>A> 8241243	Dec 25, 2025	DP		
		>A> 8241244	Nov 21, 2022	DP		
<u>TAFLUPROST - ZIOPTAN</u>						
N202514	001	5886035	Dec 18, 2017	DS DP U-778	NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N022458	001	>A> 8227230	Feb 24, 2024	DS DP	NCE	May 01, 2017
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533	001	>A> 6071970	Jun 06, 2017	U-1276	>A> I-656	Aug 28, 2015
		>A> 6071970	Jun 06, 2017	U-1178		
		>A> 7994364	Jun 27, 2025	DS DP U-1276		
		>A> 7994364	Jun 27, 2025	DS DP U-1178		
		8114383	Oct 10, 2024	DP		
		>A> RE39593	Aug 05, 2022	DS DP U-1276		
		>A> RE39593	Aug 05, 2022	DS DP U-1178		

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	>A> 6071970	Jun 06, 2017	U-1276		>A> I-656	Aug 28, 2015
	>A> 6071970	Jun 06, 2017	U-1178			
	>A> 7994364	Jun 27, 2025	DS DP U-1276			
	>A> 7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> RE39593	Aug 05, 2022	DS DP U-1276			
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	>A> 6071970	Jun 06, 2017	U-1276		>A> I-656	Aug 28, 2015
	>A> 6071970	Jun 06, 2017	U-1178			
	>A> 7994364	Jun 27, 2025	DS DP U-1276			
	>A> 7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> RE39593	Aug 05, 2022	DS DP U-1276			
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	>A> 6071970	Jun 06, 2017	U-1276		>A> I-656	Aug 28, 2015
	>A> 6071970	Jun 06, 2017	U-1178			
	>A> 7994364	Jun 27, 2025	DS DP U-1276			
	>A> 7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> RE39593	Aug 05, 2022	DS DP U-1276			
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	>A> 6071970	Jun 06, 2017	U-1276		>A> I-656	Aug 28, 2015
	>A> 6071970	Jun 06, 2017	U-1178			
	>A> 7994364	Jun 27, 2025	DS DP U-1276			
	>A> 7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> RE39593	Aug 05, 2022	DS DP U-1276			
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAZAROTENE - FABIOR</u>						
N202428 001					NDF	May 11, 2015
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N017858 001					>A> ODE	Aug 13, 2019
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		>A> M-61	May 30, 2015
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
					>A> PED	Nov 30, 2015
					PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	>A> 5922695	Jul 25, 2017	DS U-999		>A> NPP	Aug 16, 2015
	>A> 5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-250		PED	Jul 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-248			
	>A> 5922695	Jul 25, 2017	DS U-1275			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-1275			
	>A> 6043230	Jul 25, 2017	U-999			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 002	>A> 5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-250		>A> NPP	Aug 16, 2015
	>A> 5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-1275			
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 003	>A> 5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-250		>A> NPP	Aug 16, 2015
	>A> 5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-1275			
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 004	>A> 5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-250		>A> NPP	Aug 16, 2015
	>A> 5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-1275			
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	>A> 5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-250		>A> NPP	Aug 16, 2015
	>A> 5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DP U-248	Y	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DP U-250	Y	PED	Apr 01, 2014
	5935946	Jul 25, 2017	DP U-256	Y	PED	Sep 24, 2013
	5935946	Jul 25, 2017	DP U-999	Y		
	5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-1275			
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N022505 002					NCE	Nov 10, 2015
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 001	6455557	Nov 28, 2021		Y		
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 002	6455557	Nov 28, 2021		Y		



## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 003	6455557	Nov 28, 2021		Y		
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014
<u>TOPOTECAN HYDROCHLORIDE - HYCANTIN</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCANTIN</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029			U-1258	
	8211880	Mar 10, 2029			U-1257	
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					ODE	Feb 20, 2016
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	8143271	Jun 21, 2026	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	8193195	Jun 05, 2022			U-839	
	8236804	Jun 05, 2022			U-839	
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	8193195	Jun 05, 2022			U-839	
	8236804	Jun 05, 2022			U-839	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N202497 001	>A> 5543152	Jun 20, 2014	DP		>A> NP	Aug 09, 2015
	>A> 5741516	Jun 20, 2014	DP			
	>A> 5814335	Jun 20, 2014	DP			
	>A> 6723338	Mar 31, 2020	U-1271			
	>A> 7247316	Sep 25, 2020	DP			
	>A> 7887836	Mar 31, 2020	U-1271			
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001	>A> 7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 002					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 003					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 004					PC	Aug 29, 2012
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 001	>A> 8242131	Aug 20, 2029	U-1266			
	>A> 8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 002	>A> 8242131	Aug 20, 2029	U-1266			
	>A> 8252809	Feb 16, 2025	DP			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31<sup>st</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>